var title_f3_52_3904="Kirby-Bauer susceptibility";
var content_f3_52_3904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kirby-Bauer disk diffusion test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Antibiotic susceptibilities are determined by measuring the diameter of the zone of inhibition in millimeters for each of the different antibiotic disks. These are converted to susceptible, intermediate or resistant using a table from the Clinical and Laboratory Standards Institute.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3904=[""].join("\n");
var outline_f3_52_3904=null;
var title_f3_52_3905="Larynx";
var content_f3_52_3905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glidescope&reg; images of laryngeal inlet and inner larynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These images clearly show how the epiglottis juts out, covering the inner laryngeal structures. During laryngoscopy, the epiglottis often casts a shadow over the inner larynx. The curvilinear structure on the right side of bottom image is the pharyngoepiglottic fold. The true vocal cord is marked with asterisks (**). The aryepiglottic fold in the bottom image is marked with plus signs (++).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Levitan, RM, Kinkle, WC. Chapter 2, Laryngeal anatomy. In: Airway Cam Pocket Guide to Intubation, 2nd ed, Airway Cam Technologies, Wayne, PA 2007. Copyright &copy;2007 Airway Cam Technologies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3905=[""].join("\n");
var outline_f3_52_3905=null;
var title_f3_52_3906="Bilirubin circulation summary";
var content_f3_52_3906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enterohepatic and systemic circulation of bilirubin and its metabolites in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 460px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHMAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMvxD4g0jw3ZJea/qVrp1q8giWW5kCKXIJCgnvhSfwNT6Nq2na3YR32j31tfWcn3ZraVZEJ7jI7+1cN8a9E1jWLLwlNoGmvqU2leIrTU54I5o4mMMQkLYMjKuckDGe/wBa4TUvAviyfTNevI9ChQa7rkV5LpCXMbSWsCxlTICXWFpWbBIJK9D8xAwAe36prmnaVL5d/OYW8iW5z5bFRHGMuxIBAwO3U9s1Z0y+ttU0201CwlE1ndwpPDKAQHRgGVueeQQa8D8P+BvHMOg6TZX9rdEQaTrNpJHLfRvhpj/oynD4PHAPRe+KpS+G9dtfFngHwml1Lbw6polgddtEmJMH2ELkgqcAOcR5U8kUAfQWo6zp+nX+nWV7crFdajI0VrGQSZXVSxAwOOATzUWr+INM0h5l1G5MHk2kl9IxjcqsMYy7EgEcenX0FcP8ZPDuo65qXhK5stEm1qz0+7mlvLWG5jgZkaFlABd0zkkZGelcRZ+AfG8Xh1bG6ilmDeF9VsfIN6rrFPM5MEBZmG4qpC7/ALoxjOMUAe5aRrmnaw8iadOZikUM5Pluo2SruQgkAHI546d8VpV8/wBx4G8atpGt2kVvdR+fB4fitxFfIhHkLi6CkONuO543ds1f8ceEPFemahrlr4L0u6vtJ1HQPsFux1bDWtwJHYsTM+5id/DZ9iQOgB7Dp2s6fqN/qNlZXKy3WnSLFdRgEGJ2UMAcjngg8VLpmo2upwyy2Ts6RyvCxaNkw6nDDDAZ579DXz8vw+8WnxRczRaNcQXc+pafcw61/aEYS2jihjWbMYkLMW2suNuD3OK2LLwB4j1HVNBt/ENtdvo66zq9xfqNQ25t5VP2fJSQMQWx8o6dwBmgD3SivGf7O1vw3+zFq1lrbXEGr2enXoy1wJHRfMkMXzqT0Qpjnjgdq5a28FeLdS0DU7jSNPv9MtL9NL2WraorS3DpIrT3W8SHZlOMbtxxyM4FAH0fWfrGs6foq2bancrbi8uo7KDcCd80hwicDqT68V4x8Qfh34gbVp4fDVnd3VobGGDSLk6qynSbgTF5JXLvvfIIO4bm424xVXXPAXim78ex3t1o82pSp4nstRj1j7bGscVhGUzEIWcMCpDEgLz2zQB9A1W1C/s9Nt/tGo3dvaQblTzJ5BGu5jhRknGSSAB3Jrw/RfDXxBh1PQdPnsJoLXTdVv7h9UOoRyLLFKsnlN5e7cQpZflIzwOPTEv/AIZ67f8AgT+z7jwldN4htjBNc3760rjU5FnUuVBk6lN5BkC7c4HqAD6JttRtbnUbyxhkY3VoEMymNgFDglcMRg8A9Ccd8VbrwrWvBvi27n8QPY2F3BpM50R4tMfUF33FvAjC5tQ4c7W5UFiQGx1PWm6d8PvEd1F4fs9UtLqLQxrl5dS6eNR+aysXiIihZ1fLDfztQsBux0zQB7vRXE/BzRdV8PeBbfS9cSWO4t7i4WJJZxMywmVjENwJ42FeM5HSu2oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzD4k+IfE+g+K9Aj0PUNOul1C8itk0M2paeWI582Yyh/lVQM524HGT2Pp9cdrvw08K674jbXtS0+4fVmRYzcR39xEdq9FwkgGOOmOaAPPdN+J3iKfxXaXEpsTod34nn8OLYrARLGqL8s3mbvvZ5K4xjpUHgf4r69f6l4U1DWzavoviaPVJUtba0czWK2e4jlSzSllU8BckkYHavUYPh/4Yt/E7eIIdKRdVMzXPmebJsErLtaQR7tgcjqwXJ9aND+H/hjQtcfV9K0pLe/bzMP5sjLHvOX8tGYrHuPXYBmgDifir8YrXQPCKXXhtkOrXXm/Z11SCW0ULEoaRikoRmJyqqB95mGOhxjeIPih4guorNfDl5pcRg8IP4oup2h89Lh0O1oFww2jcGBOSR07V6l4vsbTWLmy0TVLWK507UY54bhGyGK7AcBgQV+oINV9Z+G/hPWbXT7fUNIWSKwt/skASeWMiHj92xRgXXgZViQaSd7iUk7rseSaz8Y/EjWms67psdjbaZoNlo93cWEsJeS7N8qMyh9w2bQ+BweRz6V7B4/8W/8ACJWmkvHps2pXGp6hHpsEEMiRkyOrspLMQAPkx+NM1T4c+E9V1W31G90aF7mBYkUK7xxssZzGHjVgjhe24HFbWt6Fp2ttpzapb+edPu0vrb52Xy5kDBX+UjOAzcHI56UxnnHh/wCM0GoXNiNT8P3umWl3b3sq3DTxyjzLTmdNqnOAOjHGT0HetfwL8R38T69Z6bcaFPppvtJ/tq1kkuEk325kVEJC/dY7wcc4rYtvAHhq0Nk1rpqo9j9rNsXlkkVDc/67KsxDBvRsgdsVzfwz+FEfgvxFLrEmqC7m+xf2fBDDDJFFFEXVzgSSyHqowAQoHQUAenUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcz4l8Y2Oj3JsbeKXUdWKhhZ22CUB6NIx+WNfcnJ7A0m0tyoQlN2ijpqyNW8S6Ho7+XqusafZycYSe4RGOemFJya4G6k13Wtza1qkltA3/LjprmJAPRpRiRvwKg+lGn6XYacpFjaQQZ5JRACx9SepPuajnfQ6o4aK+J/d/n/wAA7K08c+FrpwkXiDTBIekclwsbn6KxB/St+3niuIhJbyxyxnoyMGB/EV5xNFHMhSaNJEPVXUEH8DWU/hnRGkMg0u0ilPWSGMRv/wB9Lg0udjeHpvZtfj/kehax/wAjV4e/7eP/AEAVvV4nd6fLa61pQsNV1e2c+btb7Y8+w7f4VlLqPcYwa6SDxD4rshtZdK1ZB0Mpe0kP1Kh1J+ir9KUJ6u/9aIwjhm5S5X19Oi+X4npFFcRbeP0hONc0e/sB/wA94R9qh/OP5x9SgHvWvZeNPDN4+y31/S2l/wCeZuUVx9VJBH5VopJ9RSoVI/Z/U6CimxusiB42V1PQqcg06qMgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorj/iZqctvpEOk2EjR6hq7m2R0OGiixmWQehC8A/wB5lpN2Vy6cHUkooydf8WXes39xpfhifyLKAmO71RQGO8dYoM8Fh0LnIHQZPSlpun22m2/k2ke1Sxd2ZizyMerMx5Zj3JJNS2VrBZWsVtaRJDbxKESNBgKB0FTVlvqz0NIrlht/W4UUUUCCiiigDK1H/kPaR/22/wDQa1awNb1Gys9f0lbu8toGAlYiWVVwCuAeT0JBH4Vv1EGm5f10MaUk5TSfX9EFRXFtBcpsuYY5k/uyKGH61LRVm+xjf8IxoiuXh0y2gc9Wt08on6lcZp//AAjumf8APCT/AL/yf/FVrUUuVFe0n3ZiQTReE9e029tJJ0tHMy3luZ3ZGiSGSQyYJIBTZ1x3xnkVHYaZJq1rFqHiKS6uNSuVEsivcOFhzz5aKCAqrnHAycZOayvHRN3r3h7SYiGa9eVZlzyIAFaT8CAV/wCBV2lJauxpJuMYy6v/ADf9fIzLfTbnTZfN0HVb7T3/AIo/MM8L/WOTIH1XafetaHxL4qtf9dBo2pKP7pks2P8A6MGfy/CmUVW2xjJqXxK/9d9y6PG+qY58NPn2vo/8KX/hN9T/AOhak/8AA2P/AAqjRTu+5Ps6f8q/H/M0bf4gKN6ahoOrW8ytgCJFnRhgHIZT+GD6VreH/FllrmoS2UFvfW9xHEJitzD5eVzjI59a4nVr2W3EFvYwC61O7fyrW3zje2Mkk9kUZLHsB64Fdd4Q8KHRJ3v7/UJ7/VpohFNIQEiUZztjQDhc+pJ9TRFybIq06UYXtZvb+ux1NFFFanCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXl2pznVPHerXTHdFpyJp0HoCVWWUj6lkU/9c69RryLw25nsZ7p/9ZdXdzcN/wACmcgfgMD8Kzn0R14VfFL5ff8A8MatFFFSbhRRRQAUUUUAcl4m8Px3/i/w9qEkRdI3eOX0+VWePPtuB/OutooqIwUW2uplToxpylKP2nf8LBRRRVmoUUUUAZL6SsnihNWcAmK0NvH7Fnyx/Qfma1qRmCjLHAyB+ZxS0Ipyb3CiiigkKzYby81W7ls/DdkL+aJtk1w8nl20DejPySw/uqCR3xSWVjd+MdQlsbKSW20O3cx3t6h2tMw6wQn9GcdOg5yR6lp1ja6bYw2en28dtaQrsjijXaqj2FNLmJqVFS0er/L1MHwn4Tj0aZ7+/uDf61MmyS5ZdqRrnPlxJ/AmQPUnAJJ4x09FFaJJaI4ZzlN80gooopkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5F4cUwWd1aN9+0vbq3PPZZn2n8V2n8a9dryqy/5CviD/sJzf8AstZz3R14Z6SXoXaKKKk3CiiigAooooAKKKKACiiigArk/HGuNoF5ot2xP2dp2jnA7oRz+XB/Crut6zc2mr2ljZwwO020s0rkbdzYHAHsx/Cm+MvDMXiaziilneEw7mTaByxGBnPasKsnKLVPdHHiZzqU5xofErffe5b1uT7d4V1CTT2M/nWcphMXJclDjbjvVPwLe6lfeH7d9WhKTKNokLgmUAkZI7HjBB71a8JQWlv4fs1sIPs8TJuMW4na/wDECSTyDkUyzb+zNZubN2UWtwr3kJPGw7h5q/TLBv8AgRoV7xm30BKTnCs3urNLbXY26zbGK+8WTz2mhyG206NzFc6p6EcMkA/icdC33VP94jFP0DS7nxtIbh5J7TwuOFaNikuoHuVbqkXbIwW7EDk+n2FlbadZQ2djBHb2sKBI4o12qijoAK6Eub0OqrVVHRay/L/gjNK0+10nTbaw0+FYbS3QRxxr2A/mfU9zVuiitTgbbd2FFFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKrL/kK+IP8AsJzf+y16rXkPhgmTTZLmQ5lurq4uJD6s0zn8hwB7AVnPdHXhlpJ+hrUUUVJuFFFFABRRRQAUUUUAFFVtQv7TTrdp7+5ht4R/HK4Ufr1PtVeE63qtu82lab9jsQpY6hqmYUCj+JYv9Y3HPIQH1pXKtpzPRHNXN5aW/iEX9/MkMJvXRC/cxxCNQPU7nkwB3at//hItM7TSk+gt5CT/AOO1a+Gfhm0t9YtL24gWfURpwvZ55ly3m3MhYYHRCBGeFxjcf7xz6rUUINxb7nnYavCMW7Xu79u1+ne54lotxqP9oX1hpuhalM8kguoUmj+zBI5M5Z/MwVG9ZD0zz0q9rXhS/Y2OqeLhY/2VbTqtxY2ru6+U/wArNJIQpZQdhKhcYDZyK77VR9j8YaPe9IruOWwkP+1xJH/6BIPq1bl1bxXVrNb3CCSGZDG6N0ZSMEH8KpU7px7f8Ohe3k4OnBWs9H+K+4fGixoqRqqooAVVGAB6Cud8O+NNH8Qhm057kwLG0vnzW0kURUEKcOwCk5PTPY+lS+D7mT+z20u8YnUNMItpi3WRQPkl+jrg/XcOxrgfDHw51rS/Cuq6RcLpfnXVjNbLcx3lw+52bI3RsuxVAJ5UZ4HXJonUneLgtNb/AORx1KtS8XBXTvf17fmejaj4k0bTrC4vbvUrcW1u6xysjeYUZjhQQuTkk+nv0FXG1KxWWCJr22ElwMwoZVzIP9kZ5/CvNtZ+GU1zb6jFYJpdutxYWkMahSq+fFIGZiAvAIG3cMnk8Uav8O9RvdalvgmmeVcpb7rdZ3iW1eIAYjKp8y8ZH3OSal1ay+z/AFr/AMAh1q6fwf1r/wAD7z0z7dafvP8ASoP3YYv+8HyhfvZ9MZGfSs3UfE2l2K6c73KSwX8/2eKaJlaMNtLEs2cAYU81yM3w7ebRfEkRGnpqeo6jLdxXOzdmEzLIsMjYDbSV5AyO/NRx/D+8nure4vl0sRtq41Ceyjy0CIItm1AV+ZicE5AFN1KvSI5Va3SP9f1+Z6BJqmnx2aXkl9araOcJMZlCN9Gzg0supWMLost7bIzlQoaVQWLfdA579vWvMLj4aaj9ls1glsGFrd3jraGRkiMUzAqAwQ7WAGMbSOcVnP4E1a61DU9HisrKO3fT7S2+2XHmOsQUsT5LFfnYDA5K9vpUutVX2P6sS8RWX2P6t/SPYP7TsPtps/ttt9rAyYPNXzBxn7uc9KzrLxTpeoR20mmzG8jnuDbbohjYwzncGwcfKeQDntxXG33gTWbrxhb6lLcWEtrDqUd0rs7LJ5KrgoUCbWb/AGixz7Uui+AtR059MjC6UkNjqzX3mxFhJLERJgMNmNw3gAZIxnmn7Sq3bl0K9tWcrcun/Df8E9Eiv7Oa7ktYbu3kuY+XhWQF0+q5yKs1xPgXwvf+HXitrmDSJreAS7b9A32uYu+758rge/zHOB0rtq3pylJXkrM6KUpSjeSswoooqzQKKKKACiiigAooooAKKKKACiiigArnfGkKXFtplvNuMUuoQo6hiu5eeOK6KsHxZ/zBv+wlD/WoqfCzOr8DD/hEdD/58f8AyK//AMVR/wAIjof/AD4/+RX/APiq3qKPZw7IPZQ/lX3GD/wiOh/8+P8A5Ff/AOKryzw1oenTaNC8lvuYtICd7f32HrXrXi3VG0Xwzqmoxrult7d3jX+8+PlH4tgVwWjWQ03SbOyDbvIiWMt/eIHJ/E81nOnC+x2YehT5G3Fb9v67orf8I9pf/Pr/AORG/wAakt9F0+3mSWG32yIcqd7HH61o0UvZx7Gyo01qor7goqlqWqWeneULubbJKSsUSI0kkhHUKigs34CqNpe6lrWuro1hb/2RM8PnifVoWRpEzgmGHguR3yVxkZBzTubqDav0Nuq99e2un27T31zDbwL1eVwo/M1zXirWvAnhzRlu7zxLe+JZWbabex1SP94+CRuWJl2pxjjgdDnODe/Z38Hyw+HB4k8QJDdX+pET2omgUvbR5OCrEfKH4bAwMbaSd5cqKlBQpOrK9tlpv6f8MaFlcanq6g6Do1zPEfu3V3/osB9wWG9h7qhHvWtF4M127GNR122s42+8mn2uZAO+JZGI/HYK9BorVQXU4pYqX2Vb8fzOe0XwZoGjypPaaZA96vP2y4HnTk+vmPlv1p3jklvDNzbqSDePFZcHnE0ixnH4Oa365/xSfMvPD9sT8suoB2+kcUkmT/wJFpTSUWkcdecpxfM7t6feJ4WTfqPiC6IAL3vkIo6KkUaKB+e4/wDAq6Gue8BAv4XtbxuXv2e+Y+vnOZB+QYD8K6GnT+FMml8CffX7zG8X2st14fujajN3b4urf/rrGQ6j8SuD7E1o6fdxX9hbXlud0FxEs0Z9VYAj9DViue8D/wCj6TPprcNpt1LaAeiBt0X/AJDeOjafqD0n6/oN8T281jcw+INPjeSe1XZdQIMm4ts5YAd3T7y/8CX+Kt20uYby1iubWVJYJVDxyIchlPIINTVys4PhO+e4T/kXrmQtOvaylY5Mg9ImJO4fwk56E4T9x36Cf7t83R7/AOf+f/DlnxvrlxoGlW9zZ28VxNNdw2ypK5VfnbbnIBx+RrlNc8ea5puszaculWc1xZQxTXSJIxEgc8+Wx24CgfeYdeOK9FurW2vY0W6ghuI1dZFEiBwGByGGe47Gq+o6Npepyxy6lptldyRfce4gWQp9CRxUVITk/dlYirTqSd4SscivizWL271j+zIdKEVhdTWcdtcTMLieSNCQVA4wx6D0yazbb4mXF/o82pWFhB9mM9pYwyzOVRZ5VBk3nsibgM9z+degvpGnPqI1A2Fp/aAGFuvJTzRxjh8Z6VS0HwxpujeHxo0cX2qzJZpPtQWQylm3EvwAeT6dhUunVvpLv/wCHSr30l3/AOAcD4l8Rata6pP9pvIHEOjXczx6fcMsbOjJtOeqsAfwqxq/j3V9Ph1WWzsbKW00i3sp5zPM/myLMucLgYyOeSfwNd7H4e0WKHyo9I05IvLaHYtsgXYxyy4x0J6joalk0bS5I7hJNNsnS5VEnVoFIlVPuBhj5gvYHp2pexqa2l/VifYVdbTtf/L/ADOIPjy/bXRCltYixOt/2KEaRvtGQDulI6beOB7ivRq5SXwLpc/ilNduJJ5bpJhOkZWNVDgYByqB2x2DMRXV1pSU1fnNqEaiv7R9dAooorY3CiiigAooooAK8A+LXinxFoPi/WLq51S/j8MWaW6RPod3a+bYyMoJNxBIpaQsWUgZA247nI97nmit4XmuJEihQFnd2CqoHck9BXIXDeDNR8Q2V+2maPqN3JHJOmrrDBKIhEBnMudwIBHTpjtQBzEPxS1KXx3ceFBpEH9o21zPNMXkKItgkKyRzFjwrOXVMHgHOa4nWvjH4rufBuuzQLp2jazZLa3HktBJ5kcUlwkZIZw0cqncBuGOCSBkcevJpnhnTPEuseL7zVbczahDFYySXVxEIIY1GRGhwMbshiGJzxjAq5aaL4Ms9N1C2tNN8PQafcBPtkUUEKxSBuU8wAYOcjGeueKAPO9b+K/iGw8WXOj2ui6feHTEtWvzFK374SqGZoXOAqqD1YHJBHFLdfFDxTJ4llsdN0nRGtD4gn8PQvcXEqyGVIhIsjAKQFAPIGSeny9a6i0ufh9q9rLc3ul6HbQaHfS6PFJqNrBGsMkJwViLdFHbGPoK0ZtQ8E23iC004ppH9rXRbWLdEt0JlcgKZ1fG3zCCBnO4j1FAHnOk/Fi7u49M1290+TcPD2o389rbXL+Uz205jOFIxzsJDHJUHvXo3w617Vtes2uNYm0F/Nt4LqFNMnaRo1kDHbIG+gww4bDcDFP0aXwlb6bpOox2Ok6OLiN4rRJo4YJArtueNcHHzN8xVSck5PNXNOh8KeGruW206PQ9JuruVVkigWKB5pCMqCBgs2Dkd+aAOhrB8Wf8wb/sJQ/1rerB8Wf8wb/sJQ/1qKnwmdX4Wb1FFFWaHL/E/wD5ETVv9xP/AENa5+u71rTLbWdKutOvlZra4QxuFYqcHuCOQR1BriovBWvxMluPENq9qowJ5LEm4I9D84Qn/a2/8B71nJO90dlCpBQ5ZO2v+RlajqkFlLDBtluL2c4gtLdN80vrhfQd2OAO5FXrPwx4n1JA93dWWiRN0ijj+1XAHuxIRT7AOPc10/hPwra+HvtM/nSXupXTZuLyYAO4H3UAHCoOyj3PJJNdFQoX3CeJUdKf3/8AAMHw34U0vw+0k1qkk99Ku2W9uX8yeQehY9F/2VAX2q9reiaZrtp9l1mwtr63znZPGHAPqM9D9K0KKuytY5nUk5czepx2nfDHwXp929zbeG9PMzNuzKnmgH2DkgfhXXxosaKkaqqKAFVRgAegp1FCilsE6k6nxtv1CiiimQFcR47ujFfyyp10/Rr264znzGCrHj64krt68/1Ef2hFq8pwX1LVINLj9oInAcfpcH8axrP3bIwxD92y/q3/AAbHb6Zaiy020tV6QQpEMf7IA/pVmiitUraGyVlZBXPHdp/jYYGYNVtsHB+7ND3x/tI2M/8ATMetdDXO+ND9ltLDVRwdOvI5XPpEx8uTPsEct/wEelTU0V+xFXSPN21/z/A6KmyxpLG8ciK8bgqysMgg9QRTqKs0OX0938M6hBpdwzPo9y+ywmY5MDnJ8hj/AHf7h/4Cf4c9RVTVLC31TT57K9TfbzLtYZwR6EHsQcEHsQDWX4bv7hZp9G1Z9+pWahhKRj7VCThZQPXjDDsw9CKzXuPl6dP8jKP7t8vTp/l/kb9FFFaGoUUUUAFFFFABRRRQAUUUUAFFFFAHJfFLwtceMPCMul2c8EU3nw3CpcqWhm8uQP5coHJRsYOP1rhdc+GviDW5pLlrbwzpUkmlapYmCweTy/MuYUjjcnyxu5X5jtGBgAHFez0UAeQ3PwsnsLfwdPoGn+HZLnRreSO7sLqMx2t1NJFGjz7lQnzP3f3mQlge1Y3iL4VeLbyLxFa6bL4Zgsddi0tpoh50YtpLRYgUiAUjyz5fy55xgY717vRQB4nqPwv8SSWl3Bb3OkSQXPiS+1aW3kkdPMgn+4PNEZZHXuFGCDjdUHhf4Razoj+DZ5V0C8uNL06fT7wys/y75S6SxN5eWZQSACFxk4Ne50UAeBTfBrXx4d0uzSXQru4Xw9JoNwt2ZDHbFpC/2iA7CS/zYwQv3V5q3r3wXvb+HxaySaVcX9+dKGm310G86IWqRLKWbYShcRt90nOecV7lRQAVg+LP+YN/2Eof61vVg+LP+YN/2Eof61FT4TOr8LN6iiirNArlfHPjODwtJpVnHYXeqaxqsrQ2Nha7Q8pVdzsWYhVVRgkk9/rjqq47x/4Lk8TXuh6ppmqvpGu6LLJJZ3ggE6hZF2yI0ZI3BgAOooAST4g6TpmmWk/i0SeHby48z/Qrwh5FCHDPmPcNnQ7+mCM4qXXPiP4P0K7W21bxBY20xWOQKWJ+R/uPkAjaf73T3rnNa+Gesaq0d5P4tzrUunXGk3t22moUmtpn3FUiDgRsuMBst7g0y/8AhBBNpviCwtNWeG21PR7PR4hJb+Y0C24IVydw3kjHHy9OtAHSW/j7Rn1rWLGe8s4otPnt7XzfP3M00xYBCmPlO5cDk59qual448N6ZDdS3ur28S212LGUcswnIBEYUAktg5wAeK81X4caz4l1Xxhc6gJfD/2qfS302Z/KuH32at+8aNXK7WJGFLA+uOlM1z4Z69pEa6zpV/NrfiT+3P7VV4rSCNU3QeW4aOSZFZflGMOCMjrgmgD0K6+JHhK10y11GXWYvsV0ZfKlSKRwfKIEhO1TgKSAScDmoLD4m+GL3xTfaFFfAT2tql4bhyogkiZDJuV89Ag3EkAYI5NedaV8Gtb1LwRpVlrOtJYXaC9N1ZNB9qgJuJWYPhXVfMUHr8wGePU9LY/CP7NHPavrjPp174fg0K+iFrteQQxNGssb7/k+9naQ3TGaAOmt/iV4PuNMvtQi161+yWWwzuwZSof7hCkZYN/DgHPbNS/D7xna+NbbWbmxgeKDT9Sl09XYn99sVG34IBXO/oeRiuCtvglJFZIp161F/bS2s1neR6ZtZXgfchlBlPmDqNo2DnOK7r4deE7jwnba2L3U01K61XU5dTllS28hVaREUqF3Nx8mc57+2SAdTczR21vLPOwSKJC7segUDJNcRoUMjTeEorhCksi3mruh6q7nnPuPtRFbnjsh/DNzb9Wu3jtVT+/5kipt+hBOfbNIMS+PcAf8eumD8PNl/wDtP6VjPWSXp+f/AADnqazS9Pzv+h0FFedW/wAV9Km0fSdRWxvhFqOvr4ejU7MrMWZd55+58p9/atqz+InhK919NEtdes5NUeSSFYATnemdyZxgMMHjOa2Og6uoL61hvrK4tLpA8E8bRSKe6sMEfka5eD4leD54LyeLX7RoLRPMll+YIV3hMo2MP8xC/Lnkgd6dL8R/CEWlQalLr1olnNM9ujtuB81BloypG4OBj5SAeR6ih6g1fRmh4MupZtGFreOXvtPkayuGPVmTgP8A8CUq/wDwKt2uDt/HHhl9U0e40S7sroeISzGcXBTcsSsNwQj5iNpUjgjHPStxPGnhx7ezuBrFoILu2kvIJGfarwx/fkyewzzmpgmlZkwTjFJnQVh+J9OuLmKC/wBMA/tawJkt8nAlB+/Cx/uuBj2IU9qzbP4j+Er3T7u+tdZikt7RIpJiIpNyrI22M7du47jwMDms3VPi94P0+30m4OotPbaldvZJLFGcQugBfzQ2GXGVyME/MOMU5R5lZhKKkrM7TR9Qg1XTLe+td3lTLkBxhlPQqw7EEEEeoNXK5PTPFfhK38RXGgWOqWw1OS4laSAMxBmxukUMfl3DklQcjk461Q0T4m6Jr/ja38P6FIL+OS0muTexkiMGN1QqMrhwd33gSOKFe2o43t7253dFFFMYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWD4s/5g3/AGEof61vVg+LP+YN/wBhKH+tRU+Ezq/CzeoooqzQKKK4fxZ4+fwx4i06y1HQNQ/sq9vIdPj1RJIjGZ5RlVEe7eR2Jx2PWgDB/aEvTp+m+C7g6gmmoniW2L3cnKRL5U2WYEgEDrg8cVxVv4v1fW7jw22p+RdrNH4gittS+zmJrq3iiTyp0HRdwJzgc4r0vSPihpms+OLrw9psKulnNLb3F3Ldwx4eNSX2QlvMkUEbSwXGc9QCag8FfFew8U6zp1kml39lBqsM9xpd1OU23aQuVf5QSUPBIBHI/CgDyHSfGeqeG/Blzf6YLYXtj4N025jnlj3sWaYqQ2TyME16B4v8ea34H8QPp3iPVbSWOfQLu7tLiPT2iSW+WT93Gq7nPCdQTz1OM133iPx94W8N6ithrut2ljeMEbypSchXO1WPHC5GMngd8VDH8R/CEmjT6tHr1o9hBcizeRdxPnHoirjcxPUYByORxQB4BB4/1yz1nWtYsdWgXxDqGneH7iHSjb+YdSlkgzJHGM5QfOSSvqORjnsYPFWuQ6jfWGiT2WnTX/jm50p5za+biMW6tvKlhl8jrnt0r1DU/Hmi23gjU/FFjcLf2FkrjEOQZJVO0RDI4YsQv1NUvG3xH0rwdofn6yUTWTYterpaOWkO0cjcFOBu+XcQASKAD4P69qmv+FbiTXZ4rm/s9QurB7iOIRiYRSFQxUcAkdhXcVyUfxC8OLeafY3uoJaaherDsgkV8B5VDInmbdu4gjAzk5FaGneLtB1KXT4rDVLeeXUPO+zIhOZPKOJMDHG08HOKAG69/pHiLw7adVWaW8YeojjKj/x6VT+ApNEPn+K/EdwORGbezz/uR+Zj/wAj0v8ArvHn/Xnpn5edL/8AaP0o8JYJ1pgcltSmyc5zgKP0xj8KxWsvn+ljnWs7+f6WOGs/hA1vqNhE2vvJ4esNcOv29h9kAlW4ySqmfdygLHjZk561YX4Sxm0sLafVzJFba5c6w+LbaZFmDgxA7/lxv+9z06CvUKK2Og8pj+FWonwpb+HbjxSJNN07ym0vbpqLJA8UiujStvxLjbtIAQEEk84Is6V8LHtNb03WLvW/tOow6vPq9262nlpO8kPlbEXefLUAA8liec+3kfw88ZarbeFbPSbDU7fVbV9O1qXUbBoNzaeEaZ4pHkBz87ELg4GGGBxmm3Gt3EPhzxDqAigdj4c8NSCB1JhUvIgOFzxjPHPYUAehW3w61XTtf8I6TBA91o+l319qNzqjNHEp+0LJiJY97OWBcc4x39qp3HwPvE0FLO88Rzara6fpV5p9jaRWUcEhWXDIPML4LAqBluD7cmn+I/GnjSLTPiPqml31n5Hhy7a2trQWHmSONsTFi+7ooZjjb+Nc78QviL/wkv8Abg03VYBoOm6roctneCIqFErOZGbOCygoPToaANjw78OPGOur4km8S38miXF7BYW1vIkcYaRLcsWEkcMrDYwIBAkyeeg4rc0z4N3OmaTDDYeIYIdQt9fbXYZl039yjNCIzF5Xm9OMg7vwPWsLw/4x1XWfEfhVb6a21SzPiO8s7LVfs3lfaoEtiwdAOOG3LuHBx7E1P8MfHXi3VNV8Az65qdnd2Pii0vne1jshEbdrfGGDhiWLZ5zge1AG3D8HLaz8SXeojUo5dNmvJr820tkZJ42k3b1jlD4A+Y4+Qt2zUvw0+H0uk6joGtr4mi1XTbDSn0+xjTT/ACCYXZXUs285YbcH5Rn0Bzn1aub0EDStf1HRvu282dQsx2Cs371B/uud30lFS3ZrsRKTi12Z0lFFFUWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVg+LP+YN/2Eof61vVg+LP+YN/2Eof61FT4TOr8LN6iiirNArzjxN4A13WfiDZ+I08VQR2diVNnps+meclucAO4PmqDIfmw5UlQcDpXo9FAHlFh8G7a18ZR6s2qmTTIdRudVhsRaqsizTqFdTPuyYxgkLtB55JqbwJ8Jv8AhF9b0e7n1yTULPRILi30u3NsImhWZyzGRwx8w4OBgL9K9RooA818ffC7/hLbzxJP/bH2T+2dMg07b9m8zyfKmMm/743ZzjHGOuT0rH8c/DnUo76+1/QJZ73V5dbt9Wt4YoIsQGOAxEMJZUWRSOfvIRkY6c+xUUAeK+EPAPiT+xfDun+II4I7Y65ca7qiLIpbcGLwRYGQcuQzYOBtxk10PxB+Glz4n1fUr7TddXTDqelHSLxJLIXAePcWDId6lDliD1BHoea9JooA8e1j4M3Gpa9aX8viYvBbTWU0cM9kZGi+zhQUjbzQER9uSApOT1Pe58NvAFxonxM8Z+Iby2e3tLmdo9LheVXCxyESTyKFJ2h5AMA4IA5HNeq0UAYGh/vvE3iO467JYLQH/ciEn85jWdpGU+HN5MrMJZIrudnzyXZ5GJz9TWl4T+9rTfxHUpsn1wFA/QD8qzdL/wCSZXH/AF6XP83rCO6+f5mND+JH5/mjZ0m6W28JWd3cFmWKxSVyOSQIwT+NN8GyXk3hbTJtTbdeTQiaTLbsbvmC574BA/CpfDyLJ4Y0xJFDI1nErKRkEFBxWR4AvEhsZPDtxIRqOjE25jkzueAEiGUZ+8GQLzz8wYdRWnVHa1eMrdH/AJ/19x1dFFFWYBWH4cnl+2a5Z3EryNbXpKF2LHy5ESRcZ7AsygdttblYFuPJ8dXqr925sIZGHoySOM/iHA/4CKiWjTM56OLN+iiirNArnfGY+y29jrC8Pp1yju3/AExchJQfba276oK6Kquq2UWpaZd2NwP3NzC8L/7rAg/zqZq8WkRUjzRaRaorI8I3kt/4a0+e5P8ApPlCOf8A66p8r/8AjymtenF8yTKjLmSa6hRRRTGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWD4s/5g3/YSh/rW9WD4s/5g3/YSh/rUVPhM6vws3qKKKs0CiiigAooooAKKKKACiiigAorldXvr/V9bl0LQrr7HHbIH1C/VA7w7uVhjzx5hXLEkHaNvBLDEreF50G608Sa7DMOVZ5klX6FXQgj9fQipv2NfZpJcztck8MSJDFrkkjBUTUJ2YnsBjJpvhQxW/gbT5dSaKGF7YTS+cwCoH+YhieON2KydJgurGy8Z2V7eG7dGaZX8sJkSQKScD/a3ce3vUHhiwh8TXgutTT7Rp2lJBa2dtJzEZliVpJivRmBcICR8uwkdc1jB6r5/n/wDmoQTlq9Ip/nYZ8N/F+kNu8LnVbSe607EVpKJcreW2P3boT95gMK2CeVz0Irqte8O2msXFrdNJcWmoWu4Q3lq4SVAw+ZckEFTx8rAjIB7UeKPDGjeKdOFjr9hFeWyncqvkFDjGVYYIP0NVPCvhG08Mnbp9/q0tvgqtvdXjTRp/uhun4Vqk9nsdsp02/aQbUu3/B8+1inqB8S+HLea9S8j8QWEKGSWC5RILkKvJKOgEbHH8JVc4+8K6qzuEu7SC5hz5cyLIuRg4IyK5zx5qZWxGhae6trWrKbeCPG4xo3yyTsOyopJyeCcDqa6Oyt0s7OC2hz5cMaxrk5OAMDP5U1vYiesFJrV/kTVz90Tb+ObB2GY7qxmiB9HR0YD8Qzf9810Fc/4gbyNe8O3L/6o3EluT6M8bbT9Mrj8RSqbX9Dlq7X81+Z0FFFFWaBRRRQBz/hX9xda7Yk/8e+oPIo/2ZlWbP8A307j6g10Fc/p37vxvrcefv2dpP165adTx/wAfpXQVFPb7zOl8NvX8woooqzQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsHxZ/zBv8AsJQ/1rJ8UeMHju5tH8NrHc6rHgTzvzBZ5H8ePvPjkIOe5IHXifEtvf3w08axrV/fRteRgwny4Yu/aNVP5k1jUno0jSeHk6fNJ2/M9qoryOCwu9In+1eG76SznAw8M7NNbzD0dC2Qf9pSD9RxXeeDPEX/AAkOmyvPb/ZNQtZPIu7bdu8uTAOVPdWBBB9D6girjO+jNKlBwXNF3R0FQX9wbSxublYZJzDG0giiGXfAztUepxgU66uILS3knupo4IIxl5JGCqo9STwKbdQreWU0PmSIk0ZTzIn2sARjKsOh54NWYLu9jy/wh8WE1a2vb/Uf7Khs7W1kuri2t7iRry22HlXjdF3ehKnAP1rWi+LHh95zE9trEJWaGKRpbB1WITY8qRyfuq2eM8nnipJvhhpd299LqmpavqN1dWT6eLm5ljMkMT9Qu1ACfdgxqe6+G2j3P9oeZc34+3fYfM2yJx9k/wBXj5e/8Wc57YrFe0R6Eng272f9W/4I/UPiHpNl4kOgzxXcN+5ZIXliAjkcKWwMHdg44JAB9azPAXjy+8R6votpdWtrEl9oTaq5j3ZWQTiPaMn7uDn1qS7+Gmg2+sT65calf28YvX1N43miEKSspDMSU3bcE8FsDtgVqeFfA+laBd6Zfadc3cxs9M/syEySIytCZBJuOFGWyByMDHbvTXPfUiTwyp+7vb8df+AddUdwzpBI0KeZIFJVM43HHAz2qSsbxfqc+laDPNYqj38rJbWiP90zSMETPsCwJ9ga0bsrnHGLlJJFD4aJB/whenXETb57pTcXcjDDPcsf327PIIfcuO23HarPiOz1ozR6h4fvUFxDGytYXIzBcjOeo5R+wYZHPINZ+m+CFsoZANe1szTSNPO8c6xLJK5y7BFUBcnsP/r1MNN8SaVu/svVYdUt8ki31VSsg9hPGOnX7yMffioV7WaOiTi6jlGS+f8AX+Rl+HNTXxFd+K44oJrW9eCGOW1uF2vC5jddrevIPI4IwQcGqvhjUj4Z0+G8vI5X8OanFFeC7RN32KVo1DrKByEJAIfGFJYNgAGoSi+IvH+LkX/h7X7aw2o0brubEh5QkFJoyG5BBx3CkVY8IXuv6Pps9lc6YmsWNndT23m2UgScASEjdE5CkbWB+V89tvrlF6/f+Zz0oqM2u99L+d1Z7f1szrtc0bTfE2lCC+BmtpBvjlgmZGGRwyupB/XB9644fB7w6CCb3Xj7HU5Of1qTRykV/NH4HvIrZwDLceH9Uikt1TJ+/GCu+IZ/uhoz2APJ2pJ/GN5DIkFjo2lvtKiSW5e6O7+8FCIMDryefQVr7stWjrTq0vdhOy+78P8AK5kweF5PBGqS6n4VsZL6wuVVb6yaTfc/KOJIpJDlunMbNg9VweD2mj6lbavpdtqFkzNb3CB0LKVbHoQeQR0INY2u+IzpYi0uwT+1vEckY2Wsfy+3mykcRx55yevRcnir/hXS5NG8PWVhPMk80KfvJEXarMSScDnAyTinHR2RlVbnBSnv+a/rqa1c/rn+k+J/D1ouT5TzXzgHskZjGf8AgUwP4e1dBWBpw87xlrMz8tBBb28f+yp3ufzLD/vkUT1svP8A4Jx1NbLu/wDg/ob9FFFWaBRRRQBgR/8AI+T7c/8AINj35/66vt/9m/St+sDTf3njTXJf7lraQfkZn/8Aalb9RDZ+rM6ez9X+YUUUVZoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcT8QNdvYbi30HQ5Vg1C7iM011jJtIAdu4DoXY5C544Y84wel8R6vBoOh3mp3YZoraMtsX7zt0VF92YhR7kV5xpdvdGS51HVWV9VvmElwVOVjA+7En+ygOB6nJ6k1E30R1Yamv4ktl+f/AACXS9PttLsktbNCsa5JJO5nYnJZieSxPJJ61zfjzxFbaLPpkd1b3TgzLOHjVSpCnleSOeR+ddfWB4lh029vNKtL6WNLlbpJ4EbjzCucqD0PGTjviuerGThaO5WKhVq02qT977zbgkMsEchjeMuoYo/3lyOhx3q14CV28aa9JFlbdLS1jkHZ5d0pB/BSPruHpVW4mitoHmuJUihQbnd2Cqo9ST0rV+F0TT2ep6yQyxalc5t8jG6GNQit/wACIdgf7pWtY7o1npSk36fiXvigL8/D/XBo8U02ofZz5KQx+Y7NkdFwc/lXn2rp4yN5rGoWt14gQ2OpWKWdpFEfJlhZYxMduzLqMtnnAwfevaqKuUOZ3uc9HE+yjblT/pf5fieB/wBn+KdFtfGkeipr4vJtd+0MRESslmxTdJC23DSnBB2nIA6A0mpXHjVPC9kLe88Q3BS9uT5f2C5illi2RmNGkCGVcMz4ZlAbuflGffaKn2XmbrH63cE/+GseAR6b4htLzxndyWniNdRv9CtntkaP7QksqwMHR3VNrOrEADgkk8Gr2sp41KeIL6zufEMUunHSzp9pBCRFPujiE427MuAS5IBwCDmvcaKPZeYvr2t3FdPwt+i/FnjdvN40HxNk+2z6tDarqhWKNLWSS0lsjwvzKPLU45LMdwOeteieOrS4u/DVwbCF5722eK7t0QgMXikVwBnAydpGD1zjvXQVheJ9XudPfT7LS7eK41S/mMcKSsVjRFG55HIGdqgdupZR3quXlTuzJ1nVnFxilb9C7oWr2Wu6ZFf6bL5kEmRyCrIwOGRlPKsDwQeQaztTuPE1rcyTWVjpt/Zq3EAmaKdl9iwKbvY4B9RXNTeG/GEGvS6tot7oNhNcjF3D5UskNyRjDsuRhwBjcCCRwc4GO60kagLCMau1q17zvNqGEZ54wGJPShNvcmcYU3zRaa7HA3sujeL/ABbpsU8ci3KxSw3FlcIYbq0ZRvR1IO5DnOHQ4PYmjR9Vfwb4zv8ARNcuZ7mx1Borq21OYKNjsvlCKUgAAnyhhsAEnnk8x/Fm+s9O8U+CryeRY2t71pZ5FGWjt9uGZsciMEjJPA7103jTRk1fTkvbW3ivZ4Y2HkNgpeQMBvhPYhgAVPZgp9axs7trdP8AQxb5E5WvG+3bRXt+fnsXPFnh+DX9P258jUYMyWV4nyyW0uOGVvTpkdCOCDXBWWv6xeWlvaajrt+NZfzEvLDStNjMts0ZUPgsW2r867XP3gwI9tvw5qF/pelwS6f53iDw7krGy5+3WYBx5bq3+t29D0cY5DHmrNjrfg2DXtR1j+0LfT9VuIEjulvma1k2R5wTHLtIxnGcelaXUtUzrpStHRcy6Na/8MR6JcTaLaMuj+CtX+zu3mTTTXFv9onY9XbdKWdv98g+nauh0LxFY6zNPbwefb31uAZ7O6iMU0YPQlT1U44YZB9ar2Pi3TNRvorXTBd3pflpobZzFGOxaQgKM+gJNZ3jWe00fxB4b1y8aGGGOaaznnfAKRyQuwyfTdGvHvntTvZXT0M5Lmb9orPfr+N/+AdVfXdvYWc11eTJDbwqXkkc4CqOpNY/g6KZ7GfU7yNornVJjdGNusce0LGh9wirkf3i1ULK1uPFV3DqWrQvDo8LCSysJBgykdJph+qoenU84A66iPvvm6HDG83zdOn+YUUUVoahRRRQBgeH/n17xPJ/dvIofytoW/8AZz+tb9YHhM721qbtLqU2P+ABY/5oa36in8JnS+G/r+YUUUVZoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAed+PLhtU8UWGkA/6Jp6LqFwP78pLLCp+m13x6hDUdZ2ly/br7WdTJ3G7v5trf8ATONvJTHsVjB/4F71o1jvqeny8iUO39MKjntLa9QQXsEU0JIO2VQwDA5Dc9wec1JWfqVpeyzRz6ffeQ6KVMUke+N+c8jIIPbIPelJ2WxMpOKulczZfD9vca/pGmane6hLo17cNHLayTBkZ1RnVC2N+0lem7BwB357e2ku/Bt3Z2d9dyXnhy4cW8FzPzLZSHhI5H/jjY/KHPIOASc5HCXWrTWuuaBHrNslqi3yztcxSeZEERWLE8Bl7dRgZ68V7HdW9nq+mSQXCRXdjdRlWX7ySIw9e4IoptO9tzOriFO0Xt1XX19fzsW6K5nwlPdWd5feHtRmNxJp6Ry29y5y81u5YJv9XUoyk98A9TXTVsnc5Jx5HYKKKKZIUUUUAFcfe3lvH8V9LtrlyJ5NJuPsqkcZ82MyfjhF/BT+PYVk+ItBs9etoo7vzYpoJBNb3MDbJbeQfxI3Y9iDkEEggipkn0NKUoxfvbFnV/7S+zL/AGP9j+0bxu+1btu3B6bec5x+tcnrcPxBm8pbCfQooP8AlqYXdJ8f7DOjoD9VP4VfjbxdpY2PFp+vW6niUSfZLgj3XaY2PuCg9hTx4xtoZraLVtO1TSvPkEIku4QIlkP3VMiMyjJ4BzgkgZ5pOz30NYRlH4Upfj+G5yWm/wBl2XiDS47izuLXxG94UvV1CQSzXcUkboGWTpJGG2cLgLyCq5rpH0nUPCrtP4YjN3pOd0ujF8GP1a2Y8L6+WflPYr3b8TrW5m07SptMWH+1bfUIpLRpVyA+G+U+gYfKfY+1dF4f1SHW9EstTtgViuolkCt1QkcqfcHIPuDURVpNGaqPmlNbO118v6t1OY06Wy1XVbnUPCepx2WpsAL7T7qBhuYdDJCSro+BjeOo/vYFab3Gunat94fsbpozuSSG8BXPqA6Aqfz+taOs6DpOtBf7V061u2QfI8kYLp/ut1X8CKzV8Iwxjbbaxr0EXaMag7hfYF9xx7Zp8jWxn7Kne8JOP4/19xJNqPiBkPlaLZ2+AS0t1f4RB64VCT+n1rktOt7rxp4q0+8vZotS0HTGadZEg8q1kuMFV8oHLS7QWzITt9BnOOnl8GWV1tTU77VdStgwZrW7ui8MhHTeowGHfByPUV0qKqIqIoVVGAAMACjkb+JjUYQ1u5P7l/wfmOooorUkKK+f/G/j3XNKtvjAkWsG3udIksRpaMEDRCQLu2gj5s5PXPtXR3HxK160HjC4Oj2U+m+GIgZ2M7rcTObdZFAQIVA3H5iSMDsaAPXaK+f/ABZ8SPEFx4Z1u08yxt9U0+40qZbzS7hxC8dzIv7tmOSpwCD1yDnFS658UdSUiG/jgFzp2uPp73GmXMi284Fq8o46sQcKUJ64+lJuyuKT5VdnrngT5/C9pP8A8/TS3f182VpP/Z636+b/AIeeOtQ0nwX4cnlae8ltvCWo6kBLctsc28pCKydDwAA3UDgVu3Xxh8QaRBdnWdH0oyy6PZ6tYm2uJPLRLidYQJ2ZRjaW3EgdBjvkKC5YpChHlio9j3OivGpvirrEUMmmmz0ltaGvR6Gt6JXFhl4vN8zP3sgZXZnr37Vm3Hxn1t7LTILHSdPk1S9vb+2V9zvAwtSB8gBBYtuz14HPNUUe70V4Tqnxf8UJYareWWg6VEmkaZa6jew3Vy5f94WDxoUBUkFTgk/ge3uVrMLi2imAIEiBwD2yM0ASUUUUAFFFFABRRRQAUUUUAFFFFAHkPhT/AJAcH+/L/wCjGrWrM0mI6dfavo8uVksruRkB7wSsZImHqMMV+qGtOsFserU1k2Zl/runWFwYLu58uUAHbsY8H6CqbeI/tTGPQ7C51CToXKmGFfrI45+ihj7Vv0UWYJxXT8TM8MCLw/qNx4h8U3ML3BjZHmCkxWkWfuxjrjIG5up78AAdTAtv4fvLTUdJkVvDeqMgkjjI8qCSTHlzR+iOSFIHGWU+tY8iLIjI6hkYEMDyCPSsTwtZnR/AOlLc3dxL4W1GE2lyssm42DsxWOZGPIQnAIzhSVYYANJrsc+Koe3jzp+8tv8AL8Pn6nfa/wD8S/xboGp4xFP5mmTn08wB4yfo8e0e8ldPXC65dT6l8K9QurhQdRsYHlkC/wDPzavuyPT54sj6iu4jdZI1dDlWAYH1Faxd9UcvMp04zX9df1HUUUVZAUUUUAFFFFABVDXtMi1nRL7TZyRHdQvCWHVcjAYe46j3FX6zPEdpc3+kT2tols7S/Ky3LOqFe/KfMD9KT2Ki7STTsc9aaoNY8O+Hbm+3LerfRQ3CJ/yzuULJIpz2DBvwwaf4Oube28R+IdGtp1ktxKNQtlXkKspPmgMOCBKHOOo3Y9K53SvCd5pHizRY5pVitJbmW7eCC9uZkeRYzyVlZsHJU5HpWrcfDqK41YX73GnCYS+Z5iaVCkmN2ceYuGrKN27/ANbGsfZ89RX0f/DnfUUUVsYBRUVxcQ2yB7iWOJCQoZ2CjJ6DnvUoIYAg5B70AFFFFAGVf+HND1HU4NR1DRtNutQgx5V1Pao8seDkbXIyMH0NWodMsIZLySGytY5L07rpliUGc425c4+bjjnPHFW6KAMRPCXhyPSpdLTw/pC6bM4lktBZRiF3BBDFNuCcgc47Vi+KvDehQ6LpOlWmjabBC2pQfZ4orWNVhbfukZABhWMauMjnmu1rnbtjqHjOyt0/1OlRNdSn/prIrRxr9dhlJ+q+tRU2t3M6useXvp/XyLUfhfQIoEgi0PS0hS3e0WNbSMKsDnLxAYwEY9V6HvUzaBo7EltJ08k2osSTbJzbg5EPT/Vj+709q0qKs0OU8QeA9E1fwwNAgt4tL0wSiUQ2NrbhMjP/ACzeNkI5z93sKboXw88NaT4Wh8PvplvqOnRytOV1GJJ98jEkuQV25yewGK62igDIXwxoC288C6HpYguIVt5oxaR7ZIl+6jDGCoycA8CtZFVFVUUKqjAAGABS0UAFFFFABRRRQAUUUUAFFFFABRRRQBxHxG0eYeT4i0yJ5b2xQpcQRjLXNtnLKB3dTl1/4Ev8VYun31rqNqlzYXEVxA3R42DD6fX2r1GuV8QeCrDU7s6hYO2l6uTlru2UfvvaVOkg9z8w7EVnKLvdHXSrx5VCf3mDRTZdE8VWb7GtNO1JO01vOYCfrG4OPwc0kekeK7mVUTTbCyXktLc3fmD2AVF5P1I/Gp17HR7u/MvvKPiG6ltNHuZLYZu3Aht1zjdM5CRj8WZRXodjoVpbeFYNAdBLZR2a2TKw++gTYc/UVhaF4IEN5BqGv38mpX0LCSKJAYbaBh0Kxg5Yj+85b1GK7OrjHqzmr1U7Rg9jzn4bE3Ok3ekX5y1zaq0nPWVVNtcD6iSLcfeSul+Hty934G0GWYgzfYokkI6F1UK2PbINcTq16nhvxDrCzySRXSfabrTxFA7PdCeNSY0wMFhLHyM/3ScV6J4Y0/8Asnw5pWn7Nn2W1ihK5zgqgHXv061FLTTsZyi4RlfZu69Hr+tvkadFFFbGIUUUUAFFFFABRRRQBg6uf+Kq8Pjv/pB/8cFb1YEo83x3bbukGnSFB7vImT+UY/M1v1EN36mcN5Pz/RBRRRVmhl+I9MbV9Le0R7ZCzBv9JtVuIyAehRiAfzrkPhBpjwaY1+bfQ4VnVoz/AGZbG3+ZZGBDIGKj8MGu11nVbLRbB73U51gt0IXJBJZicBVUcsxPAABJrB8D21wt5rV+2mSaVZ6hNHPDbSFQ+QgVnZFJCFtqkjr685qH8SOiDfsZLp/Wh1lFFFWc5z1/4ssNOvJYNQttVgEbEef/AGdNJC3Gc+YilQPqRW/FIssaSRnKOAwPqDXC+JfD9tJ4x0c291qdk98bhrg2l/NEJCsYIJUNt4+ld1Enlxom5m2gDcxyT7n3qU3d3NakYqMXHqV9TvoNM065vbt9lvbxtK59gM8eprN8I2Vxb6c91qC7dS1CQ3dyv9xmACx/8AQKv/Ac96pb18U6xtjYPoenS5cjlbq5U8L7pGeT2L4/umupqV7z5uiOWPvy5ui2/r+uoUUUVoahRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBg6x/wAjV4e/7eP/AEAVvVg6x/yNXh7/ALeP/QBW9UR3l6/ojOG8vX9EFFFFWaGN4u8RWXhXQZ9V1ESvDEVVY4V3SSuxAVFHckkVmWvjFbfT57vxTplz4eVHRIxdOkvnF87QnlltzcHK4yKu+OPDNv4t8OzaXczy2xZ0liuIvvRSIwZWAPB5HT0J+tYF54K1zUra0fVvFK3OqWN3FeWdwunLHFGyKykNGH+YMHOfmGMDGO+b5r6HVSVFw992d/PbS1une9/kaS+OdMn1vR7OykiuLLUbW4ulvVlASNYcbgQR7nOcYwc1Na+O/DF1YXt7DrFsbWzVXnkO5discK2CMlSejDg1zdp8KraM2wudUlnX7NfwXeIQhna7PzspBwmOcDB+tVbr4TzX2iajZ6hr/nXU+mQaRbzpZBFht4pA4ygf52JHJyPpSvU7GvJhH9p/0/Tt6Hd+HfE+i+JPtX9h6jBe/ZXCTeWTlCenXscHB6HFXtR1C20+LfdTIhIJRCwDSEdlBPJ9q5i6s4PCOseKPFdxcPcf2olpFHZxxYcyRqyIinPzM7OAOBj9aseHPDX7yfVvEttZ3Wu3bB3bYHW2QAbYYy3O1cZJ43MSfTFJvbqYShTXvJ+7p63srrpt3OTvPEPiaLxnZ3UulWOm211arCBdytI0IZxtMuzhSX+XAyASMnmutm1PxRpoaW+0az1G1Xljptw3nKO+InUBvwfJ7AmlSxg1XxN4iiv41mga1gszG3TYQ7N+JL/+OipPD2oyWVwNB1qZjfxZFtPJx9tiHRgehcDhh1yCcYIrKF09XuzlhXSk+aKs3/wO4uleN/DWq3qWdlrFo14w4t3by5Af7pVsEMO6nkela+r6pZaPYSXmqXMVrbJ1eQ457AepPYDk9q57xv4J0/xNF9oEFrFq8XMVzJAsgfH/ACzlU/6yM9Cp6dRg81c0jwjounzW12ml2i30K/LIAXEbEc+XuJ2/hg4rX3tjqao2Uk36f8H/AIBhaBejxl4xm1GawuINO0MeRbJdrtZrlwrNJs/hKoVAydw3tkA131VLTTrOzu7y5tbeOKe8cPOyjHmMBgE++ABn2q3TirbmdWam/d0S/r8wooqG8uoLO2lubuaOC3iUs8kjBVUDuSelUZnOTTR6j8QtPSBxJFp2nyzyFDkB5nVI+fpHNUV7dXHiq7m03SZnh0eFjHe38ZwZSOsMJ/RnHToOckct8OtFvNV0/UbpIp9K0fVryW8JLEXFxCzHy40PWOPbg+pLHbgcn1GytYLG0itbOFILeJQkcaLhVA7AVir1PQMQuefs18K09e/yuJZWkFjaQ2tnCkNvCoSONBhVA7AVPRRW2wJW0QUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnfxJ8Y2XhPxHoE2o2l/JCFmYPAisGJAXaMsORwT7EV6JXP+LfDsfiGXRDLs2WGoJeMGGS4VW+UfVipPsK6CsoKSnJvboY04zU5uWztb7gooorU2CiiigAooooA5jVP+Jl440mxHMOmQvqUwz/y0bdFCD+BnP1Qfh09clcXKaL8QPMuRJHZ6xbw26zFcxi5RpNqluxZWwM8EqAOTz1tTHqa1VZR7W/4f8TB0c58U+If+3cf+QzWlq2m2mrWbWt/CJYiQw5IKsOjKRyrDsRyKzPCw33WvztzJLqLgn2SONAPyUfmazPiPqeq+HbS18QaTDLe29o4S/sE5MsDEDeg7OhwfcFs9BiFbk121/Mww9P2vud7/AJlyKXW9CIiuYJdb08HCXERUXUY7CRDgPj+8pB9V71N/wlmnoM3Fvq1v/wBddMuAP++ghH61b8NeINL8S6VDqGi3kVzbSqGyp+ZM9mHVTwRg+latNRf2XoJ0p03y3t6mD/wl2h/8/wB/5Cf/AOJpD4s0xzttBe3kn9y2s5X/ADO3C/iRW/WVq3iHSdIaZdTv4LZoohM6yNghCSqnHckggAckjih8y3a+7/ggoVZOyf4f8EpPqGv3/wAmnaSunIf+XjUpFYj3EUbHP0LLXCa54ffxT4zt9Jl1K41izt0b+2HmUCG3O5GSOJVwqyMAynqwRs7gcZ69W1zxRkp9o0DRW6MVAvrgewPECn3y/wDuGug0bSrLRrBLPTbdYLdSWwCSWYnJZieWYnkkkkmp5ObfU3jTVF80neX4L9Lrp/SLiKqIqIoVVGAAMACnUUVsZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVh+Odcbwz4O1nW44BcNp9rJciEttDlVzjODityqWtaZaa1pF7pmpRedZXkLwTR5I3IwwRkcjg9aAPPp/itDY6pp0WpWPlWE/hv/hIZ543LtEARmMLj5uvXI+lW/8AhZlhJqViUS6t9Omsru8ZbuwmhmkSBEcvHux8uG6kc9qgt/g9oi2l7Deanrd+9xpR0WKa6njL2tqf4I8RgZ6fMwY8da29X+H+lapPp8txcXytZaZPpUex0AMUyKjMcqfmAUYIwM9jQBm6T8WNB1U3K21nrSyRacuqxJLYtG1zbEgeZFn7wywGeB3zjmobP4x+FrnShfL/AGiP+Jimlm3S1MsondGdQFjLbgQpxtzzxS6p8IPD2p2FvZ3VzqflQaHFoCbZkB8iOSORXPyf6zdEv+yeQV5qDRPhf4cWcT22s6hfz2+sQatI/nwH/SIY2jVWCRgBcMcqADnGCBxQBqr8TtA+1fZJV1CC/wDtNnafZJrZkm8y5TfECh5Hyhs5+7tbPSuh1HxDYaf4i0fRLlpBfaqs7WwVMqRCqs+T24YVyOq+BEuvjNYeNr5rKKxsNO8iMGQiSS4LMA7gjbtVHYA5zk+wrc8Y+CrLxTqOj6hPfanp9/pTSm3uNPnET7ZFCuhJB4IUeh44IoAydI+LHhzV7vSrbTk1S4l1K2S7h8qxkcJC0zQ75CoIjUMjZZsADnNUrn4u6Rc6DrN1o0V19pg0q71PT2vLdo4b5IFOWjOcldwGQcHBz71p+CvhlovhC7tLjTp7+drbS/7JVbl0ZWh855ssAgy25yPTGOO9UbL4P6BaWl1a/bNWmtpNPuNLtY5p1YWFvPnzFh+TrzwX3nAA6cUAZ6/F+0k0GF5IpNO1jyLG4eK9tHEckdw6pviAOSu4lQT04yKsaX8Rrq61eazuls7cL4pm0CICN2MsaQhwcg4Vzk8njA6UyD4S+G5hc2Nzreq6hfxRWcW+e5iae2t4ZPMhiCrGAqFlzyuTg81qWngDw82tzS2+o3Ut7a662vzQrPGxjuJYgmxlC5CFeQDz3yRQBBpfxh8L6hdW0eNTtba5iuZoby6s3jgkFuGMwV+5UIxOOOMZzxTovi94Z/sy9vbsajZC2torxYbm1Ky3MMrbIniUZ3BmwB0OTzinWvwm8PQ6boOnySX9xaaOL5Yo5ZExMt4JFlWTCjIxIwG3bjjOay9V+D2nnw3qVraXV9qWpy2lvZ2k+pXmw20MMgeOON44/lAIzkqxJAznmgDTm+LXh23srua7h1K2uba7jsWsprfbOZ5E3qgGcfdySSQB61EfjD4aew0+5s4dXvZL2O4eO2tbJpJl8ggSqyj7pGe5x78isTw/8HpLvTNVPjfUZLnVb3Uo9RjubSUM9u8cflqd7RqrkjOQYwvP3eK6vS/hvplhqGnXpv8AUri5sYbmBGlaIB1n27yVSNRkbRjaAPUGgDpfDetWXiPQbHWNLkaSyvYlmiZlKnB9QehrSrH8IeH7Xwr4Z07Q9PknktLGIRRvOwLkZ7kADPPYCtigDgfFmkXXjTVdW0VdUuNPsbO1hGIlVhJO7F8uCMkKqJjBByxIIIBrX8A3WtyaVLZeJ7Z01KwkNu11txHeoPuzL9R1HY/WnaIQvjbxNG3DmO0lCnqUKOoP0yjD8DXS1EVrzHTUqWj7O2mj/BX+8wfCf/MZ/wCwlN/Stq4mjtreWeZtkUal3b0AGSaxfCf/ADGf+wlN/Stq4hS4t5YZVDRyKUYHuCMGin8Jx0fhVzz3w34Sj1HSIddgX+xtbu7h7+Ce3jAeKKRsrDIOjqUxuU9CTjBANbx1DxRpoxfaRbavEP8AltpkwikP/bGUgD8JDUvw4nafwFoLSP5jpZxxM4xhyg27h7Hbn8a6OiMdNDsq1XztSV7P+vM5V9b8QaiPL0bw9LZ7uPtWrSJGie4jjZnb6HaD60zR/A9lba62vavM+ra++3/SplCJFtBAEcQ+VQATgnLcn5uTXW0U+XuZ+2aTUNL9goooqjIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMbxpa31/4O1600limpXFhPFasG2kStGwQ57fMRzXh/wh8Pa/a6/Fc+HtHfw8tv4WtNOu21TT5I4Z9RSYF5DGGQy/IHG8HGWHJ6H6JooA+e/2kPDXjvX/AAakP2W31W1tYEkkj0sSxySXRnA3Lb4kLosWRjeMF2Y/dAr0n4rXHiNPhbeT6FFdW/iJvsuI9OzcPGxni80IduWAUvztHAJwK7uigDwSxtPHOmeJ7dl1LxVe2dt4rSxVLlN8cmnvCWeV8RjcobAD52r0GDWZ8P8AxbrqeOvDFt4i1XWUvZk1SfXILsbbRPLGYjDxt8sDnKkjpzmvo6siw8MaBp1xdT6foel2s92GFxJBaRo0wY5IcgZbJ65oA8qtF8RTfCTxX4v8PQ3A8TeJJvt9usaBpktAypEiDuwtwWA/vNXKRQ6/preNbvRdO8ZyQahqGlxx3lzFcR3ZhFuVklYBPMkVWABVADyOQAa+lY0SKNY41VEUBVVRgADoAKdQB8x3viD4jaF4L0O7a51KTUL2/vNAjgv4zDK7S5+yzhWG4lSpOTnIxnNfSWlW0llpdpaz3Ml1NDCkb3Ev35WAALn3J5/Gi806yvZ7Wa8s7a4mtX823eWJXaF8Y3ISPlOO4q1QAUUUUAFFFFAHLa+iWnjXw5qGWj+0GbT5HDEK+UMiKw6dUbBPc4/irqaz9d0iz13S5rDUYvMgkwcqdrIwOVdWHKsDggjoRWf4Ivrq80PydTYSahYzPZXEo6SvGceZ/wACXa2OxYjtUrR2NZe9BPtoO8J/8xn/ALCU39KqeNTLqFxpXh+C4ltxqckhuZIW2uLaNcyBT2LM0aZHIDnBzirOgL5HiHxJAh/dNPFcAejPEob89mfqTVXRWGreNdW1NATbafGNLgfs0m7fOR7Z8pPrG1RH4bGeF0XN2v8Afsvx1OltLeGztYba1jWK3hRY441GAqgYAHsAKloorUW4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcnLax6T8QLSezXy01iCZbuNSQryxhCkuOm7bvUnqRt9K6ysvXtBsNciiW/SXzISWhmhmeKSJj/ABKykEGlJXNKclF67M830C1vdH+JXjfVdZ1a9bTNOi+2CIzv5bJIrsuVzghFV1APQgY6V3/gWxm07wlplvdRiO5MXmzIP4ZHJdx74Zjz361hr4Xj1LUb+0v9f1a8jiWJJoWSGPzE5dFd1jDOBluOOpznrXc1jRp8i+/8zKlThRpuEHe7b/y3CiiitxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYOj/wDI1eIf+3f/ANANb1YOj/8AI1eIf+3f/wBANb1RT2+b/MzpbfN/mwoooqzQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzHwbrPiG9+K3iiwubWzh0+2cea4Rt5XBEGDuwCynceOx6V6dVG20u1ttXvtShUrdXiRRzHPDCPdtOPX5yPwFXqypQcFZu+rMaFN04tSd9X+YUUUVqbBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfNPgPx34ytPCOr+NNd/trVNMsorkxhprRbWV1l2Ku1V85cdSx4+U+1dPbfFvxF9ljt7zSNMhvrvULWzs715WjtCs6SNvcZLceUwAyN2RjHNegeKdd8IfDnw3nV/sOlaTIzIttDbgLKzHLBY1HzZySePUmsfxdd+A/AdhNaaj4Ygi0u8AlvPseieZbKobaHnKJtHJ43c+lAHKeOvi5rfhe3QQp4f1O8tbVrq/itHldNoneMFZCQFztxj52DZGMDJ6/wCFGsXur6v44N5czzQwax5dukj7hDGYY22L6DJP51n6hqfwzbX7bw3J4csb66to4kijg0L7RFBFN8y4ZYyqI27PYcknvXfTjRfDNhf6jJHY6ZaZ+0Xc6osSsQAN7kDk4AGT6CgDy62+Msk9po5S1sDe3l9qFrPbrPl4Vt1kZWI6jdsXr/eqS1+JXie60bwjM+naFZXPidt1pNLcyvBBGsBkYy/KuHbGFUE/U1uWuoeA73w3F400zw9b6hDezSGOaz0bzbqeTc8bnaE3knDgk9s9jVS58bfD2+8E6QG02O/0m7le2stIXS/NffCDvUW+35dgBzxgDp1FAHGP8Tde1TUfD2uaY9lYRT+Hr28ms764cWpeGcKWBGM52naeOGzz0NfxF8RdT1Wxvb2wa+0uWW20K7CrdNhBcSjeirwACOCR94da9dtLHwT4x8O6brf9l6JqOlLb5tZ7myjZYYh1A3r8gBHI4xj2qzOPBt7PK048PXE08sNvIX8l2kkQ7okOeSwPKjqOooA88i+IOsWt3f2elWkFzd3XjC40WI6hdSGOMLArhhgEquf4AMdemc1Uh+MGvXFnb2y6fo1rq0a6i91LczOLZvsjhWWLoctnPJ4Azg16mYPCkWrfZTFoaamLr7b5RWITC4dcedt+95hHG7qR3rPuLXwje+Im8KTaBp9zPFCdWkjaxieGNnkK7zkcSMwY9MnaSTQB57rvxo1NNPmv9K0zT7eC00K21meLUJmEspn+7HEBjIHdj1yOBV2T4s61N45l0qw0O3k06zvLa0uy7lZgsqqTKCSFCjeMKQd2Oo6U7xrpXgL4g+NDp2patI5sNLW4mNs1t9mWATMpUzFDJG2eGCsvGK75bLwbrN3Zaqtt4f1C5RxFa3myGV1ZeQqPycj0B4oA4LwP8UPEGuaz4RGpaXpcOk+I3v4YGt5pGmie235Lgjbg7CMDPrntXsdZGm6RoAjspNM0/Swlg8v2VreGPFuz5EnllR8hbLbsYzk5rXoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4D43+Ftb8a+Abzw7oH9mo980fmzXszxiNUkSQbQqNuJKY5x1rK+Jvhvx34v03TNOgHh2LS2VZNWs5LydftLhsiISLFnyuFzwrHkcDr6pRQB414l+Gmva34x0/VYIfDukeVPaTy6jZTXAvAIo1DwquAhTIIBOPlxlc5z6ENAl0ufU9S0W4vbvU7kMUt9S1S4a1DM27AU7xGOw2rwOBxXR0UAeR+BPBvjLwt8I4fCfl+G7m6gaSLL3dwIp4JWkZwWWNWjcF8AgHgdj0ytH+FfijQ7Dwje2F9o82t6Bd300VpK0qWixXS7TGsm0yHb1BYZOTmvcaKAPOdB+H1zonwLn8DQXcE18+mXVoJ3ysfmziQ56E7Q0nXGcDp2rhr/4GXT6dqkdlB4fgup9P0q3tpVQqYp7eRWnfIjyu8AgEct3xXv9FAHzdN4X1pfilDZWujPdW/8Awl412XVns5o3SHYcxGV08tkXOF2uc8fKOa9I8NeGdQ1fQfG17qom03VvFDzwpuH7y1t1RobcYz1C5fju5r0migDwOy+E3i2C1vPs7eF9NuT4dg0WA2weVJJI5xIZZFeIAF1BG7DEEg84zWbrPw18QeGfAXiS9t4ll1waraatpEOltLePFOm1Dncikggvk4xjk4HFfR1FAHO/Dzw4nhLwVpGiKweS1gAmkBz5kx+aR/xcsfxroqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3906=[""].join("\n");
var outline_f3_52_3906=null;
var title_f3_52_3907="Hutchinson teeth";
var content_f3_52_3907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Hutchinson teeth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hutchinson teeth are smaller and more widely spaced than normal and are notched on their biting surfaces. The sides of the teeth taper toward the biting edges. The upper central incisors of the permanent (not the deciduous) teeth are most often affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robinson HBG, Miller AS. Colby, Kerr, and Robinson's Color Atlas of Oral Pathology. JB Lippincott, Philadelphia 1990. Copyright &copy; 1990 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3907=[""].join("\n");
var outline_f3_52_3907=null;
var title_f3_52_3908="Lateral canthal rhytides";
var content_f3_52_3908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Lateral canthal rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple wrinkles are present lateral to the eye (left). The wrinkles are more prominent during smiling (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3908=[""].join("\n");
var outline_f3_52_3908=null;
var title_f3_52_3909="Pneumococcal conjugate vaccine (10-valent): Drug information";
var content_f3_52_3909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pneumococcal conjugate vaccine (10-valent): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13739550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synflorix&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13739552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13739610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing established for infants and children.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13739609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     I.M.:",
"     <i>",
"      Infants 6 weeks to 6 months:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Three-dose primary series: 0.5 mL/dose for 3 doses, followed by a booster dose (for a total of 4 doses). The first dose may be given as young as 6 weeks of age, but is typically given at 2 months of age. The second and third doses should be administered at 4- and 6 months of age. The booster dose should be administered at 12-15 months; allow a minimum interval of 1 month between each of the first 3 doses, and 6 months between dose 3 and the booster dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Two-dose primary series: 0.5 mL/dose for 2 doses, followed by a booster dose (for a total of 3 doses). The first dose may be given as young as 6 weeks of age, but is typically given at 2 months of age. The second dose should be administered at 4 months of age. The booster dose should be administered at 11-12 months; allow a minimum interval of 2 months between doses 1 and 2, and 6 months between doses 2 and the booster dose.",
"     <b>",
"      Note:",
"     </b>",
"     May not provide optimal protection particularly in infants at high risk for pneumococcal disease (eg, asplenia, sickle-cell disease, immunosuppressed).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Previously unvaccinated Older Infants and Children:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Children 7-11 months:",
"     </i>",
"     0.5 mL/dose for a total of 3 doses; 2 doses administered at least 1 month apart, followed by a third dose administered after 1 year of age, separated from the second dose by at least 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Children 12-23 months:",
"     </i>",
"     0.5 mL/dose for a total of 2 doses, administered at least 2 months apart (manufacturer labeling suggests that a booster dose may be necessary for optimal protection).",
"     <b>",
"      Note:",
"     </b>",
"     Two-dose regimen in children 12-23 months of age at high risk for pneumococcal disease (eg, asplenia, sickle-cell disease, immunosuppressed) may not provide optimal protection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Children &ge;24 months to &lt;6 years:",
"     </i>",
"     0.5 mL/dose for a total of 2 doses, administered at least 2 months apart",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13739632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13739639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Synflorix&trade;: 1 mcg of each capsular saccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3 mcg each of serotypes 4, 18C, and 19F (bound to protein D [from nontypeable",
"     <i>",
"      H. Influenzae",
"     </i>",
"     ], tetanus toxoid, or diphtheria toxoid) per 0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in packaging]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13739638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13739633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well before use. Administer by I.M. injection only, preferably into the anterolateral aspect of the thigh in infants and into the deltoid in children. Do not administer intravenously or intradermally. Subcutaneous administration has not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rule out bleeding disorders in patients &lt;2 years of age prior to immunization. NACI recommends that patients with bleeding disorders receive all routine recommended vaccinations according to schedule.  Bleeding disorders should be corrected prior to immunization (when possible) or immunization should be scheduled shortly after antihemophilia or other similar therapy. In patients with bleeding disorder that cannot be corrected, I.M. gluteal injections should be avoided (if possible). When immunizing patients with bleeding disorders, a fine-gauge needle of the appropriate length can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 5 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy (eg, aspirin, warfarin, heparin) may be immunized via intramuscular injection without discontinuation of their anticoagulant therapy (NACI, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13739554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunization of infants and children against",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     infection and invasive diseases caused by serotypes included in the vaccine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13739549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Synflorix&trade; may be confused with Synagis&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13739580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not always defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Irritability (51% to 66%), drowsiness (33% to 58%), fever (&ge;38&deg;C rectally ages &lt;2 years: 26% to 37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Loss of appetite (17% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions: Pain (23% to 57%), redness (38% to 53%), swelling (28% to 37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (&gt;39&deg;C rectally age &lt;2 years: 2% to 3%; &ge;38&deg;C rectally age 2-5 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site induration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal crying; allergic reactions (allergic dermatitis, atopic dermatitis, eczema); apnea in premature infants &le;28 weeks gestation, diarrhea, fever (&gt;39&deg;C rectally age 2-5 years; &gt;40&deg;C rectally age &lt;2 years), injection site hematoma, injection site hemorrhage, injection site nodule, rash, seizure (febrile and nonfebrile), urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13739557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the vaccine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13739558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Apnea: Apnea has been reported following I.M. vaccine administration in premature infants; consider risk versus benefit in infants born prematurely. Infants born &le;28 weeks gestation, particularly those with a prior history of respiratory immaturity, may require respiratory function monitoring for 2-3 days after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pneumococcal infections: Not to be used to treat pneumococcal infections. Safety and efficacy in children at increased risk for pneumococcal infection (eg, sickle cell disease, splenic dysfunction, HIV infection, malignancy, nephrotic syndrome) has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acetaminophen: Administration prior to or immediately following vaccination may reduce incidence and severity of vaccine related fever, although it has been reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination, decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the Canadian National Advisory Committee on Immunization (NACI) recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, HIV, patients receiving chemo/radiation therapy, or other immunosuppressive therapy including high dose corticosteroids); may have a reduced response to vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Routine immunization: Antibody response is provided only against pneumococcal serotypes included in the vaccine. Antibody response may also be observed to diphtheria toxoid, tetanus toxoid, and protein D (derived from nontypeable",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     ); however, recommended routine administration schedules for diphtheria, tetanus, or",
"     <i>",
"      H. influenzae",
"     </i>",
"     type b vaccines should still be followed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13769083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13769081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13739555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Inactivated vaccines have not been shown to cause increased risks to the fetus (CDC, 2011). This product is indicated for use in infants and toddlers.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13739556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13739637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consider respiratory monitoring for 48-72 hours in premature infants (born &le;28 weeks gestation) due to risk of apnea. Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13739599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunization against invasive disease caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     capsular serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, all which are individually conjugated to a carrier protein (protein D, tetanus toxoid, or diphtheria toxoid); the aluminum salt, a mineral adjuvant, enhances the antibody response.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006. Available at file://www.phac-aspc.gc.ca/publicat/cig-gci/index.html",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3909/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Croxtall JD and Keating GM, &ldquo;Pneumococcal Polysaccharide Protein D-Conjugate Vaccine (Synflorix&trade;; PHiD-CV),&rdquo;",
"      <i>",
"       Pediatr Drugs",
"      </i>",
"      , 2009, 11(5):349-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3909/abstract-text/19725600/pubmed\" id=\"19725600\" target=\"_blank\">",
"        19725600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy TM, Faden H, Bakaletz LO, et al, &ldquo;Nontypeable",
"      <i>",
"       Haemophilus influenza",
"      </i>",
"      as a Pathogen in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(1):43-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3909/abstract-text/19057458/pubmed\" id=\"19057458\" target=\"_blank\">",
"        19057458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Peeters P, Chrobok V, et al, &ldquo;Pneumococcal Capsular Polysaccharides Conjugated to Protein D for Prevention of Acute Otitis Media Caused by Both Streptococcus Pneumoniae and Non-Typable Haemophilus Influenzae: A Randomised Double-Blind Efficacy Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9512):740-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3909/abstract-text/16517274/pubmed\" id=\"16517274\" target=\"_blank\">",
"        16517274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3909/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17136 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3909=[""].join("\n");
var outline_f3_52_3909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739550\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739552\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739610\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739609\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739632\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739639\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739638\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739633\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739554\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739549\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739580\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739557\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739558\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769083\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769081\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739555\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739556\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739637\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13739599\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_52_3910="Magnetic resonance imaging of the thorax";
var content_f3_52_3910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Magnetic resonance imaging of the thorax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Daniel Chernoff, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Paul Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Nestor L Muller, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3910/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/52/3910/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has become an important tool in assessment of diseases of the heart, mediastinum, pleura, and chest wall. Strengths of MRI include excellent tissue contrast, multiplanar imaging capability, sensitivity to blood flow, and lack of ionizing radiation. Application of MRI in intrinsic lung disease has been limited by signal loss from physiologic lung motion, a paucity of protons, and magnetic field inhomogeneities induced by the",
"    <span class=\"nowrap\">",
"     air/tissue",
"    </span>",
"    interfaces in lung, problems that may be overcome in the future with improvements in imaging hardware and pulse sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The clinical indications for thoracic MRI will be presented here; technical aspects of MRI are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chest wall and diaphragm",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is an excellent imaging modality for assessment of primary chest wall tumors, chest wall infections, and chest wall or diaphragmatic extension of intrathoracic masses. On T1-weighted images, particularly with contrast enhancement, the extent of invasion of normal tissues can usually be established (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74264 graphicRef53251 graphicRef65039 \" href=\"UTD.htm?0/25/407\">",
"     image 1A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78372 graphicRef56298 graphicRef64987 graphicRef75753 \" href=\"UTD.htm?5/4/5193\">",
"     image 2A-D",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61630 graphicRef67306 \" href=\"UTD.htm?2/10/2212\">",
"     image 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66436 graphicRef78690 graphicRef59287 \" href=\"UTD.htm?4/34/4648\">",
"     image 4A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular encasement or invasion is frequently well visualized in T1-weighted images. GRE (bright blood) sequences can sometimes demonstrate vascular invasion more clearly, and can regularly demonstrate the vascular supply of tumors. T2-weighted sequences play a secondary role in evaluation of the chest wall. Their primary use is in demonstrating areas of cystic degeneration, inflammation, and edema.",
"   </p>",
"   <p>",
"    The ability of MRI to image in arbitrary planes of section used to be an advantage over CT in assessment of the lung apices, diaphragm, and spinal column. However, the newer generation of multislice CT scanners, which have enabled clinically practical imaging of the entire thorax at submillimeter resolution, has considerably narrowed this advantage. The ability to manipulate the relative signal intensities of normal and abnormal tissue through appropriate use of MRI pulse sequences remains a relative advantage of MRI over CT. Although cortical destruction is better demonstrated by CT, bone marrow involvement by tumor is better visualized on MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pleura",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is comparable to CT in evaluating pleural disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. MRI may also be better at demonstrating extension of pleural lesions into the chest wall, mediastinum, and diaphragm. Imaging in sagittal and coronal planes is especially helpful in assessing the extent of malignant tumors, such as mesothelioma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66436 graphicRef78690 graphicRef59287 \" href=\"UTD.htm?4/34/4648\">",
"     image 4A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. MRI can potentially characterize pleural effusions, and differentiate between exudates, transudates, and hemothoraces [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/11\">",
"     11",
"    </a>",
"    ]. However, CT remains advantageous for visualizing calcification within pleural lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Paravertebral masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is well suited for evaluation of paraspinal masses because of its multiplanar imaging capability. It can clearly demonstrate the craniocaudal extent of disease, involvement of the vertebral column,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extension into the spinal canal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69331 graphicRef76000 \" href=\"UTD.htm?10/59/11187\">",
"     image 5A-B",
"    </a>",
"    ). CT evaluation of intraspinal extent of paraspinal masses can suffer from beam-hardening artifact produced by the high attenuation vertebral column; MRI has no similar limitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mediastinum and hila",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is useful in evaluating mediastinal and hilar disease, though it cannot match the superior spatial resolution of CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63277 graphicRef75079 \" href=\"UTD.htm?20/8/20611\">",
"     image 6A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78631 graphicRef56669 \" href=\"UTD.htm?26/28/27075\">",
"     image 7A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59535 \" href=\"UTD.htm?30/2/30767\">",
"     image 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. An advantage of MRI includes its multiplanar capability which enhances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mediastinal tumor staging. Coronal and sagittal sections reliably detect subcarinal and aorticopulmonary lymph node masses.",
"     </li>",
"     <li>",
"      Assessment of local tumor extension. Lack of signal from flowing blood in spin echo images permits distinction of solid tissue (such as lymph nodes) from blood vessels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of MRI in lymphoma staging is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], although the generally greater spatial resolution of CT makes it superior to MRI for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/15\">",
"     15",
"    </a>",
"    ]. MRI can also be valuable in lesion characterization, as with distinguishing hematoma or fibrosis from neoplasm.",
"   </p>",
"   <p>",
"    Both MRI and CT have been partially replaced by positron emission tomography (PET) with fluorodeoxyglucose (FDG) in mediastinal tumor staging [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/16\">",
"     16",
"    </a>",
"    ]. Unlike MRI and CT, which are primarily anatomic imaging techniques, FDG-PET can identify malignant tumors based on their high glucose utilization, in addition to their appearance. Integrated PET-CT scanners provide additional advantages by combining functional information from PET with anatomic information from CT in a single examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lung parenchyma",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI currently plays only a limited role in evaluation of the lung. This is the result of many factors, including poorer spatial resolution than CT, low proton density, long imaging times causing physiologic motion artifact, and magnetic susceptibility-induced signal loss at the border between the alveolar wall and alveolar gas. In interstitial lung disease, MRI may find a niche in distinguishing active disease (high signal on T2-weighted images) from inactive",
"    <span class=\"nowrap\">",
"     disease/fibrosis",
"    </span>",
"    (low T2 signal intensity) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Novel lung techniques are being investigated. Imaging of inhaled hyperpolarized helium or xenon is being studied as a way to determine the apparent diffusion coefficient of helium or xenon and regional lung ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Blood tagging techniques with gadolinium or arterial spin labeling are being studied as a way to evaluate regional lung perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/21\">",
"     21",
"    </a>",
"    ]. Assessment of lung morphology with balanced steady-state free precession MR imaging has been shown to be inferior to CT in imaging lung parenchymal disease, yet it represents an alternative radiation-free imaging modality in patients with pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/22\">",
"     22",
"    </a>",
"    ]. These techniques are not widely available in clinical practice at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bronchogenic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is comparable to CT in staging lung cancer complicated by chest wall, diaphragm, pleura, or mediastinal involvement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74264 graphicRef53251 graphicRef65039 \" href=\"UTD.htm?0/25/407\">",
"     image 1A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78372 graphicRef56298 graphicRef64987 graphicRef75753 \" href=\"UTD.htm?5/4/5193\">",
"     image 2A-D",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61630 graphicRef67306 \" href=\"UTD.htm?2/10/2212\">",
"     image 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78631 graphicRef56669 \" href=\"UTD.htm?26/28/27075\">",
"     image 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. MRI may have greater specificity in the diagnosis of adrenal masses found on staging examinations in patients with lung cancer. However, MRI currently plays only an adjunctive role to CT for staging of lung cancer, because of higher cost, poorer spatial resolution, longer examination duration, less availability, and because CT can diagnose and stage lung cancer in a single examination. The use of MRI is reserved for those cases in which the tumor is suspected to be unresectable, but CT findings are not definitive (as in Pancoast [superior sulcus] tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/26\">",
"     26",
"    </a>",
"    ] or cases in which the patient has a history of reaction to iodinated contrast agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=see_link\">",
"     \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is an excellent imaging tool for the diagnosis of aneurysm and aortic dissection. Spin echo sequences and other \"black blood\" techniques, can detect the medio-intimal flap and determine the type and extent of dissection. Gradient echo sequences can differentiate the true lumen (with higher flow and higher signal intensity) from the false lumen (with lower flow and lower signal intensity). Contrast-enhanced MR angiography is widely used for evaluation of aortic disease as technical capabilities of scanners have improved. In the past, transesophageal echocardiography and MRI have been considered the two methods of choice for diagnosing dissections. However, advances in CT technology and the greater availability of multislice CT have caused this latter modality to assume a primary role in imaging of aortic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary artery dilation, a finding suggestive of pulmonary artery hypertension, can be imaged well by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/27\">",
"     27",
"    </a>",
"    ]. MR angiography is able to detect vascular intraluminal filling defects, but pulmonary emboli are currently better visualized using CT [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/28\">",
"     28",
"    </a>",
"    ]. New MR sequences may further facilitate visualization of pulmonary emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/29\">",
"     29",
"    </a>",
"    ]. The use of intravenous gadolinium (as a first pass perfusion agent) and arterial spin labeling (endogenous perfusion assessment without injection) may expand the role of MRI in the diagnosis of pulmonary vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3910/abstract/1,30-34\">",
"     1,30-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI is an important tool in the evaluation of chest structures. Although CT plays a primary role in noncardiac chest imaging, the multiplanar capabilities and excellent tissue contrast of MRI make it equal or&nbsp;superior to CT in several areas including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessment of the apices, diaphragm, and spinal column",
"     </li>",
"     <li>",
"      Evaluation of pleural disease",
"     </li>",
"     <li>",
"      Evaluation of paraspinal masses",
"     </li>",
"     <li>",
"      Assessment of local tumor extension, particularly chest wall invasion, and delineation of blood vessel invasion",
"     </li>",
"     <li>",
"      Metastatic invasion of the bone marrow",
"     </li>",
"     <li>",
"      Certain aspects of staging of bronchogenic carcinoma; however, MRI still plays an adjunctive role to CT in this setting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT remains the preferred technique in the following settings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evaluation of lung parenchymal disease",
"     </li>",
"     <li>",
"      Evaluation of mediastinal lymph nodes and lymphoma staging",
"     </li>",
"     <li>",
"      Assessment of cortical bone metastases",
"     </li>",
"     <li>",
"      Staging of bronchogenic carcinoma (in most cases)",
"     </li>",
"     <li>",
"      Aortic aneurysms and dissection",
"     </li>",
"     <li>",
"      Detection of pulmonary embolism",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/1\">",
"      Vogt FM, Goyen M, Debatin JF. MR angiography of the chest. Radiol Clin North Am 2003; 41:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/2\">",
"      Hatabu H, Stock KW, Sher S, et al. Magnetic resonance imaging of the thorax. Past, present, and future. Radiol Clin North Am 2000; 38:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/3\">",
"      Fortier M, Mayo JR, Swensen SJ, et al. MR imaging of chest wall lesions. Radiographics 1994; 14:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/4\">",
"      Kuhlman JE, Bouchardy L, Fishman EK, Zerhouni EA. CT and MR imaging evaluation of chest wall disorders. Radiographics 1994; 14:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/5\">",
"      Padovani B, Mouroux J, Seksik L, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology 1993; 187:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/6\">",
"      Schmutz GR, Fisch-Ponsot C, Regent D, Sylvestre J. Computed tomography (CT) and magnetic resonance imaging (MRI) of pleural masses. Crit Rev Diagn Imaging 1993; 34:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/7\">",
"      McLoud TC. CT and MR in pleural disease. Clin Chest Med 1998; 19:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/8\">",
"      Hierholzer J, Luo L, Bittner RC, et al. MRI and CT in the differential diagnosis of pleural disease. Chest 2000; 118:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/9\">",
"      Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 159:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/10\">",
"      Heelan RT. CT and MR imaging in the evaluation of pleural masses. Chest Surg Clin N Am 1994; 4:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/11\">",
"      Davis SD, Henschke CI, Yankelevitz DF, et al. MR imaging of pleural effusions. J Comput Assist Tomogr 1990; 14:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/12\">",
"      Link KM, Samuels LJ, Reed JC, et al. Magnetic resonance imaging of the mediastinum. J Thorac Imaging 1993; 8:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/13\">",
"      Grover FL. The role of CT and MRI in staging of the mediastinum. Chest 1994; 106:391S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/14\">",
"      Carlsen SE, Bergin CJ, Hoppe RT. MR imaging to detect chest wall and pleural involvement in patients with lymphoma: effect on radiation therapy planning. AJR Am J Roentgenol 1993; 160:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/15\">",
"      Hoane BR, Shields AF, Porter BA, Borrow JW. Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging. Am J Hematol 1994; 47:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/16\">",
"      Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/17\">",
"      M&uuml;ller NL, Mayo JR, Zwirewich CV. Value of MR imaging in the evaluation of chronic infiltrative lung diseases: comparison with CT. AJR Am J Roentgenol 1992; 158:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/18\">",
"      Fain SB, Korosec FR, Holmes JH, et al. Functional lung imaging using hyperpolarized gas MRI. J Magn Reson Imaging 2007; 25:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/19\">",
"      van Beek EJ, Wild JM. Hyperpolarized 3-helium magnetic resonance imaging to probe lung function. Proc Am Thorac Soc 2005; 2:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/20\">",
"      Driehuys B, Martinez-Jimenez S, Cleveland ZI, et al. Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients. Radiology 2012; 262:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/21\">",
"      Bolar DS, Levin DL, Hopkins SR, et al. Quantification of regional pulmonary blood flow using ASL-FAIRER. Magn Reson Med 2006; 55:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/22\">",
"      Rajaram S, Swift AJ, Capener D, et al. Lung morphology assessment with balanced steady-state free precession MR imaging compared with CT. Radiology 2012; 263:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/23\">",
"      Mayr B, Lenhard M, Fink U, et al. Preoperative evaluation of bronchogenic carcinoma: value of MR in T- and N-staging. Eur J Radiol 1992; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/24\">",
"      Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/25\">",
"      Templeton PA, Caskey CI, Zerhouni EA. Current uses of CT and MR imaging in the staging of lung cancer. Radiol Clin North Am 1990; 28:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/26\">",
"      Bruzzi JF, Komaki R, Walsh GL, et al. Imaging of non-small cell lung cancer of the superior sulcus: part 1: anatomy, clinical manifestations, and management. Radiographics 2008; 28:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/27\">",
"      Kr&uuml;ger S, Haage P, Hoffmann R, et al. Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography. Chest 2001; 120:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/28\">",
"      Finn JP, Baskaran V, Carr JC, et al. Thorax: low-dose contrast-enhanced three-dimensional MR angiography with subsecond temporal resolution--initial results. Radiology 2002; 224:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/29\">",
"      Kalb B, Sharma P, Tigges S, et al. MR imaging of pulmonary embolism: diagnostic accuracy of contrast-enhanced 3D MR pulmonary angiography, contrast-enhanced low-flip angle 3D GRE, and nonenhanced free-induction FISP sequences. Radiology 2012; 263:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/30\">",
"      van Beek EJ, Wild JM, Fink C, et al. MRI for the diagnosis of pulmonary embolism. J Magn Reson Imaging 2003; 18:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/31\">",
"      Ley S, Kreitner KF, Fink C, et al. Assessment of pulmonary hypertension by CT and MR imaging. Eur Radiol 2004; 14:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/32\">",
"      Levin DL, Chen Q, Zhang M, et al. Evaluation of regional pulmonary perfusion using ultrafast magnetic resonance imaging. Magn Reson Med 2001; 46:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/33\">",
"      Uematsu H, Levin DL, Hatabu H. Quantification of pulmonary perfusion with MR imaging: recent advances. Eur J Radiol 2001; 37:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3910/abstract/34\">",
"      Mai VM, Liu B, Polzin JA, et al. Ventilation-perfusion ratio of signal intensity in human lung using oxygen-enhanced and arterial spin labeling techniques. Magn Reson Med 2002; 48:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6976 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3910=[""].join("\n");
var outline_f3_52_3910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chest wall and diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pleura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Paravertebral masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mediastinum and hila",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lung parenchyma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bronchogenic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6976|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/20/37199\" title=\"diagnostic image 1A\">",
"      Lung cancer extension CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/3/7216\" title=\"diagnostic image 1B\">",
"      Lung cancer extension MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/41/18079\" title=\"diagnostic image 1C\">",
"      Lung cancer extension MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/29/41439\" title=\"diagnostic image 2A\">",
"      Pancoast tumor CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/0/5\" title=\"diagnostic image 2B\">",
"      Pancoast tumor MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/25/23967\" title=\"diagnostic image 2C\">",
"      Pancoast tumor MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/57/25488\" title=\"diagnostic image 2D\">",
"      Pancoast tumor MRI III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/56/38799\" title=\"diagnostic image 3A\">",
"      Chest wall extension MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/54/40815\" title=\"diagnostic image 3B\">",
"      Chest wall extension MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/8/41088\" title=\"diagnostic image 4A\">",
"      Mesothelioma MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/27/40383\" title=\"diagnostic image 4B\">",
"      Mesothelioma MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/2/25632\" title=\"diagnostic image 4C\">",
"      Mesothelioma MRI III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/49/14111\" title=\"diagnostic image 5A\">",
"      Paravertebral mass MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/42/36527\" title=\"diagnostic image 5B\">",
"      Paravertebral mass MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/36/36431\" title=\"diagnostic image 6A\">",
"      Mediastinal goiter MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/32/22031\" title=\"diagnostic image 6B\">",
"      Mediastinal goiter MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/55/12144\" title=\"diagnostic image 7A\">",
"      Paratracheal mass MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/31/7679\" title=\"diagnostic image 7B\">",
"      Paratracheal mass MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/2/30767\" title=\"diagnostic image 8\">",
"      Paracardiac mass on MRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=related_link\">",
"      Role of imaging in the staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_52_3911="Articaine and epinephrine: Drug information";
var content_f3_52_3911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Articaine and epinephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/48/41731?source=see_link\">",
"    see \"Articaine and epinephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Articadent&trade;;",
"     </li>",
"     <li>",
"      Orabloc&trade;;",
"     </li>",
"     <li>",
"      Septocaine&reg; with epinephrine 1:100,000;",
"     </li>",
"     <li>",
"      Septocaine&reg; with epinephrine 1:200,000;",
"     </li>",
"     <li>",
"      Zorcaine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F730244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Astracaine&reg; with epinephrine 1:200,000;",
"     </li>",
"     <li>",
"      Astracaine&reg; with epinephrine forte 1:100,000;",
"     </li>",
"     <li>",
"      Posicaine N;",
"     </li>",
"     <li>",
"      Posicaine SP;",
"     </li>",
"     <li>",
"      Septanest&reg; N;",
"     </li>",
"     <li>",
"      Septanest&reg; SP;",
"     </li>",
"     <li>",
"      Ultracaine&reg; DS;",
"     </li>",
"     <li>",
"      Ultracaine&reg; DS Forte;",
"     </li>",
"     <li>",
"      Zorcaine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Summary of recommended volumes and concentrations for various types of anesthetic procedures; dosages (administered by submucosal injection and/or nerve block) apply to normal healthy adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Infiltration: Injection volume of 4% solution: 0.5-2.5 mL; total dose: 20-100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nerve block: Injection volume of 4% solution: 0.5-3.4 mL; total dose: 20-136 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral surgery: Injection volume of 4% solution: 1-5.1 mL; total dose: 40-204 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Special populations: The clinician is reminded that these doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes to be used depend upon a number of factors, such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, the smallest dose that will produce the desired result should be given. Dosages should be reduced for pediatric patients, elderly patients, and patients with cardiac and/or liver disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Maximum recommended dosages:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults (normal, healthy): Submucosal infiltration and/or nerve block: Not to exceed 7 mg/kg (0.175 mL/kg)",
"     <b>",
"      or",
"     </b>",
"     3.2 mg/lb (0.0795 mL/lb) of body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The following numbers of dental cartridges (1.7 mL) provide the indicated amounts of articaine hydrochloride 4% and epinephrine 1:100,000:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 cartridge provides 68 mg articaine HCl (4%) and 0.017 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 cartridges provides 136 mg articaine HCl (4%) and 0.034 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 cartridges provides 204 mg articaine HCl (4%) and 0.051 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 cartridges provides 272 mg articaine HCl (4%) and 0.068 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 cartridges provides 340 mg articaine HCl (4%) and 0.085 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 cartridges provides 408 mg articaine HCl (4%) and 0.102 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7 cartridges provides 476 mg articaine HCl (4%) and 0.119 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 cartridges provides 544 mg articaine HCl (4%) and 0.136 mg vasoconstrictor (epinephrine 1:100,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The following numbers of dental cartridges (1.7 mL) provide the indicated amounts of articaine hydrochloride 4% and epinephrine 1:200,000:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 cartridge provides 68 mg articaine HCl (4%) and 0.0085 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 cartridges provides 136 mg articaine HCl (4%) and 0.017 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 cartridges provides 204 mg articaine HCl (4%) and 0.026 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 cartridges provides 272 mg articaine HCl (4%) and 0.034 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 cartridges provides 340 mg articaine HCl (4%) and 0.043 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 cartridges provides 408 mg articaine HCl (4%) and 0.051 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7 cartridges provides 476 mg articaine HCl (4%) and 0.060 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 cartridges provides 544 mg articaine HCl (4%) and 0.068 mg vasoconstrictor (epinephrine 1:200,000)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F136658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Give smallest dose that will produce desired result",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Children &lt;4 years:",
"     </i>",
"     Safety and efficacy have not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children 4-16 years",
"     </i>",
"     (dosages in a clinical trial of 61 patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simple procedures: 0.76-5.65 mg/kg (0.9-5.1 mL) was administered safely to 51 patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Complex procedures: 0.37-7.48 mg/kg (0.7-3.9 mL) was administered safely to 10 patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Approximately 13% of the pediatric patients required additional injections for complete anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maximum recommended dosages:",
"     </b>",
"     Children (use in pediatric patients &lt;4 years is not recommended): Not to exceed 7 mg/kg (0.175 mL/kg)",
"     <b>",
"      or",
"     </b>",
"     3.2 mg/lb (0.0795 mL/lb) of body weight",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer smallest dose to produce desired result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Geriatric patients (dosages in a clinical trial):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     65-75 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Simple procedures: 0.43-4.76 mg/kg (0.9-11.9 mL) was administered safely to 35 patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Complex procedures: 1.05-4.27 mg/kg (1.3-6.8 mL) was administered safely to 19 patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;75 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Simple procedures: 0.78-4.76 mg/kg (1.3-11.9 mL) was administered safely to 7 patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Complex procedures: 1.12-2.17 mg/kg (1.3-5.1 mL) was administered safely to 4 patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Approximately 6% of the patients 65-75 years of age (none of the patients &ge;75 years of age) required additional injections for complete anesthesia, compared to 11% of the patients 17-65 years of age who required additional injections.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution in patients with severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Articadent&trade;:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Articadent&trade;:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:200,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orabloc&trade;:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.8 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orabloc&trade;:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:200,000 (1.8 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Septocaine&reg; with epinephrine 1:100,000: Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Septocaine&reg; with epinephrine 1:200,000: Articaine hydrochloride 4% [40 mg/mL] and epinephrine   1:200,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zorcaine&trade;: Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Astracaine&reg; with epinephrine 1:200,000: Articaine hydrochloride 4% and epinephrine 1:200,000 (1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Astracaine&reg; Forte with epinephrine forte 1:100,000: Articaine hydrochloride 4% and epinephrine 1:100,000 (1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Septanest&reg; N: Articaine hydrochloride 4% and epinephrine 1:200,000 (1.7 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Septanest&reg; SP: Articaine hydrochloride 4% and epinephrine 1:100,000 (1.7 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ultracaine&reg; DS: Articaine hydrochloride 4% and epinephrine 1:200,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ultracaine&reg; DS Forte: Articaine hydrochloride 4% and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11309884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local, infiltrative, or conductive anesthesia during simple and complex dental procedures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions to Septocaine&trade; are characteristic of those associated with other amide-type local anesthetics; adverse reactions to this group of drugs may also result from excessive plasma levels which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &ge;1% (in controlled trial of 882 patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4%), paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gingivitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Pain (body as a whole 13%), facial edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (adverse and intercurrent events recorded in 1 or more patients in controlled trials, occurring at an overall rate of &lt;1%, and considered clinically significant): Abdominal pain, accidental injury, arthralgia, asthenia, back pain, constipation, diarrhea, dizziness, dry mouth, dysmenorrhea, dyspepsia, ear pain, ecchymosis, edema, facial paralysis, glossitis, gum hemorrhage, hemorrhage, hyperesthesia, lymphadenopathy, malaise, methemoglobinemia, migraine, mouth ulceration, myalgia, nausea, neck pain, nervousness, neuropathy, osteomyelitis, pharyngitis, pruritus, rhinitis, salivation increased,  skin disorder, somnolence, stomatitis, syncope, tachycardia, taste perversion, thirst, tongue edema, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Additional adverse reactions reported with articaine and epinephrine: Arrhythmia, myocardial depression, asthma, convulsions, allergic reactions, injection site reactions, tissue necrosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to local anesthetics of the amide type or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Systemic absorption of local anesthetics may produce cardiovascular effects. Changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal at blood concentrations produced by therapeutic doses. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to AV block, ventricular arrhythmias, and cardiac arrest (sometimes resulting in death). In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs should be done following each local anesthetic injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Has been reported with articaine; may be treated with methylene blue, 1-2 mg/kg I.V. infused over several minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with impaired cardiovascular function, since they may be less able to compensate for function changes associated with prolonged AV conduction produced by these drugs. Use with caution in patients with heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic disease;",
"     <i>",
"      in vitro",
"     </i>",
"     studies show that &sim;5% to 10% of articaine is metabolized by the human liver microsomal P450 isoenzyme system; however, no studies have been performed in patient with liver dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vascular disease: Local anesthetic solutions containing a vasoconstrictor should be used cautiously. Patients with peripheral vascular disease or hypertensive vascular disease may exhibit exaggerated vasoconstrictor response, possibly resulting in ischemic injury or necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epinephrine: Contains epinephrine, which can cause local tissue necrosis or systemic toxicity, usual precautions for epinephrine administration should be observed. Administration of articaine HCl with epinephrine results in a three- to fivefold increase in plasma epinephrine concentrations compared to baseline; however, in healthy adults, it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; General anesthetics: Use with caution in patients during or following the administration of a potent general anesthetic agent, since cardiac arrhythmias may occur under these conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;4 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Products may contain sodium metabisulfite, which may cause allergic-type reactions (including anaphylactic symptoms, and life-threatening or less severe asthmatic episodes) in certain susceptible patients. The overall prevalence of the sulfite sensitivity in the general population is unknown, and is seen more frequently in asthmatic than in nonasthmatic persons.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate dosing: To avoid serious adverse effects and high plasma levels, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may cause significant increases in blood levels with each repeated dose due to the possibility of accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with patient status. Reduced dosages, commensurate with age and physical condition, should be given to debilitated patients, elderly patients, acutely-ill patients, and pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental blocks: Small doses of local anesthetics injected into dental blocks may produce adverse reactions similar to systemic toxicity seen in unintentional intravascular injections at larger doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving such blocks should be observed constantly with resuscitative equipment and personnel trained in treatment of adverse reactions immediately available. Dosage recommendations should not be exceeded.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2105784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2105785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F136646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether articaine is excreted in human milk.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bucanest (AU);",
"     </li>",
"     <li>",
"      Deltazine (AU);",
"     </li>",
"     <li>",
"      Septanest (AU, CH, DK, IT, NZ);",
"     </li>",
"     <li>",
"      Septanest N (IL);",
"     </li>",
"     <li>",
"      Septocaine (DK, NO, SE);",
"     </li>",
"     <li>",
"      Ubestesin Adrenalinee (FR);",
"     </li>",
"     <li>",
"      Ubistesin (EE, FI, HK, HN, IL, NZ, SE);",
"     </li>",
"     <li>",
"      Ubistesin Forte (HK, IL);",
"     </li>",
"     <li>",
"      Ultracain Epinefrina (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Clinically, the order of loss of nerve function is as follows: 1) pain, 2) temperature, 3) touch, 4) proprioception, and 5) skeletal muscle tone.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-6 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Complete anesthesia: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via plasma carboxyesterase to articainic acid (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Articaine: 1.8 hours; Articainic acid: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gaffen AS and Haas DA, \"Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,\"",
"      <i>",
"       J Can Dent Assoc",
"      </i>",
"      , 2009, 75(8):579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3911/abstract-text/19840499/pubmed\" id=\"19840499\" target=\"_blank\">",
"        19840499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garisto GA, Gaffen AS, Lawrence HP, et al, \"Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(7):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3911/abstract-text/20592403/pubmed\" id=\"20592403\" target=\"_blank\">",
"        20592403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hersh EV, Giannakopoulos H, Levin LM, et al, &ldquo;The Pharmacokinetics and Cardiovascular Effects of High-Dose Articaine With 1:100,000 and 1:200,000 Epinephrine,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(11):1562-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3911/abstract-text/17082283/pubmed\" id=\"17082283\" target=\"_blank\">",
"        17082283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore PA, Boynes SG, Hersh EV, et al, &ldquo;The Anesthetic Efficacy of 4 Percent Articaine 1:200,000 Epinephrine: Two Controlled Clinical Trials,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(11):1572-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/52/3911/abstract-text/17082284/pubmed\" id=\"17082284\" target=\"_blank\">",
"        17082284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8551 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3911=[""].join("\n");
var outline_f3_52_3911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136653\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730244\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136663\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136654\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136658\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136655\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673209\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673210\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136641\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950023\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136631\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11309884\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136661\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136644\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136634\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298774\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136638\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136639\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105784\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105785\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136646\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869365\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136633\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136643\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/48/41731?source=related_link\">",
"      Articaine and epinephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_52_3912="Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues";
var content_f3_52_3912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3912/contributors\">",
"     David W Cohen, MA, MT(ASCP)SBB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3912/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/52/3912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmune hemolytic disease of the newborn (HDN) is a condition in which the red cells of the fetus or newborn are destroyed by maternally-derived alloantibodies. These antibodies arise in the mother as the direct result of a blood group incompatibility between the mother and fetus, as when an Rh(D) negative mother carries an Rh(D) positive fetus.",
"   </p>",
"   <p>",
"    In this example, the mother becomes initially sensitized to Rh(D) positive red cells either through a prior transfusion of Rh(D) positive red cells or through the process of fetal-maternal hemorrhage, in which a variable volume of fetal red cells passes through the placental barrier and gains entrance into the maternal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The presence of these \"foreign\" fetal red cells initiates the formation of anti-Rh(D) IgG antibodies in the mother (isoimmunization), which are then capable of crossing the placenta and causing hemolysis during the fetal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neonatal period. This disorder is called erythroblastosis fetalis when it occurs in the fetus and HDN when it occurs in the newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of antenatal and postpartum Rh immune globulin administration Rh(D) sensitization is infrequently seen nowadays in patients receiving prenatal care. Chronic transplacental hemorrhage, failure to administer Rh immune globulin when indicated, or non-detection of a large fetal bleed at delivery may all still lead to Rh sensitization and associated complications during a subsequent Rh positive pregnancy. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of other antibodies that may be detected during pregnancy varies from innocuous to capable of causing severe hemolytic disease of the newborn (HDN) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Antibody is IgM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the generally innocuous antibodies are those directed against such specificities as A, P(1), Le(a), M, I, IH and Sd(a). Most of these antibody specificities are IgM in nature and therefore cannot cross the placental barrier. Lewis antibodies and cold agglutinins of I and IH specificity are particularly prevalent during gestation. Although Lewis specificities occasionally have an IgG component, clinically significant HDN has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Antigen poorly expressed on fetal red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some other antibodies are directed against high frequency red cell antigens and are capable of causing significant hemolytic transfusion reactions. However, their corresponding antigens &mdash; Lu(b), Yt(a), and VEL &mdash; are not well developed at birth. Thus, even if the corresponding antibody is IgG and present in high titers, it will not attach to fetal or newborn red cells after crossing the placenta. These antibodies are almost invariably detectable in the newborn's serum and, if the infant were very premature and required exchange transfusion for reasons other than HDN, or replacement red cell therapy were needed due to iatrogenic anemia, red cells negative for the corresponding antigen would need to be transfused. Procuring compatible blood for patients with antibodies directed against high frequency antigens will be discussed below (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Prenatal testing'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     High risk antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those antibodies that are responsible for the majority of cases of HDN include",
"    <strong>",
"     anti-c, anti-D, anti-E, and anti-K(Kell)",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Prenatal monitoring of patients with such antibodies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, antenatal Rh(D) immune globulin administration has significantly reduced the frequency of HDN due to anti-D antibodies, although it is still the most common cause of red cell alloimmunization. As an example, in a study of 110 pregnant mothers with 111 at-risk fetuses and maternal serum titers of 1:16 or greater, antibodies to D, K, E, and c were present in 84, 18, 8, and 3 fetuses, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/5\">",
"     5",
"    </a>",
"    ]. HDN due to these alloantibodies may require intrauterine or direct fetal transfusion during pregnancy or exchange transfusion postpartum.",
"   </p>",
"   <p>",
"    Special mention should be made of Rh negative women presenting with what appears to be anti-C+D during pregnancy. Additional serologic testing must always be performed to determine if separable anti-D is present, rather than anti-G. The G antigen is present on any red cell that is D+",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C+, and thus anti-G will look like anti-C+D in a preliminary antibody investigation. Immunohematology reference laboratories can readily distinguish between the two. If only anti-G is present, then the mother would still be a candidate for Rh immune globulin, since sensitization to the D antigen could still be prevented. Anti-G itself rarely causes significant hemolytic disease of the newborn or fetus. One should never assume that the presence of anti-C+D is evidence for the patient being actively immunized to the D antigen, and thus not a candidate for Rh immune globulin, without first determining whether separable anti-D is present and obtaining an accurate history to determine whether the mother has received antenatal Rh immune globulin in the past six months.",
"   </p>",
"   <p>",
"    Anti-K can be particularly troublesome, since the severity of HDN can dramatically change over the course of one week, due to the antibody's ability to also suppress erythropoiesis, sometimes requiring immediate intervention when the bilirubin levels in the amniotic fluid indicate a severely affected fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/6\">",
"     6",
"    </a>",
"    ]. Kell antigen immunization is responsible for approximately 10 percent of fetuses that are severely affected by HDN.",
"   </p>",
"   <p>",
"    Ultrasound monitoring to assess fetal liver size may be useful in K-sensitized pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/7\">",
"     7",
"    </a>",
"    ], particularly when the antibody titer exceeds 16. Increased liver size may be a good predictor of fetal anemia. In one report of 21 alloimmunized pregnancies, all fetuses with a hemoglobin of less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had a liver length that was greater than the ninetieth percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/7\">",
"     7",
"    </a>",
"    ]. Monitoring should be performed at least weekly when the antibody titer exceeds 64 and the presumed father's red cells are known to be K-positive. Upon delivery, the red cells of approximately 20 percent of severely affected infants may type as K-, due to blockage of K antigen sites by maternal antibody. Typing for K using DNA technology will yield the expected positive results.",
"   </p>",
"   <p>",
"    However, it is important to emphasize that anti-K can cause severe HDN in the K+ fetus regardless of titer. Advances in measuring peak systolic velocity of the fetus' middle cerebral artery via Doppler ultrasound has proved to be extremely valuable in detecting significant fetal anemia in sensitized pregnancies, particularly those due to anti-K [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/5\">",
"     5",
"    </a>",
"    ]. This procedure has supplanted serial amniocentesis in many tertiary centers as the first line of testing in women with high-risk pregnancies due to Rh and Kell system antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lower risk antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most other common clinically significant alloantibodies (eg, anti-C, anti-e, anti-Jk(a), anti-Jk(b), anti-Fy(a), anti-Fy(b), anti-S, and anti-s) generally cause only mild to moderate HDN if the fetus inherits the corresponding antigen. The antibody titers tend to be lower and the rate of fetal red cell destruction is proportionately less. Subclassing of IgG into its four known subclasses is not commonly performed, but the subclass is an important determinant of the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/8\">",
"     8",
"    </a>",
"    ]. IgG1 antibodies tend to cross the placental barrier earlier in gestation and are usually responsible for greater morbidity prenatally; in comparison, IgG3 antibodies cross the placenta later in gestation, but tend to be more hemolytic than IgG1 antibodies, resulting in a more severe clinical course postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/9\">",
"     9",
"    </a>",
"    ]. IgG2 and IgG4 antibodies do not normally play a significant role in red cell hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Warm autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Warm autoimmune hemolytic anemia is often exacerbated during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .) In some cases, the specificity of the autoantibody is anti-e, which can cross the placenta and mimic HDN due to an alloantibody. If the woman is carrying an Rh(D) negative female infant and the antibodies have enough hemolytic potential to attach to the e+ red cells of the fetus, exchange transfusion may be required shortly after delivery. This creates a therapeutic dilemma. Since only about 1 in 20,000 Rh(D) negative units are e-, these ideal units may not be available. More readily available units are not ideally suited for the situation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the Rh(D) negative female infant is exchanged with Rh(D) positive, e- blood (2 percent of Rh(D) positive donor units are e&ndash;), the transfused cells will enjoy normal survival but may sensitize the patient to the Rh(D) antigen.",
"     </li>",
"     <li>",
"      If, on the other hand, Rh(D) negative, e+ blood is used for exchange, the transfused cells will have a shortened survival and will probably add to the bilirubin load while not appreciably improving red cell oxygen carrying capacity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal is to improve oxygen carrying capacity, while reducing serum bilirubin concentrations below the critical levels that lead to kernicterus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=see_link&amp;anchor=H15#H15\">",
"     \"Bilirubin metabolism\", section on 'Bilirubin toxicity'",
"    </a>",
"    .) Thus, an initial exchange with Rh(D) positive, e&ndash; red cells might be indicated in such a patient until Rh(D) negative, e&ndash; red cells can be obtained from a rare donor file repository. If the residual Rh(D) positive circulating red cell volume can be reduced to less than 15 mL by serial exchanges with",
"    <span class=\"nowrap\">",
"     D-/e-",
"    </span>",
"    donor red cells, one dose of Rh(D) immune globulin can then be given to the infant (after the serum bilirubin has stabilized) in order to prevent sensitization to the D antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRENATAL TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal testing in the Rh negative patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evaluation of the father",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a significant antibody is present in the maternal circulation, it is recommended that the red cells of the presumed father be tested to determine the likelihood of his passing on the corresponding antigen to the fetus. If, for example, the mother has anti-K, then the presumed father's red cells are tested for K and its alternate allele, k. If the father's cells type as K+, k+, then the fetus has a 50 percent chance of inheriting the K antigen.",
"   </p>",
"   <p>",
"    Should the father's cells type as K+k&ndash; (present in only 1 in 400 individuals), then the fetus has virtually a 100 percent chance of inheriting the K antigen. When Rh antibodies are involved, the calculations are more involved since an Rh phenotype (what is expressed) can represent a number of different genotypes (ie, how the antigens are inherited on a chromosome) and the frequency of various genotypes will vary depending on the presumed father's ethnic group. It is also important to keep in mind that the current biologic father may not be the father of prior children of the woman in question.",
"   </p>",
"   <p>",
"    Knowing the likelihood that the fetus will inherit the antigen against which the maternal antibody is directed is important for planning the newborn's postpartum treatment course, particularly when the chances of the infant being affected exceed 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/12\">",
"     12",
"    </a>",
"    ]. For prevalence information for Caucasians and Afro-Americans based upon various Rh haplotypes, the reader is directed to the chapter on the Rh system in the most recent version of the AABB (formerly the American Association of Blood Banks) Technical Manual [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21705518\">",
"    <span class=\"h2\">",
"     Fetal DNA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance of the D antigen by a fetus can be determined with 100 percent accuracy by testing cell-free fetal DNA in the maternal plasma of Rh negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/14\">",
"     14",
"    </a>",
"    ]. The same technology has been applied for successfully determining the presence of the K, C, c, and E antigens in the fetus. This non-invasive technique takes the guesswork out of trying to determine the likelihood of a fetus inheriting any of the listed antigens to which the mother has developed a clinically significant antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal amniotic fluid is also a source of fetal cells which can be tested using a DNA polymerase chain",
"    <span class=\"nowrap\">",
"     reaction/fluorescence",
"    </span>",
"    monitoring technique to determine whether the antigen in question is present. These techniques are particularly valuable when a sample from the presumed father is unavailable, the presumed father is deceased, or his red cells are known to be heterozygous for the antigen in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21705525\">",
"    <span class=\"h3\">",
"     Technical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using molecular technology (DNA analysis), one can also predict that the fetus is",
"    <strong>",
"     not",
"    </strong>",
"    at risk of hemolytic disease of the",
"    <span class=\"nowrap\">",
"     newborn/fetus",
"    </span>",
"    (HDNF), sparing the family the need for aggressive monitoring of the pregnancy.&nbsp;Moreover, the fetal Rh D status can also be determined in non-sensitized Rh negative mothers in order to determine whether Rh immune globulin would need to be administered.&nbsp;Rh D testing also makes sense in women who have been sensitized to other clinically significant antigens, such as E or K. Since DNA testing can be performed fairly early in gestation,&nbsp;earlier than normal interventions can be undertaken if the fetus is predicted to have inherited the antigen in question [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the fetus is D+, then intrauterine or direct fetal transfusion, if indicated, could be performed with D+ red cells. In women who have the",
"    <span class=\"nowrap\">",
"     CDe/Cde",
"    </span>",
"    phenotype and have formed anti-c, the situation could exist that the fetus might be genetically",
"    <span class=\"nowrap\">",
"     Cde/cde,",
"    </span>",
"    having inherited the cde haplotype from the father. Using molecular testing to test for the presence of D and c would allow one to use the relatively common",
"    <span class=\"nowrap\">",
"     CDe/CDe",
"    </span>",
"    red cells for fetal or exchange transfusion if the fetus typed as D+ and c+.&nbsp;Should the fetus test as D= and c+, and be female, then one would be obliged to procure&nbsp;the very rare",
"    <span class=\"nowrap\">",
"     Cde/Cde",
"    </span>",
"    blood to avoid exposing an Rh negative fetus to the D antigen.",
"   </p>",
"   <p>",
"    A further reason for using molecular testing is in determining the fetal antigen status in sensitized pregnancies due to anti-K or anti-Ge3. In both of these instances, the maternal antibody strength is a poor indicator of the degree of anemia present in the fetus carrying the corresponding antigen.&nbsp;Low titers have resulted in severely affected infants and fetal death, despite a recent amniotic fluid analysis within normal limits.",
"   </p>",
"   <p>",
"    There are always caveats that need to be considered in any testing protocol.&nbsp;In general, detection of fetal DNA in maternal plasma is preferable to testing of fetal amniocytes in amniotic fluid, if for no other reason than there is always the risk of introducing fetal red cells into the maternal circulation during the procedure.&nbsp;This may result in boosting the titer of a clinically significant antibody already present, or result in de novo production of another significant antibody.&nbsp;",
"   </p>",
"   <p>",
"    Prior to DNA testing, a comprehensive history should always be obtained on the mother, to determine whether she has undergone such procedures as in vitro fertilization or artificial insemination, or if in fact she is a surrogate mother.&nbsp;Furthermore, in order to accurately evaluate fetal DNA testing, maternal DNA testing for the same antigens must always be performed.&nbsp;Finally, because aberrations exist in the strength of the Rh D antigen in Afro-American and Asian populations,&nbsp;it is essential that when using molecular technology, at least two regions of the Rh D complex need to be probed in order to accurately predict the Rh D antigen status [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibodies against high frequency antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planning is somewhat different in women with antibodies against high frequency antigens, such as k, Kp(b) or Co(a). If the antigen is developed at birth, the great majority of such antibodies can cause moderate to severe HDN. Identifying the specificity (as well as any underlying clinically significant antibodies being masked by its presence) in a timely manner is essential so that donor blood is available should intrauterine or direct fetal transfusion be required prior to delivery, or the mother",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the newborn require transfusion postpartum.",
"   </p>",
"   <p>",
"    However, random screening of the donor base is unlikely to turn up compatible units because of the low percentage of donors who would lack the high frequency antigen in question. There are three general options in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the mother is medically able, collection of one to two autologous units during the second trimester is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/18\">",
"       18",
"      </a>",
"      ]. The red cells can then be frozen and thawed if necessary for the mother or the baby (if ABO compatible).",
"     </li>",
"     <li>",
"      The mother's siblings can be tested to determine if any have red cells that are compatible with her serum. There is a 25 percent chance that this will be so if both parents are heterozygous for the corresponding low frequency antigen. Such units can be collected and frozen until needed.",
"     </li>",
"     <li>",
"      The local blood center can contact the American Rare Donor File to inquire where frozen units lacking the high frequency antigen in question may be found. Such units could then be held for, or shipped to the local facility and stored for future use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If compatible blood cannot be obtained and either intrauterine or exchange transfusion becomes imperative, group O red cells which are heterozygous positive for the high frequency antigen (eg, K+k+ when anti-k is present) is preferred to incompatible blood containing a double dose of the offending antigen. The homozygous cells are likely to have a shorter survival than the",
"    <span class=\"nowrap\">",
"     fetus/newborn's",
"    </span>",
"    own red cells which, in this example, would also be K+k+.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibodies of uncertain clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In occasional patients, antibodies are detected during pregnancy that are of variable or uncertain clinical significance. In this setting, the hemolytic potential of the antibody can be estimated either by performing",
"    <sup>",
"     51",
"    </sup>",
"    Cr survival studies with incompatible cells or a monocyte macrophage assay (also called a monocyte monolayer assay) with maternal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal",
"    <sup>",
"     51",
"    </sup>",
"    Cr survival suggests that the antibody at its current titer is innocuous. However, there are a number of concerns about the 51Cr survival procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standardization is difficult.",
"     </li>",
"     <li>",
"      Informed consent must be obtained whenever the mother is given allogeneic red cells.",
"     </li>",
"     <li>",
"      Exposure of the mother to incompatible red cells may stimulate antibody production to a higher titer that might become clinically significant. It may also prompt the production of other clinically significant blood group antibodies if the blood is not phenotype matched for other clinically significant antigens which the patient lacks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The monocyte monolayer assay is an in vitro test that measures the amount of phagocytosis when antibody-coated red cells are exposed to adult macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/20\">",
"     20",
"    </a>",
"    ]. It is the preferred test because there is no risk of stimulating the mother's antibody titer and the endpoint is more clear-cut. However, since random donor peripheral blood monocytes are utilized in this test, the state of activation of the immune system in the fetus or mother cannot be taken into account when interpreting test results. Chemiluminescence testing has been suggested as an alternative to the monocyte monolayer assay [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that looked at a number of antibodies to high frequency antigens using a monocyte assay, the following antibodies demonstrated low activity and did not cause HDN: anti-HY, -Dib, -Jra, -Sc1, -Inb, -Wrb and -U [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/22\">",
"     22",
"    </a>",
"    ]. Two antibodies (anti-Ena and -Rh29) demonstrated high activity and caused severe HDN. The remaining four antibodies (anti-Cra, -Inb, and 2 examples of anti-U ) demonstrated moderate activity and titers greater than 128, but did not cause HDN. The absence of HDN in the presence of anti-U could not be explained, given the fact that anti-U has been responsible for severe HDN on numerous occasions in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     POSTNATAL TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no prenatal antibody identification has been performed, then antibody identification must be performed postnatally using maternal serum. If clinically significant antibodies have been previously identified, the postpartum maternal sample must be evaluated for the presence of additional alloantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ABO, Rh type, and direct antiglobulin test (DAT, direct Coombs' test) must be performed on either the cord blood or a peripheral blood sample from the newborn. In rare instances of HDN due to potent anti-D antibodies, the baby's D antigen sites may be blocked by maternally derived antibodies and the baby's red cells may erroneously type as Rh negative. However, an eluate prepared from the baby's cells will demonstrate anti-D activity. Elution procedures enable the laboratory to remove cell bound antibody into an aqueous solution for subsequent identification. Blocked sites may occur more commonly in HDN due to anti-K since its antigen site density is relatively low and proportionally less antibody is needed to block the K antigen red cell sites.",
"   </p>",
"   <p>",
"    Eluates should also be obtained in cases of suspected HDN in order to identify the antibody(s) coating the baby's red cells. If the mother is Rh negative and the antibody eluted from the baby's red cells is other than anti-D, the mother will still be a candidate for postpartum Rh immune globulin providing the baby is Rh positive and there is no anti-D detectable in the maternal serum.",
"   </p>",
"   <p>",
"    Guidelines for the postpartum use of Rh immune globulin in the Rh negative mother who has delivered an Rh positive infant are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rh immune globulin is always given to the Rh negative woman without detectable anti-D in her serum who subsequently delivered an Rh positive infant, in order to prevent sensitization to the Rh factor due to a fetal bleed at the time of delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/24\">",
"       24",
"      </a>",
"      ]. Insufficient anti-D remains from the antenatal injection to prevent sensitization in the majority of women without a post-partum dose.",
"     </li>",
"     <li>",
"      If there is anti-D in the maternal serum, and the mother did",
"      <strong>",
"       NOT",
"      </strong>",
"      receive antenatal Rh immune globulin, then she would",
"      <strong>",
"       NOT",
"      </strong>",
"      be a candidate for Rh immune globulin postpartum, since she has apparently already been sensitized to the Rh(D) factor.",
"     </li>",
"     <li>",
"      If the mother did receive antenatal Rh globulin, she is still a candidate for Rh immune globulin postpartum whether or not anti-D is detectable in the postpartum sample.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are occasions when additional alloantibodies are detectable in maternal serum that cannot be eluted from the baby's red cells. If the antibodies are IgG, the baby's serum should be tested to see if these antibodies are detectable. If so, the baby must receive blood lacking the corresponding antigen(s). Suppose, for example, a weak anti-Jk(a) antibody in the maternal serum cannot be demonstrated in either the baby's eluate or the baby's serum using sensitive techniques, but anti-c has been eluted off the baby's cells and anti-K is detectable in the baby's serum (also in the maternal serum). In this setting, it is uncertain whether Jk(a)- as well as c&ndash; and K&ndash; blood should be ordered for exchange transfusion. If the situation is not urgent, then blood probably should be obtained lacking all three antigens. If, however, the situation is urgent and no c&ndash;, K&ndash;, Jk(a)- units are readily available, then donor units that are solely c&ndash; and K&ndash; and ABO compatible with the maternal serum may be used. The ABO of the blood for exchange or replacement transfusion must always be ABO compatible with the maternal serum and not contain an ABO antigen that the baby lacks from his or her red cells.",
"   </p>",
"   <p>",
"    Blood is normally crossmatched using the maternal serum, and antigen negative blood is selected based on the clinically significant antibodies present. Lewis antibodies and other cold agglutinins (anti-IH, P(1), M) are commonly seen during pregnancy and may cause in vitro incompatibilities with crossmatched units even though the great majority of these antibodies do not cross the placental barrier. In this setting, the newborn's serum can be used for crossmatching as long as the donor units are ABO compatible with the maternal serum and lack the antigens to which the mother has formed clinically significant antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ABO-induced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike HDN caused by Rh or K system antibodies, ABO HDN is restricted almost exclusively to group A and B infants of group O mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/25\">",
"     25",
"    </a>",
"    ]. It may be particularly pronounced in group B African-American newborns in whom the B antigen is more developed at birth than in the general population.",
"   </p>",
"   <p>",
"    The direct antiglobulin test (DAT) may only be weakly positive in the newborn, because of incomplete development of A and B antigens, although eluates will demonstrate copious amounts of antibody. In most cases, however, eluates do not need to be performed. If the baby is type B, for example, one need only demonstrate free anti-B antibodies in the baby's serum via an indirect antiglobulin test to confirm the presence of ABO HDN. A positive test suggests that all the B sites on the baby's cells have been saturated and free anti-B antibodies are spilling into the serum.",
"   </p>",
"   <p>",
"    Many institutions will hold the cord blood for 10 days and not perform any ABO or DAT testing (in the absence of unexpected clinically significant maternal antibodies) unless the baby's bilirubin begins to rise, or unexplained anemia develops.",
"   </p>",
"   <p>",
"    It is rare for exchange transfusion to be required in ABO HDN, as the combination of phototherapy (ie, bili-lights) and insuring adequate hydration is usually sufficient to reduce the serum bilirubin. However, there are cases in which the maternal ABO IgG titers are so high that the serum bilirubin concentration cannot be controlled by these steps alone, and exchange transfusion must be performed. If the baby is group A, one must",
"    <strong>",
"     never",
"    </strong>",
"    exchange with group A blood, even though it is compatible with the baby's red cells. Adult group A red cells contain more A antigens than newborn red cells, and there is at least one case report in the literature of a baby dying after such an exchange.",
"    <strong>",
"     Group O",
"    </strong>",
"    is always the blood of choice should exchange be necessary.",
"   </p>",
"   <p>",
"    Another issue that may come up is when an A negative or B negative baby of an O negative mother is typed for D. Apparent weak D positivity may be present at the antiglobulin stage because of a weakly positive DAT resulting from the ABO incompatibility. This weak D typing is almost invariably a false positive reaction. In general, if the auto control tube (or the DAT) is equal in strength to the weak D typing, the baby's red cells would not be considered Rh positive, and Rh immune globulin would not be indicated. Alternatively, an",
"    <span class=\"nowrap\">",
"     adsorption/elution",
"    </span>",
"    technique could be performed using the baby's cells and commercial anti-D to definitively determine whether the baby's red cells are weakly D positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antibodies against low frequency antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDN can be induced by antibodies directed against a low frequency antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3912/abstract/26\">",
"     26",
"    </a>",
"    ]. Since most antibody screening cells lack low frequency antigens, the prenatal maternal antibody screen will be negative in the majority of cases. Thus, there may be no serologic clues that HDN is present and, even with standard prenatal care, the diagnosis may not become evident until delivery, when the baby is found to have a positive DAT and clinical evidence of HDN.",
"   </p>",
"   <p>",
"    This condition is caused by the father's passing a low frequency antigen to the fetus, whose red cells sensitize the mother to the antigen, usually during a prior pregnancy. During the current pregnancy, with a second fetus that has also inherited the paternal antigen, maternal antibodies cross the placenta and sensitize the fetus' red cells.",
"   </p>",
"   <p>",
"    The cause can be determined postpartum by testing the presumed father's red cells against the maternal serum (if ABO compatible), or preferably versus an eluate prepared from the baby's cells, which will contain the antibody to the low frequency antigen. If the father's cells are positive against either sample, then HDN due to a low frequency antigen is confirmed.",
"   </p>",
"   <p>",
"    The identity of the antigen may be difficult to determine, particularly if it is extremely rare. Fortunately, if blood is needed for the baby, the vast majority of random ABO compatible units will be crossmatch compatible, since they lack the low frequency antigen. If the mother were planning on having additional children, then identification of the low frequency antigen against which the antibody is directed is essential in order to determine, based upon the literature, what the severity of HDN is likely to be for the given specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7763276\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In alloimmune hemolytic disease of the newborn (HDN), red cells of the fetus or newborn are destroyed by maternally-derived alloantibodies arising as the result of a blood group incompatibility between the mother and fetus (eg, when an Rh(D) negative mother carries an Rh(D) positive fetus).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether or not maternally-derived alloantibodies cause significant HDN depends upon the nature of the antibody (eg, IgG versus IgM, IgG subclass) as well as the red cell antigen in question. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk categories'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antibodies responsible for the majority of cases include anti-c, anti-D, anti-E, and anti-K(Kell)&nbsp;",
"     </li>",
"     <li>",
"      Anti-C, anti-e, anti-Jk(a), anti-Jk(b), anti-Fy(a), anti-Fy(b), anti-S, and anti-s generally cause only mild to moderate HDN if the fetus inherits the corresponding antigen.",
"     </li>",
"     <li>",
"      HDN involving the ABO blood system is restricted almost exclusively to group A and B infants of group O mothers. It may be particularly pronounced in group B African-American newborns in whom the B antigen is more developed at birth than in the general population. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'ABO-induced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HDN can be induced by antibodies directed against a low frequency antigen. The diagnosis may not become evident until delivery, when the baby is found to have a positive direct Coombs test and clinical evidence of HDN. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibodies against low frequency antigens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In rare cases a mother with autoimmune hemolytic anemia may pass her IgG antibody on to a susceptible fetus, causing hemolysis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Warm autoimmune hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal testing of the mother and father is required in most cases of alloimmune hemolytic disease in order to make the correct serologic diagnosis, determine the appropriate treatment if any, and assess the probability of hemolysis in subsequent pregnancies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prenatal testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Postnatal testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/1\">",
"      Riley JZ, Ness PM, Taddie SJ, et al. Detection and quantitation of fetal maternal hemorrhage utilizing an enzyme-linked antiglobulin test. Transfusion 1982; 22:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/2\">",
"      Salama A, David M, Wittmann G, et al. Use of the gel agglutination technique for determination of fetomaternal hemorrhage. Transfusion 1998; 38:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/3\">",
"      Kornstad L. New cases of irregular blood group antibodies other than anti-D in pregnancy. Frequency and clinical significance. Acta Obstet Gynecol Scand 1983; 62:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/4\">",
"      Moran P, Robson SC, Reid MM. Anti-E in pregnancy. BJOG 2000; 107:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/5\">",
"      Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/6\">",
"      Caine ME, Mueller-Heubach E. Kell sensitization in pregnancy. Am J Obstet Gynecol 1986; 154:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/7\">",
"      Roberts AB, Mitchell JM, Pattison NS. Fetal liver length in normal and isoimmunized pregnancies. Am J Obstet Gynecol 1989; 161:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/8\">",
"      Lambin P, Debbia M, Puillandre P, Brossard Y. IgG1 and IgG3 anti-D in maternal serum and on the RBCs of infants suffering from HDN: relationship with the severity of the disease. Transfusion 2002; 42:1537.",
"     </a>",
"    </li>",
"    <li>",
"     Schanfield MS. immunoglobulin (IgG) subclasses and their biologic properties. In: Blood Bank Immunology, American Association of Blood Banks, Washington, DC 1977. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/10\">",
"      Chaplin H Jr, Cohen R, Bloomberg G, et al. Pregnancy and idiopathic autoimmune haemolytic anaemia: a prospective study during 6 months gestation and 3 months post-partum. Br J Haematol 1973; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/11\">",
"      Baumann R, Rubin H. Autoimmune hemolytic anemia during pregnancy with hemolytic disease in the newborn. Blood 1973; 41:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/12\">",
"      Kanter MH. Derivation of new mathematic formulas for determining whether a D-positive father is heterozygous or homozygous for the D antigen. Am J Obstet Gynecol 1992; 166:61.",
"     </a>",
"    </li>",
"    <li>",
"     The Rh system. In: Technical manual, 16th ed, American Association of Blood Banks, Bethesda, MD 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/14\">",
"      Daniels G, Finning K, Martin P, Soothill P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004; 87:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/15\">",
"      Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007; 47:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/16\">",
"      Reid ME, Denomme GA. DNA-based methods in the immunohematology reference laboratory. Transfus Apher Sci 2011; 44:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/17\">",
"      Reid ME. Transfusion in the age of molecular diagnostics. Hematology Am Soc Hematol Educ Program 2009; :171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/18\">",
"      Kruskall MS, Leonard S, Klapholz H. Autologous blood donation during pregnancy: analysis of safety and blood use. Obstet Gynecol 1987; 70:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/19\">",
"      Nance SJ, Nelson JM, Horenstein J, et al. Monocyte monolayer assay: an efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol 1989; 92:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/20\">",
"      Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004; 44:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/21\">",
"      Lucas GF, Hadley AG, Nance SJ, Garratty G. Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test. Transfusion 1993; 33:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/22\">",
"      Garner SF, Devenish A. Do monocyte ADCC assays accurately predict the severity of hemolytic disease of the newborn caused by antibodies to high-frequency antigens? Immunohematology 1996; 12:20.",
"     </a>",
"    </li>",
"    <li>",
"     Nossaman JK. Laboratory evaluation of the immunized patient. In: Prenatal and Perinatal Immunohematology, American Association of Blood Banks, Washington, DC 1981. p.33.",
"    </li>",
"    <li>",
"     Prevention of D isoimmunization. In: ACOG Technical Bulletin, Number 147, American College of Obstetrics and Gynecology, Washington, DC 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3912/abstract/25\">",
"      Desjardins L, Blajchman MA, Chintu C, et al. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr 1979; 95:447.",
"     </a>",
"    </li>",
"    <li>",
"     Sabo BH. Evaluation of the neonatal direct antiglobulin test. Notes on low frequency antigens in hemolytic disease of the newborn. In: A Seminar on Perinatal Blood Banking, American Association of Blood Banks, Washington, DC 1978. p.31.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7921 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3912=[""].join("\n");
var outline_f3_52_3912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7763276\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk categories",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Antibody is IgM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Antigen poorly expressed on fetal red cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - High risk antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lower risk antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Warm autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRENATAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evaluation of the father",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21705518\">",
"      Fetal DNA testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21705525\">",
"      - Technical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibodies against high frequency antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibodies of uncertain clinical significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      POSTNATAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ABO-induced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antibodies against low frequency antigens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7763276\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_52_3913="Diagnosis of invasive aspergillosis";
var content_f3_52_3913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of invasive aspergillosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3913/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3913/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3913/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3913/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/52/3913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1064485271\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"aspergillosis\" refers to illness due to allergy, airway or lung invasion, cutaneous infection, or extrapulmonary dissemination caused by species of Aspergillus, most commonly A. fumigatus, A. flavus, and A. terreus. Aspergillus species are ubiquitous in nature, and inhalation of infectious conidia is a common event. However, tissue invasion is uncommon and occurs most frequently in the setting of immunosuppression associated with receipt of therapy for hematologic malignancies or hematopoietic cell or solid organ transplantation.",
"   </p>",
"   <p>",
"    The diagnosis of invasive aspergillosis will be reviewed here. The epidemiology, clinical manifestations, and treatment of invasive aspergillosis are discussed separately; the diagnosis of invasive aspergillosis in HIV-infected patients, as well as the diagnosis of other syndromes caused by Aspergillus spp, are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11178?source=see_link\">",
"     \"Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486416\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus species are frequently inhaled into the airways, but because of effective conidial clearance in the majority of individuals, disease usually does not result. Because we inhale conidia constantly, culture isolation of Aspergillus species from the airway does not necessarily indicate disease. Thus, the diagnosis of invasive aspergillosis is based upon both isolating the organism (or markers of the organism) and the probability that it is the cause of disease. The latter is a function of the host&rsquo;s risk factors for disease (eg, immune status) and the clinical presentation. Demonstration of hyphal elements invading tissues (from biopsy of any affected site, such as the lung or skin) represents a proven diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the above issues, the diagnosis of invasive aspergillosis is often referred to within a scale of certainty: possible, probable, or proven [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These definitions have been developed in order to maintain consistency in clinical and epidemiologic studies, not to drive therapeutic decision making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58499699\">",
"    <span class=\"h2\">",
"     Direct examination of respiratory specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory specimens are usually stained with calcofluor white with 10 percent potassium hydroxide to detect the presence of fungal elements [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/3\">",
"     3",
"    </a>",
"    ]. Gomori methenamine silver can be used to stain cytology preparations. Organisms can be observed as narrow (3 to 6 microns wide), septated hyaline hyphae with dichotomous acute angle (45&deg;) branching [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/4\">",
"     4",
"    </a>",
"    ]. However, several filamentous fungi, including Scedosporium spp and Fusarium spp, have similar appearances to Aspergillus spp on direct microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486423\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of the organism, in combination with evidence of tissue invasion on histopathology, or culture from a normally sterile site, provides the most certain evidence of invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/1\">",
"     1",
"    </a>",
"    ]. However, both microscopic examination and culture are insensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/5\">",
"     5",
"    </a>",
"    ], and therapy should not be withheld in the absence of such confirmation. Furthermore, performing a biopsy is not feasible in some patients due to bleeding risk or risk of other complications. In patients with risk factors and clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic features that are suggestive of invasive aspergillosis, culture of Aspergillus spp from respiratory secretions provides adequate evidence of invasive disease.",
"   </p>",
"   <p>",
"    Aspergillus is a rapidly growing fungus in the laboratory, and is often visible in culture within one to three days of incubation. However, identification of the species requires sporulation in order to microscopically examine spore-bearing structures.",
"   </p>",
"   <p>",
"    Occasionally, organisms can be difficult to identify due to slow sporulation. Slow sporulating organisms may have been disregarded as non-pathogens in the past. However, more recently, slow-sporulating species (eg, A. lentulus, Neosartorya udagawae) with variable susceptibility profiles have been identified and implicated in invasive infections [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H458851271#H458851271\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Antifungal resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with documented invasive aspergillosis have negative cultures. This has been observed in surveillance studies, and the prevalence of negative cultures varies depending upon the population being evaluated. As an example, in multicenter surveillance studies only 25 to 50 percent of hematopoietic cell transplant recipients who met criteria for invasive aspergillosis based upon galactomannan antigen results had positive cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of positive sputum or bronchoalveolar lavage (BAL) cultures is dependent upon both the host and the clinical presentation. In a study that evaluated the predictive value of lower respiratory tract cultures in different patient populations with probable or proven invasive pulmonary aspergillosis, the positive predictive value was highest in hematopoietic cell transplant recipients, patients with hematological malignancies and granulocytopenic patients (72 percent), compared with solid organ transplant recipients and patients receiving glucocorticoids (58 percent), and HIV-infected patients (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/9\">",
"     9",
"    </a>",
"    ]. The positive predictive value was highest in BAL cultures, in part because the prevalence of invasive aspergillosis is higher amongst patients who have radiographic abnormalities warranting bronchoscopy. Clinical and radiographic findings suggestive of invasive aspergillosis were present significantly more often among infected patients compared with uninfected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14377219\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of invasive disease, organisms can be observed in biopsy specimens as narrow (3 to 6 microns wide), septated hyaline hyphae with dichotomous acute angle (45&deg;) branching (",
"    <a class=\"graphic graphic_picture graphicRef68747 \" href=\"UTD.htm?25/58/26531\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57220 \" href=\"UTD.htm?17/49/18202\">",
"     picture 2",
"    </a>",
"    ). The organism can be seen using Gomori methenamine silver or periodic acid-Schiff staining. However, several filamentous fungi, including Scedosporium spp and Fusarium spp, have similar appearances to Aspergillus spp in histopathologic sections. Since the treatment of infections caused by these fungi may differ, it is important to confirm genus and species by culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and treatment of Scedosporium infection\", section on 'Histopathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link&amp;anchor=H773301077#H773301077\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histopathologic examination can usually distinguish the above organisms from the Mucorales order (the agents of mucormycosis), which appear as broad, non-septate hyphae that exhibit right angle branching (",
"    <a class=\"graphic graphic_picture graphicRef66476 \" href=\"UTD.htm?4/58/5030\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72487 \" href=\"UTD.htm?25/12/25806\">",
"     picture 4",
"    </a>",
"    ). Occasionally, this distinction can be difficult, especially when small hyphal fragments are present or when the organism folds back on itself to create &ldquo;pseudo-septations.&rdquo; Determining whether the fungus is one of the Mucorales or another fungus is important because the Mucorales are not susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , which is the treatment of choice for invasive aspergillosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486430\">",
"    <span class=\"h2\">",
"     Galactomannan antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactomannan is a major constituent of Aspergillus cell walls that is released during growth of hyphae. Early techniques to detect this antigen utilized methods such as latex agglutination, which were not sufficiently sensitive for diagnostic use. More recent assays that use a double sandwich enzyme-linked immunosorbent assay (ELISA) have higher sensitivity and are available for use on serum samples as an adjunctive test for the diagnosis of aspergillosis. The galactomannan assay has been approved for use by the United States Food and Drug Administration (FDA) for serum and bronchoalveolar lavage fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22230119\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The galactomannan antigen assay is performed with an optical read-out that is interpreted as a ratio relative to the optical density (OD) of a threshold control provided by the manufacturer; this ratio is called the OD index. Initial use of the test, largely in Europe, utilized a relatively high OD index (1 to 1.5) as a cut-off for positivity in order to ensure few false positive results. Subsequent studies demonstrated that lower thresholds (0.5 to 0.7) provide relatively better performance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The assay cleared by the United States Food and Drug Administration (FDA) has a suggested threshold OD index of 0.5; thus, an OD index &ge;0.5 is considered to be a positive result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486437\">",
"    <span class=\"h3\">",
"     Serum",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, galactomannan antigen can be detected in the serum before the presence of clinical signs or symptoms of invasive aspergillosis. Several studies have assessed its test characteristics, and the performance of the test has been addressed in a review and meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Some inconsistency in the reported performance of the test has been introduced by studies that used different cut-offs for positivity, as well as other variables, such as different populations evaluated and testing on patients receiving concurrent antifungal drugs. One review noted that the sensitivity of the test varied from 30 to 100 percent, whereas specificity remained relatively high and constant (&gt;75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis that included 27 studies with a total of 4000 patients (mainly with hematologic malignancies), reported that overall sensitivity and specificity of the galactomannan antigen assay for proven invasive aspergillosis were 71 percent (95% CI 68-74 percent) and 89 percent (95% CI 88-90 percent), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/13\">",
"     13",
"    </a>",
"    ]. When combining proven and probable cases, the sensitivity and specificity were 61 percent (95% CI 59-63 percent) and 93 percent (95% CI 92-94 percent), respectively.",
"   </p>",
"   <p>",
"    Subgroup analyses suggested that the assay performs better in patients who have a hematologic malignancy or who have received a hematopoietic cell transplant; in comparison, the test performance may be limited in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/13\">",
"     13",
"    </a>",
"    ]. This is perhaps related to the higher prevalence of invasive disease in patients with hematologic malignancies, or differences in the fungal burden. Few cases were included in these analyses; more patients, who have different underlying diseases, will need to be studied to establish the usefulness of this assay in disparate populations. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486444\">",
"    <span class=\"h4\">",
"     Caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following caveats should be considered when using the galactomannan assay:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity in serum is decreased by concomitant administration of mold-active antifungal therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False positive serum results have been demonstrated in patients who are receiving certain beta-lactam antibiotics, especially intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      , due to the presence of galactomannan (or a cross-reactive antigen) in the antibiotic formulations [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/12,16\">",
"       12,16",
"      </a>",
"      ]. False positive results may persist for as long as five days after discontinuation of these drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many fungi demonstrate galactomannans on their cell walls. False positive results of the Aspergillus galactomannan assay may be seen with infections caused by organisms that share cross-reacting antigens. These include filamentous organisms (eg, Fusarium species [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/17\">",
"       17",
"      </a>",
"      ] ), as well as other fungi (eg, Histoplasma capsulatum) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False positive results are more likely to occur during the first 100 days following hematopoietic stem cell transplantation and in patients with gastrointestinal tract mucositis caused by chemotherapy or graft-versus-host disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/19\">",
"       19",
"      </a>",
"      ]. The proposed mechanism is that galactomannan in foods or bacteria having cross-reactive epitopes may translocate across the intestinal mucosa during periods of reduced mucosal integrity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False positive results have been reported in patients who received transfusions of blood products that were collected in bags produced by a single manufacturer (Fresenius Kabi, Germany), but not in patients who received blood products that were collected in bags produced by other manufacturers [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some false positive results have been reported in children, in whom the assay has been less well studied. However, results of recent studies suggest relatively little false positivity, with similar risks as demonstrated in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/21\">",
"       21",
"      </a>",
"      ]. The FDA has not approved the serum galactomannan assay for use in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613737206\">",
"    <span class=\"h4\">",
"     Role of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the serum galactomannan assay report relatively low (&lt;50 percent) and high (&gt;90 percent) positive and negative predictive values, respectively. These values are largely a function of the low prevalence of disease, even when measured in high-risk populations (which is usually &lt;20 percent). One should thus consider the clinical context to determine the probability of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators have suggested using the serum galactomannan assay for screening (weekly or twice weekly) in order to detect invasive aspergillosis prior to the development of clinical signs or symptoms. Screening as a means to guide preemptive therapy or to withhold empiric treatment of fever has yet to be validated in randomized trials. More prospective studies are necessary to address the issue of when an antifungal can be withheld in this setting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when the antigen result alone should guide therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H833586#H833586\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Preemptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of the serum galactomannan assay has been best established in the setting of suspected disease. In the setting of clinical disease suspicion, prevalence is higher, assuring better predictive performance.",
"   </p>",
"   <p>",
"    Some investigators have suggested a role for serial galactomannan testing in patients with documented invasive aspergillosis, both as a prognostic measure of effectiveness of antifungal therapy, and to differentiate between worsening fungal infection and worsening radiographic findings developing as a result of the host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. The prognostic value of the serum galactomannan assay is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169260052\">",
"    <span class=\"h3\">",
"     Bronchoalveolar lavage fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The galactomannan assay detects fungal antigens even when the organism does not grow in the laboratory, providing an indication of potentially invasive disease. The galactomannan antigen assay performed on BAL fluid provides additional sensitivity compared to culture, estimated in most studies to exceed 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal threshold OD index for positivity continues to be debated; a higher threshold OD index results in lower sensitivity but higher specificity for invasive aspergillosis. A retrospective study was performed in which 251 patients who were at risk for invasive aspergillosis and who presented with unexplained nodular lesions or consolidation on lung imaging underwent galactomannan antigen testing of BAL fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients had a variety of underlying diseases, including solid organ transplantation in 29 percent, hematologic malignancy in 20 percent, and non-hematologic malignancy in 13 percent. Using a threshold OD index of &ge;0.8, the sensitivity of galactomannan antigen testing of BAL fluid for diagnosing proven or probable invasive aspergillosis was 86 percent and the specificity was 91 percent, whereas an OD index threshold &ge;0.5 resulted in a sensitivity of 93 percent and a specificity of 87 percent. As noted above, The United States FDA considers an OD index of &ge;0.5 to be positive for galactomannan antigen testing of both serum and BAL fluid.",
"   </p>",
"   <p>",
"    It is important to note that false positive results occur, and these are especially common in the setting in which the detection of fungi in the airways represents colonization as occurs in lung transplant recipients, or when the fluid that is used for BAL washes is contaminated with galactomannan. However, one study performed in lung transplant recipients suggested that specificity is high (95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/27\">",
"     27",
"    </a>",
"    ]. Many centers have begun to utilize this assay on BAL fluid as an adjunct to other diagnostic tests when invasive aspergillosis is suspected. Because performance may be dependent on technical variables, such as type and amount of BAL fluid, institutions should establish specific protocols for testing.",
"   </p>",
"   <p>",
"    The use of the galactomannan assay on BAL fluid from lung transplant recipients is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H1838389#H1838389\">",
"     \"Fungal infections following lung transplantation\", section on 'Galactomannan, beta-D-glucan, and PCR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486458\">",
"    <span class=\"h3\">",
"     Other specimen types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the galactomannan assay has been approved by the United States FDA for use only on serum and bronchoalveolar lavage fluid, galactomannan can also be detected in other samples, including cerebrospinal fluid, and pleural fluid, depending on the clinical context [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486465\">",
"    <span class=\"h2\">",
"     Beta-D-glucan assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;1,3-Beta-D-glucan, a cell wall component of many fungi, is detected by the beta-D-glucan assay. There are several different commercial assays available in different countries. The Fungitell assay has been approved by the United States Food and Drug Administration for the diagnosis of invasive fungal infections. These assays utilize the same principal as serum endotoxin assays, measuring activation of Factor G. Since the different marketed tests utilize different horseshoe crab substrates and different methods to measure output, performance may be variable. The output of the serum assay currently available in the US is based on spectrophotometer readings, in which optical density is converted to beta-D-glucan concentrations; the results are interpreted as negative (range &lt;60",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    indeterminate (60 to 79",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    or positive (&gt;80",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2011 meta-analysis that included 16 studies evaluating beta-D-glucan assays for the diagnosis of invasive fungal infections, the pooled sensitivity was 77 percent (95% CI 67-84 percent), and the pooled specificity was 85 percent (95% CI 80-90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/33\">",
"     33",
"    </a>",
"    ]. A 2012 meta-analysis that included six cohort studies of patients with hematologic malignancies noted a lower sensitivity (50 percent, 95% CI 34-65 percent) and a higher specificity (99 percent, 95% CI 97-100 percent) than previously reported; however, there were few cases of invasive aspergillosis tested to provide definitive conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/34\">",
"     34",
"    </a>",
"    ]. In individual studies, the sensitivity has ranged from 55 to 95 percent and the specificity has ranged from 77 to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/32,35-39\">",
"     32,35-39",
"    </a>",
"    ]. As in studies evaluating other fungal diagnostics, likely reasons for the differences in sensitivity and specificity between studies are that different thresholds were considered positive, different assays were used, patient populations varied, and study design was not uniform. Despite the substantial heterogeneity among different studies, the beta-D-glucan assay has good accuracy for distinguishing patients with proven or probable invasive fungal infections from patients without invasive fungal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/33\">",
"     33",
"    </a>",
"    ]. Additional prospective studies need to be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486472\">",
"    <span class=\"h3\">",
"     Caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following caveats should be considered when using the beta-D-glucan assay: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The beta-D-glucan assay is not specific for Aspergillus species and can be positive in patients with a variety of invasive fungal infections, including candidiasis and Pneumocystis jirovecii (formerly P. carinii). Although the beta-D-glucan assay may be positive in patients with a variety of invasive fungal infections, it is typically negative in patients with mucormycosis or cryptococcosis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/37,38,40,41\">",
"       37,38,40,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H18#H18\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Beta-D-glucan assay'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The specificity of the assay can be decreased by multiple other clinical variables; the following factors have been reported to cause false positive results [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/40\">",
"       40",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemodialysis with cellulose membranes",
"     </li>",
"     <li>",
"      Intravenous immunoglobulin",
"     </li>",
"     <li>",
"      Albumin",
"     </li>",
"     <li>",
"      Use of cellulose filters for intravenous administration",
"     </li>",
"     <li>",
"      Gauze packing of serosal surfaces",
"     </li>",
"     <li>",
"      Intravenous amoxicillin-clavulanic acid &nbsp;",
"     </li>",
"     <li>",
"      Bloodstream infections with certain bacteria, such as Pseudomonas aeruginosa [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14378086\">",
"    <span class=\"h3\">",
"     Role of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beta-D-glucan assay may be used for detecting invasive fungal infections early in the course of infection, prior to the onset of overt clinical findings. One study evaluated a screening strategy in which 95 patients receiving chemotherapy for acute leukemia underwent beta-D-glucan testing twice weekly in the absence of fever and daily in the presence of fever [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/44\">",
"     44",
"    </a>",
"    ]. Screening appeared to shorten the time interval between suspected infection and established diagnosis, when compared to waiting for clinical signs and symptoms of disease. However, this strategy has not been validated in randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H833586#H833586\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Preemptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486480\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigational DNA detection assays (eg, by polymerase chain reaction [PCR]) have shown mixed results, with some studies suggesting superior performance compared to antigen based assays, and others reporting the opposite [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/15,32,35,45-49\">",
"     15,32,35,45-49",
"    </a>",
"    ]. Results of multiple assays that use different technologies and microbial targets have been reported. A systemic review and meta-analysis suggested that sensitivity and specificity of PCR to detect invasive aspergillosis was 88 and 75 percent. However, this review emphasized that results cannot be generalized with non-homogeneity of methods and patients evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/50\">",
"     50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486487\">",
"    <span class=\"h2\">",
"     Precipitin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of precipitin antibodies may be useful for the diagnosis of allergy to various molds, including Aspergillus, but has no role in the diagnosis of invasive aspergillosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link&amp;anchor=H9#H9\">",
"     \"Allergic bronchopulmonary aspergillosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3038539\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging is an important component of the diagnostic evaluation. The lungs are the most commonly affected site in invasive aspergillosis; computed tomography (CT) scanning of the lungs often helps to support the diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56195 \" href=\"UTD.htm?41/47/42738\">",
"     image 1",
"    </a>",
"    ). In patients with clinical findings suggestive of sinus involvement, CT of the sinuses should be performed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66095 \" href=\"UTD.htm?29/0/29711\">",
"     image 2",
"    </a>",
"    ). When brain involvement is suspected, brain magnetic resonance imaging is indicated (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71228 \" href=\"UTD.htm?33/31/34289\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50013 \" href=\"UTD.htm?21/18/21807\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The imaging findings associated with invasive pulmonary aspergillosis, such as nodules with surrounding hypoattenuation, termed the halo sign, can be seen with other angioinvasive pulmonary infections (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56195 \" href=\"UTD.htm?41/47/42738\">",
"     image 1",
"    </a>",
"    ). However, this finding most often represents invasive aspergillosis because it is the most common mold to cause invasive infection. Imaging findings in patients with invasive aspergillosis are presented in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H429431#H429431\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064486494\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of Aspergillus spp in combination with the histopathologic demonstration of tissue invasion by hyphae provides definitive evidence of invasive aspergillosis. However, biopsy is frequently not feasible due to the risks of complications (eg, bleeding risk in patients with thrombocytopenia). A rational first step to establishing the diagnosis of invasive aspergillosis involves the use of non-invasive modalities, such as serum biomarkers (galactomannan and beta-D-glucan assays), and obtaining sputum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoalveolar lavage (BAL) specimens for fungal staining and culture. When BAL is performed, a sample should be sent for galactomannan antigen testing.",
"   </p>",
"   <p>",
"    A positive sputum fungal stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture should prompt therapy of hosts who are at risk for invasive aspergillosis. The galactomannan assay is relatively specific for invasive aspergillosis, and in the right clinical context, provides adequate evidence of invasive pulmonary disease. In contrast, a positive beta-D-glucan assay can occur in the setting of various invasive fungal infections, including candidiasis.",
"   </p>",
"   <p>",
"    Patients with clinical and radiographic findings that are suggestive of an invasive fungal infection, but in whom both the serum galactomannan assay and fungal stain and culture of the sputum are negative (or are not able to be obtained), should ideally undergo bronchoscopy with BAL. Lung biopsy should be performed if feasible. Studies have demonstrated that bronchoscopy is safe, and frequently yields important diagnostic information, especially when performed early in the evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of patients with pulmonary infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3913/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for biopsy include bronchoscopy with transbronchial biopsy, CT-guided transthoracic needle biopsy, and video-assisted thorascopic surgery. The most appropriate technique depends upon the location of the lesion(s), the individual patient&rsquo;s risk of complications from each procedure, and the necessity to establish the diagnosis. The decision regarding the need for a histopathologic diagnosis must be made on a patient-by-patient basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1057542070\">",
"    <span class=\"h2\">",
"     Outbreak of fungal meningitis and septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to diagnosis of patients affected by the 2012 United States outbreak of fungal meningitis and septic arthritis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link&amp;anchor=H19514050#H19514050\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/23/12658?source=see_link\">",
"       \"Patient information: Invasive aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14375356\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspergillus conidia are frequently inhaled into the airways, but because of effective clearance in the majority of individuals, disease usually does not result. Because we inhale conidia constantly, culture isolation of Aspergillus species from the airway does not necessarily indicate disease. Thus, the diagnosis of invasive aspergillosis is based upon both isolating the organism (or markers of the organism) and the probability that it is the cause of disease. (See",
"      <a class=\"local\" href=\"#H1064486416\">",
"       'Diagnostic modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Culture in combination with evidence of tissue invasion on histopathology, or culture from a normally sterile site, provides the most certain evidence of invasive aspergillosis. However, both microscopic examination and culture are insensitive and therapy should not be withheld in the absence of such confirmation. (See",
"      <a class=\"local\" href=\"#H1064486423\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Performing a biopsy is not feasible in some patients due to the risk of bleeding or other complications. In patients with risk factors and clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic features that are suggestive of invasive aspergillosis, culture of Aspergillus spp from respiratory secretions or finding typical hyphae on staining of respiratory secretions provides adequate evidence to warrant therapy. (See",
"      <a class=\"local\" href=\"#H1064486423\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspergillus organisms observed in biopsy specimens are typically narrow (3 to 6 microns wide), septated hyaline hyphae with acute angle branching (",
"      <a class=\"graphic graphic_picture graphicRef68747 \" href=\"UTD.htm?25/58/26531\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57220 \" href=\"UTD.htm?17/49/18202\">",
"       picture 2",
"      </a>",
"      ). However, several filamentous fungi including Scedosporium spp and Fusarium spp, have similar appearances to Aspergillus spp in histopathologic sections. The treatment of infections caused by these fungi may differ, so it is important to confirm genus and species by culture. (See",
"      <a class=\"local\" href=\"#H14377219\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histopathologic examination can usually distinguish Aspergillus spp and the other fungi described above from the Mucorales, which appear as broad, non-septate hyphae that exhibit right angle branching (",
"      <a class=\"graphic graphic_picture graphicRef66476 \" href=\"UTD.htm?4/58/5030\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72487 \" href=\"UTD.htm?25/12/25806\">",
"       picture 4",
"      </a>",
"      ). Determining whether the fungus is a Mucorales is important because these molds are not susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , which is the treatment of choice for invasive aspergillosis. (See",
"      <a class=\"local\" href=\"#H14377219\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Galactomannan is a major constituent of Aspergillus cell walls that is released during growth of hyphae. A double sandwich enzyme-linked immunosorbent assay (ELISA) that detects the galactomannan antigen is available for use on serum and bronchoalveolar lavage (BAL) fluid as an adjunctive test for the diagnosis of aspergillosis. The utility of the serum galactomannan assay has been best established in the setting of suspected disease in patients with hematologic malignancies. (See",
"      <a class=\"local\" href=\"#H1064486430\">",
"       'Galactomannan antigen detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      1,3-Beta-D-glucan, a cell wall component of many fungi, is detected by the beta-D-glucan assay. However, this assay is not specific for Aspergillus species, and can be positive in patients with a variety of invasive fungal infections, including candidiasis and Pneumocystis jirovecii (formerly P. carinii). (See",
"      <a class=\"local\" href=\"#H1064486465\">",
"       'Beta-D-glucan assay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rational first step to establishing the diagnosis of invasive aspergillosis involves the use of non-invasive modalities, such as serum biomarkers (galactomannan and beta-D-glucan assays) and obtaining sputum for fungal staining and culture. If the diagnosis is not made by these methods, a more invasive approach is indicated when feasible. Options include bronchoscopy with BAL, transbronchial biopsy, CT-guided transthoracic needle biopsy, and video-assisted thorascopic surgery. When BAL is performed, a sample should be sent for galactomannan antigen testing. (See",
"      <a class=\"local\" href=\"#H1064486494\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/1\">",
"      De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/2\">",
"      Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.",
"     </a>",
"    </li>",
"    <li>",
"     Procop, GW, Hayden, RT, Roberts, GD. Filamentous fungi. In: Diagnostic Microbiology of the Immunocompromised Host, Hayden RT, Carroll, KC, Tang, YW, Wolk, DM (Eds), ASM Press, Washington DC 2009. p.195.",
"    </li>",
"    <li>",
"     Verweij, PE, Brandt, ME. Aspergillus, Fusarium, and Other Opportunistic Moniliaceous Fungi. In: Manual of Clinical Microbiology, 2, 9th, Murray, PR, Baron, EJ, Landry, ML, Jorgenesen, JH, et al (Eds), ASM Press, Washington DC 2007. p.1802.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/5\">",
"      Cuenca-Estrella M, Bassetti M, Lass-Fl&ouml;rl C, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66 Suppl 1:i15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/6\">",
"      Balajee SA, Kano R, Baddley JW, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/7\">",
"      Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/8\">",
"      Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/9\">",
"      Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/10\">",
"      Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/11\">",
"      Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/12\">",
"      Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/13\">",
"      Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/14\">",
"      Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41 Suppl 6:S381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/15\">",
"      Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/16\">",
"      Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42:4744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/17\">",
"      Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2012; 50:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/18\">",
"      Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 2007; 14:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/19\">",
"      Asano-Mori Y, Kanda Y, Oshima K, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008; 61:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/20\">",
"      Mart&iacute;n-Rabad&aacute;n P, Gij&oacute;n P, Alonso Fern&aacute;ndez R, et al. False-positive Aspergillus antigenemia due to blood product conditioning fluids. Clin Infect Dis 2012; 55:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/21\">",
"      Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/22\">",
"      Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/23\">",
"      Miceli MH, Maertens J, Buv&eacute; K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007; 110:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/24\">",
"      Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/25\">",
"      Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/26\">",
"      Nou&eacute;r SA, Nucci M, Kumar NS, et al. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011; 53:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/27\">",
"      Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008; 15:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/28\">",
"      Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42:5517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/29\">",
"      Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/30\">",
"      D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/31\">",
"      Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/32\">",
"      Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1-&gt;3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/33\">",
"      Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. &beta;-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/34\">",
"      Lamoth F, Cruciani M, Mengoli C, et al. &beta;-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/35\">",
"      Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1--&gt;3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/36\">",
"      Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1--&gt;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/37\">",
"      Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/38\">",
"      Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/39\">",
"      Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1--&gt;3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/40\">",
"      Marty FM, Koo S. Role of (1--&gt;3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47 Suppl 1:S233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/41\">",
"      Obayashi T, Yoshida M, Mori T, et al. Plasma (1--&gt;3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/42\">",
"      Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008; 46:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/43\">",
"      Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/44\">",
"      Pazos C, Pont&oacute;n J, Del Palacio A. Contribution of (1-&gt;3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/45\">",
"      Costa C, Costa JM, Desterke C, et al. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002; 40:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/46\">",
"      Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006; 42:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/47\">",
"      Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002; 185:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/48\">",
"      Raad I, Hanna H, Sumoza D, Albitar M. Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients. Cancer 2002; 94:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/49\">",
"      Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/50\">",
"      Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/51\">",
"      Shannon VR, Andersson BS, Lei X, et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3913/abstract/52\">",
"      Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011; 117:3424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15717 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3913=[""].join("\n");
var outline_f3_52_3913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14375356\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1064485271\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486416\">",
"      DIAGNOSTIC MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58499699\">",
"      Direct examination of respiratory specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486423\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14377219\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486430\">",
"      Galactomannan antigen detection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22230119\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486437\">",
"      - Serum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1064486444\">",
"      Caveats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H613737206\">",
"      Role of testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H169260052\">",
"      - Bronchoalveolar lavage fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486458\">",
"      - Other specimen types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486465\">",
"      Beta-D-glucan assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486472\">",
"      - Caveats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14378086\">",
"      - Role of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486480\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486487\">",
"      Precipitin antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3038539\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1064486494\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1057542070\">",
"      Outbreak of fungal meningitis and septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14375356\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15717\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15717|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/47/42738\" title=\"diagnostic image 1\">",
"      CT pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/0/29711\" title=\"diagnostic image 2\">",
"      Aspergillus sinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/31/34289\" title=\"diagnostic image 3\">",
"      Aspergillus brain abscesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/18/21807\" title=\"diagnostic image 4\">",
"      Aspergillus cortical infarct with hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15717|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/58/26531\" title=\"picture 1\">",
"      Aspergillus silver stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/49/18202\" title=\"picture 2\">",
"      Aspergillus bronchopneumonia histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/58/5030\" title=\"picture 3\">",
"      Rhizopus hyphae lung tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/12/25806\" title=\"picture 4\">",
"      Mucorales hyphae",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=related_link\">",
"      Clinical manifestations and diagnosis of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=related_link\">",
"      Diagnosis and treatment of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11178?source=related_link\">",
"      Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/23/12658?source=related_link\">",
"      Patient information: Invasive aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_52_3914="Recognition and management of allergic disease during pregnancy";
var content_f3_52_3914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recognition and management of allergic disease during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Michael Schatz, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/52/3914/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/52/3914/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy may be complicated by new onset or preexisting allergic disease, including rhinitis, urticaria, angioedema, or atopic dermatitis. In contrast to asthma in pregnancy, relatively few studies have examined the management of other allergic disorders in pregnant women.",
"   </p>",
"   <p>",
"    This topic reviews the recognition and management of rhinitis, urticaria, angioedema, and atopic dermatitis in pregnancy, as well as general principles of medication use during pregnancy. The diagnosis and management of asthma in pregnancy, anaphylaxis in pregnancy, the various dermatoses of pregnancy, and the management of allergic rhinitis in nonpregnant patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"     \"Physiology and clinical course of asthma in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=see_link\">",
"     \"Management of asthma during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link\">",
"     \"Dermatoses of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     General approach to treating allergy in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In any form of allergic disease, a primary element of management is avoidance of the culprit allergen, when possible. Allergen avoidance is particularly important during pregnancy because the use of systemic medications should be minimized.",
"   </p>",
"   <p>",
"    Women with significant allergic disease should ideally be evaluated",
"    <strong>",
"     before",
"    </strong>",
"    they become pregnant, so that any skin testing, challenge procedures, or other exposures that might be necessary for definitive diagnosis can be safely performed. This is especially important for women with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergies to medications that may be needed during pregnancy, such as local anesthetics or drugs used in general anesthesia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/27/442?source=see_link\">",
"       \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Allergies for which there are definitive treatments, such as stinging insect venom (yellowjackets, bees, fire ants, others). Some patients with these allergies are candidates for venom immunotherapy, which can be continued during pregnancy, but should not be initiated in a woman who is already pregnant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link&amp;anchor=H13#H13\">",
"       \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\", section on 'Pregnant women'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any woman who has experienced anaphylaxis. Anaphylaxis can be devastating to both the mother and fetus. As a result, it is imperative to prevent a recurrence during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=see_link\">",
"       \"Anaphylaxis in pregnant and breastfeeding women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Medication use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the use of medications in a pregnant woman, the potential risk of a drug must be balanced against the effects of untreated disease. Medication use during pregnancy can have a variety of serious adverse effects on the fetus or the pregnancy. These include abortion, fetal death, and, particularly with first trimester exposure, congenital malformations. Despite the potential for harm, few drugs have been proven harmful in pregnancy, and fewer than 1 percent of congenital malformations can be attributed to drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/1\">",
"     1",
"    </a>",
"    ]. However, statistical and ethical considerations make it unlikely that any drug will ever be \"proven safe.\"",
"   </p>",
"   <p>",
"    Many allergic disorders can be managed with topical medications, including nasal sprays, eye drops, and topical lotions and creams. These preparations allow the drug to be concentrated at the site of inflammation, so that less total drug is required to obtain clinical benefit. However, not all topical preparations are considered appropriate for use in pregnancy, as detailed in the discussions of specific disorders below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     FDA categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration established five categories to describe a drug's potential for causing adverse effects during pregnancy and mandated that drugs introduced after 1980 be classified into one of these categories in the package insert (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/2\">",
"     2",
"    </a>",
"    ]. The categories are based on the results of animal studies, human data, and consideration of whether the benefit of the drug's use during pregnancy outweighs the risk. The assessment of the risk of medication use based upon animal and human studies is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of asthma during pregnancy\", section on 'Assessing risk of medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no allergy medications that meet the requirements for category A (adequately controlled studies show no risk) (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). Most category B drugs are labeled as such because of reassuring animal studies without \"adequate and controlled\" human data. One may wish to choose a class B versus a class C drug (risk cannot be ruled out) among equally effective alternatives due to the reassuring animal studies. Category D (positive evidence of risk) provides a relative contraindication to use in pregnancy, and category X refers to drugs that are contraindicated in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is uncommon during pregnancy. However, it is important to recognize it rapidly and treat it effectively, as the maternal hypoxia and hypotension that can result may be catastrophic to both mother and fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RHINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that the most common causes of nasal symptoms necessitating treatment during pregnancy are [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy rhinitis",
"     </li>",
"     <li>",
"      Allergic rhinitis",
"     </li>",
"     <li>",
"      Rhinitis medicamentosa",
"     </li>",
"     <li>",
"      Sinusitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2251392\">",
"    <span class=\"h2\">",
"     Non-drug therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions may be considered first in pregnant women with rhinitis symptoms. These include saline nasal sprays or nasal irrigation, regular physical exercise, and use of adhesive strips that mechanically dilate the nasal passages.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline nasal sprays or nasal irrigation: Nasal irrigation is a nonpharmacologic intervention that is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/4\">",
"       4",
"      </a>",
"      ]. A variety of devices, including bulb syringes and bottle sprayers, may be used to perform nasal lavage (",
"      <a class=\"graphic graphic_table graphicRef71059 \" href=\"UTD.htm?42/33/43548\">",
"       table 2",
"      </a>",
"      ). Patients should use at least 200 mL in each nostril. This can be performed daily or only as needed for intermittent symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/5\">",
"       5",
"      </a>",
"      ]. In a randomized trial of pregnant women, nasal saline irrigation was shown to be beneficial for treatment of allergic rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Regular physical exercise, which leads to physiologic nasal vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of adhesive strips that mechanically dilate the nasal valve area (external nasal dilators), which are available over-the-counter [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevation of the head of the bed by 30 to 45 degrees: Placing bricks or other objects under the legs of the bed is more effective than using extra pillows [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy normally induces hyperemia and edema of the nasal mucosa. This and other pregnancy-related changes in the upper respiratory tract are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Twenty to 30 percent of pregnant women develop symptomatic nasal congestion during pregnancy, a condition called pregnancy rhinitis (or rhinitis of pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Pregnancy rhinitis may be defined as nasal symptoms during pregnancy lasting six or more weeks without other signs of respiratory tract infection and with no known allergic cause, disappearing completely within two weeks after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients complain of persistent nasal congestion, accompanied by watery or viscous clear nasal secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/14\">",
"     14",
"    </a>",
"    ]. Nasal congestion can lead to mouth breathing at night and reduced quality of sleep. The other causes of rhinitis listed above must be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of pregnancy rhinitis is not known. In the past, it was attributed to changes in estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone, although there is little specific evidence to support this assertion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/16\">",
"     16",
"    </a>",
"    ]. Smoking and allergic sensitization to dust mite were identified as risk factors for the development of pregnancy rhinitis in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/17\">",
"     17",
"    </a>",
"    ]. However, neither asthma nor hay fever is more common among women who develop the pregnancy rhinitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy rhinitis does not usually require therapy, nor does it respond well to medications. In those who seek specific treatment, nonpharmacologic measures are suggested. (See",
"    <a class=\"local\" href=\"#H2251392\">",
"     'Non-drug therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several medications have been studied in pregnancy rhinitis, although none have demonstrated clear efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intranasal glucocorticoid sprays were NOT beneficial for pregnancy rhinitis in a randomized trial of 53 women [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anecdotal evidence supports the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (0.03 percent) nasal spray, which is typically administered as two sprays to each nostril three times a day.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       Pseudoephedrine",
"      </a>",
"      is also occasionally used for severe pregnancy rhinitis, although oral vasoconstrictors should be avoided in the first trimester and in women with hypertension. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Decongestants'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of pregnancy rhinitis can complicate the diagnosis of coexisting upper respiratory tract infections or sinusitis, and these disorders should be considered in women who seek evaluation for nasal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36344?source=see_link\">",
"     \"Treatment of respiratory infections in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effect of pregnancy on preexisting rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preexisting rhinitis may worsen, improve, or remain unchanged during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/3\">",
"     3",
"    </a>",
"    ]. These trends are similar to those seen with asthma, and one study found concordance between the course of asthma and that of rhinitis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/19\">",
"     19",
"    </a>",
"    ]. This suggests that mechanistic factors involved in both diseases may be similarly altered during pregnancy.",
"   </p>",
"   <p>",
"    Data suggest that rhinitis does not directly affect pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/20\">",
"     20",
"    </a>",
"    ]. However, uncontrolled rhinitis can indirectly affect pregnancy by impacting gestational nutrition, sleep, or stress. In addition, uncontrolled rhinitis may be a cause of snoring, which may increase the risk of gestational hypertension, preeclampsia, and intrauterine growth retardation, although not all studies have confirmed this association [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncontrolled rhinitis may also exacerbate coexisting asthma or predispose to sinusitis during pregnancy. Thus, appropriate management of rhinitis during pregnancy can help women avoid exposures to other medications, such as antibiotics and oral glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Allergic rhinitis/conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic rhinitis is usually preexisting, although it may develop or be recognized for the first time during pregnancy. Patients with allergic rhinitis sometimes report prominent sneezing, nasal pruritus, and watery rhinorrhea, and some have concomitant ocular itching and irritation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with preexisting allergic rhinitis, information from",
"    <strong>",
"     prior",
"    </strong>",
"    skin testing may provide information about which allergens should be avoided. Common triggers for allergic rhinitis include dust mites, animal danders, molds, and pollens. Measures to avoid specific allergens are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If prior skin testing was not performed in the past, then this evaluation should be",
"    <strong>",
"     deferred",
"    </strong>",
"    until after delivery, since skin testing has the potential to induce systemic allergic reactions in highly sensitive patients. In vitro tests for allergen-specific IgE are widely available, although skin testing is more sensitive for the diagnosis of sensitivity to inhaled allergens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic therapies should be considered initially. (See",
"    <a class=\"local\" href=\"#H2251392\">",
"     'Non-drug therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cromolyn sodium nasal spray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    may be considered a first-line therapy for mild allergic rhinitis in pregnancy because of its excellent safety profile. Cromolyn sodium is minimally absorbed into the systemic circulation when applied to a mucosal surface, and it is designated as a category B drug (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/23\">",
"     23",
"    </a>",
"    ]. There are no safety data specific to nasal or ophthalmic preparations, although three human studies of over 600 pregnancies, including first trimester use, failed to detect any increased risk for congenital defects with inhaled cromolyn sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing of intranasal cromolyn is one spray per nostril up to six times daily. The need for frequent dosing, combined with lower efficacy compared to newer therapies, has limited the utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    . However, the safety of this therapy and its availability without a prescription make it a reasonable initial choice for many patients. A second therapy may be added for those with persistent symptoms after two to four weeks of intranasal cromolyn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Glucocorticoid nasal sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intranasal glucocorticoids are highly effective for allergic rhinitis and are considered to be appropriate for use during pregnancy, based on reassuring data available for their use as inhaled preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/25\">",
"     25",
"    </a>",
"    ], which deliver higher doses than nasal sprays. The lowest effective dose should be used during pregnancy.",
"   </p>",
"   <p>",
"    No important differences in efficacy or safety appear to exist between the various intranasal glucocorticoid preparations. Thus, if a patient is already well-controlled on any of the intranasal glucocorticoid preparations, it would be reasonable to continue it during pregnancy. Some clinicians choose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    if starting intranasal glucocorticoids for the first time during pregnancy, since it is classified as a category B drug based on reassuring data from the population-based Swedish Medical Birth Registry, whereas most of the other agents are categorized as category C [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'FDA categories'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines are less effective for the treatment of allergic rhinitis compared with intranasal glucocorticoids, particularly for the relief of nasal congestion and post-nasal drip. Several studies have evaluated the safety of antihistamines during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Most pregnant women who require antihistamines are most appropriately treated with a second generation agent, because these drugs are less sedating and have fewer cholinergic side effects compared with first generation agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among second generation antihistamines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      (10 mg once daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (10 mg once daily) may be considered the second generation antihistamines of choice in pregnancy. There are reassuring human data for each of these drugs in a large number of pregnant patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      First generation agents are widely available, inexpensive, and can be useful on an as needed basis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      before bed. Among the first generation agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"       chlorpheniramine",
"      </a>",
"      has been recommended as the first generation antihistamine of choice for use during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/27\">",
"       27",
"      </a>",
"      ]. The dosing of chlorpheniramine is 4 mg every four to six hours. Sustained release formulations are available (8 mg up to three times daily and 12 mg twice daily). Dosing should not exceed 24 mg per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antihistamine nasal sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human safety data are not available for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/25/33168?source=see_link\">",
"     olopatadine",
"    </a>",
"    nasal sprays, although animal studies are reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/20\">",
"     20",
"    </a>",
"    ]. Until more information is available, we would suggest avoiding these medications during pregnancy unless a patient was uniquely responsive to one of them prior to pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Decongestants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decongestants are vasoconstrictors that are available as both oral preparations and nasal sprays.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intranasal decongestants &mdash; Decongestant nasal sprays can be used",
"      <strong>",
"       very briefly",
"      </strong>",
"      (eg, three days or less) for temporary relief of severe nasal congestion. Some reassuring human data exist for intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"       oxymetazoline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. Short-term use (ie, three days or less) would be acceptable for use during pregnancy. However, patients should be warned about dependence with prolonged use. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Rhinitis medicamentosa'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Oral decongestants &mdash; Oral decongestants are probably best avoided altogether during the first trimester because of an uncertain risk of a rare birth defect, gastroschisis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       Pseudoephedrine",
"      </a>",
"      is the agent of choice in the second and third trimesters, in women without hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/25\">",
"       25",
"      </a>",
"      ]. Pseudoephedrine is administered at a dose of 60 mg, given at a maximum frequency of four times daily, or 120 mg of the long-acting preparation given twice daily.",
"      <br/>",
"      <br/>",
"      A possible association between pseudoephedrine and gastroschisis (baseline incidence of 1 in 10,000 births) was raised in a case-control study [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/34\">",
"       34",
"      </a>",
"      ]. In addition, a significant relationship between infant gastroschisis and maternal phenylpropanolamine use has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/35\">",
"       35",
"      </a>",
"      ], suggesting a possible drug class effect. However, reassuring data on pseudoephedrine also exist. A Swedish study prospectively examined the pregnancy outcomes of 2474 women who had reported use of oral decongestants (mostly phenylpropanolamine or pseudoephedrine) in early pregnancy and 1774 women who used these medications in later pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/36\">",
"       36",
"      </a>",
"      ]. No teratogenic effects were detected in either group. In addition, the use of these medications in later pregnancy (after the first antenatal visit) was associated with lower rates of premature birth, low birth weight, small-for-date infants, and perinatal death, prompting the authors to hypothesize that rhinitis of pregnancy may be a sign of good placental function. Although these data are reassuring, they do not have adequate power to exclude an increased risk of gastroschisis due to maternal first trimester use of oral decongestants.",
"      <br/>",
"      <br/>",
"      Concern has also been raised regarding potential adverse effects of pseudoephedrine on uteroplacental blood flow; although a single dose study did not show any significant adverse effect [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       Phenylephrine",
"      </a>",
"      should probably be avoided in pregnancy because of uncertain efficacy and questionable safety. Phenylephrine had been increasingly used as a substitute for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      in many over-the-counter preparations in the United States, due to escalating abuse of pseudoephedrine as a stimulant in athletics and in the illegal production of methamphetamines. However, phenylephrine is less effective for the treatment of rhinitis symptoms, and may not be superior to placebo at the 10 mg dose that is commonly available over-the-counter [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. In addition, phenylephrine (unlike pseudoephedrine) has strong alpha agonist properties, and uterine blood vessels selectively express alpha adrenergic receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/40\">",
"       40",
"      </a>",
"      ]. Therapeutic doses of phenylephrine were shown to reduce uterine blood flow substantially in animal models [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/41\">",
"       41",
"      </a>",
"      ]. Studies of congenital defects and phenylephrine exposure have been inconclusive [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antihistamines and decongestants combined",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with allergic rhinitis who have prominent nasal congestion often report more relief with the combination of an antihistamine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    than with either drug alone. However, since pseudoephedrine should be avoided in the first trimester, it is preferable to recommend glucocorticoid nasal sprays instead to such patients during pregnancy. Glucocorticoids sprays provide particularly effective relief of nasal congestion. Efficacy studies of these agents are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link&amp;anchor=H25107347#H25107347\">",
"     \"Pharmacotherapy of allergic rhinitis\", section on 'Intranasal glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Allergen immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen immunotherapy is NOT initiated during pregnancy due to the potential harm that could result if a systemic reaction or anaphylaxis were to occur. However, patients who were tolerating and deriving benefit from immunotherapy prior to pregnancy may continue it through pregnancy in many cases.",
"   </p>",
"   <p>",
"    Considerations AGAINST beginning immunotherapy during pregnancy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The propensity for systemic reactions in that patient is unknown",
"     </li>",
"     <li>",
"      Systemic reactions are more likely during initiation of immunotherapy",
"     </li>",
"     <li>",
"      Immunotherapy takes months to work, so the patient would not derive clinical benefit for most of the pregnancy anyway",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The continuation of allergy immunotherapy during pregnancy appears to be safe, aside from the risk of systemic reactions. Two studies of 130 pregnancies in 171 women receiving inhalant allergen immunotherapy reported no increase in abortions, perinatal deaths, prematurity, toxemia, or congenital malformations in the treated patients in comparison to both a nontreated pregnant allergic control group and to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on this information, it is recommended that allergen immunotherapy be continued during pregnancy in patients already receiving it, who also [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appear to be deriving benefit",
"     </li>",
"     <li>",
"      Are not prone to systemic reactions",
"     </li>",
"     <li>",
"      Are receiving a maintenance or at least a substantial (ie, therapeutic) dosage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose is not increased during pregnancy, and some clinicians reduce the dose slightly in an effort to lower the risk of a systemic reaction further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rhinitis medicamentosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinitis medicamentosa refers to rhinitis symptoms resulting from application of topical agents to the nasal mucosa. The most common precipitant is over-the-counter decongestant nasal sprays containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Decongestants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several days of nasal decongestant use leads to rebound nasal congestion as the medication wears off, prompting patients to increase the dose in an effort to obtain relief of symptoms, and establishing a vicious cycle of nasal congestion and escalating medication use. Rhinitis medicamentosa may complicate viral respiratory infections or various causes of chronic rhinitis for which patients may resort to decongestant sprays.",
"   </p>",
"   <p>",
"    Treatment involves discontinuation of the nasal decongestant, and in most cases, concomitant treatment with intranasal glucocorticoids. Treatment options are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H7#H7\">",
"     \"An overview of rhinitis\", section on 'Topical nasal medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute bacterial rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that acute bacterial rhinosinusitis was more common in pregnant than nonpregnant patients, although this finding has not been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/44\">",
"     44",
"    </a>",
"    ]. A high index of suspicion must be maintained for sinusitis during pregnancy because many pregnant women with sinusitis lack classic clinical findings. The diagnosis and treatment of sinusitis in pregnancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36344?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of respiratory infections in pregnant women\", section on 'Sinusitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     URTICARIA AND ANGIOEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria, with or without angioedema, may occur during pregnancy because of any of the causes defined in the nonpregnant state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urticaria limited to pregnancy is rare, but affected patients may experience recurrences in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The pathogenesis of urticaria of pregnancy is unknown, although speculation includes allergic sensitization to endogenous hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of urticaria is largely based on the appearance of the lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urticaria that occurs during gestation must be differentiated from several of the dermatoses of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autoimmune progesterone dermatitis of pregnancy",
"     </li>",
"     <li>",
"      Polymorphic eruption of pregnancy (PEP)",
"     </li>",
"     <li>",
"      Other pruritic dermatoses of pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Autoimmune progesterone dermatitis of pregnancy",
"    </strong>",
"    &nbsp;A distinctive syndrome termed autoimmune progesterone dermatitis of pregnancy is characterized by a papulopustular eruption, transient arthritis, peripheral and tissue eosinophilia, spontaneous abortion, and delayed hypersensitivity to intradermal aqueous progesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune progesterone urticaria also occurs in nonparous women, usually 7 to 10 days premenstrually [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Progesterone-induced anaphylaxis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Pruritic urticarial papules and plaques of pregnancy",
"    </strong>",
"    &nbsp;Pruritic urticarial papules and plaques of pregnancy (PUPPP) is an urticarial, pruritic eruption that develops in and around the abdominal striae in about 0.5 percent of pregnancies (",
"    <a class=\"graphic graphic_picture graphicRef55164 graphicRef67980 \" href=\"UTD.htm?42/62/44004\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dermatologic conditions that affect pregnant women are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link\">",
"     \"Dermatoses of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Laryngopathia gravidarum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngopathia gravidarum is an acute or chronic noninfectious, mildly inflammatory process of the laryngeal tissues in multigravid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/55\">",
"     55",
"    </a>",
"    ]. The pathogenesis remains speculative, but it may comprise several different entities. It has been attributed to an abnormal effect of pregnancy hormones on the laryngeal mucosa because of its rapid reduction after delivery.",
"   </p>",
"   <p>",
"    The acute form occurs just before parturition, whereas the chronic form occurs earlier in pregnancy and may recur in subsequent pregnancies. Both forms spontaneously subside post-partum. Symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progressive dyspnea (occasionally necessitating an artificial airway)",
"     </li>",
"     <li>",
"      Hoarseness",
"     </li>",
"     <li>",
"      Nonfebrile sore throat and odynophagia",
"     </li>",
"     <li>",
"      Malaise",
"     </li>",
"     <li>",
"      Lymphadenopathy",
"     </li>",
"     <li>",
"      Cough",
"     </li>",
"     <li>",
"      Elevated white blood count and erythrocyte sedimentation rate (40 to 60",
"      <span class=\"nowrap\">",
"       mm/hour)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The larynx, and frequently the epiglottis, demonstrate patchy localized edema and congestion, but the aryepiglottic folds, arytenoids, vestibular region, and true vocal cords are unaffected. Microscopically, the surface epithelium and mucus glands are normal, but the submucosa appears edematous, being infiltrated with lymphocytes and plasma cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with new onset urticaria, identification and avoidance of offending agents or causes would ideally prevent urticaria or angioedema symptoms and obviate pharmacologic treatment. In contrast, there are no identifiable triggers in most patients with chronic urticaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacologic therapy of chronic urticaria in pregnancy is reviewed separately. When symptomatic therapy is required, H1 antihistamines are recommended. Severe flares are usually controlled with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Dosing of antihistamines and prednisone in pregnant women with chronic urticaria is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H22#H22\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'Systemic glucocorticoids for rescue therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ATOPIC DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other atopic disorders, atopic dermatitis (AD) may worsen, remain the same, or improve with pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In one study, most of the women whose symptoms worsened during pregnancy reported this trend by the twentieth week [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pregnant women with AD are aware of their disease before pregnancy since AD typically has its onset in infancy or early childhood. The most important clinical features essential to making the diagnosis of atopic dermatitis are [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Chronic or recurring course",
"     </li>",
"     <li>",
"      Typical appearing rash and distribution",
"     </li>",
"     <li>",
"      Atopy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of atopic dermatitis in pregnant women is the same as in nonpregnant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis during pregnancy must be differentiated from other pregnancy-related pruritic skin changes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic pruritus (pruritus gravidarum) has its usual onset during the first trimester, and only excoriations are seen. It may be caused by a functional hepatic disturbance induced by estrogens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35816?source=see_link&amp;anchor=H10#H10\">",
"       \"The skin, hair, nails, and mucous membranes during pregnancy\", section on 'Pruritus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cholestasis of pregnancy is a disorder presenting with pruritus of the palms and soles, generally without primary skin lesions (ie, other than excoriations) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/58\">",
"       58",
"      </a>",
"      ]. Elevation of serum bile acids triggers pruritus. Cholestasis of pregnancy is associated with an increased incidence of stillbirth, intrapartum fetal distress, and preterm labor, so it is important to make this diagnosis by assessing liver function in pregnant patients with unremitting pruritus and excoriations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link\">",
"       \"Intrahepatic cholestasis of pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"       \"Pruritus associated with cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prurigo of pregnancy occurs in the second or third trimesters and is an erythematous, papular eruption with excoriations, primarily localized to the anterior abdomen (",
"      <a class=\"graphic graphic_picture graphicRef72147 \" href=\"UTD.htm?21/39/22132\">",
"       picture 2",
"      </a>",
"      ). The mechanism has not been determined. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link\">",
"       \"Dermatoses of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pruritic folliculitis of pregnancy usually occurs during the third trimester and presents with follicular papules and pustules on the trunk, which spread to the arms and legs. It usually resolves before delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link\">",
"       \"Dermatoses of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, symptoms of atopic dermatitis should be optimally controlled before conception so that the medications can be tapered to the lowest effective dose in preparation for conception and early pregnancy.",
"   </p>",
"   <p>",
"    Certain medications should be discontinued in advance of conception:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      for severe AD (used by either the female or male partner) should be discontinued at least three month prior to conception.",
"     </li>",
"     <li>",
"      Psoralens plus ultraviolet A (PUVA) should be stopped prior to conception, although a specific drug-free interval has not been established [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Emollients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of AD during pregnancy should emphasize avoidance of triggering factors and maximize the use of emollients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Oral antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orally administered antihistamines should be used to control pruritus. As discussed previously,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    are the preferred agents. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Antihistamines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of topic corticosteroids in pregnancy has not been well defined. Until more information is available, we recommend using the smallest amount of the least potent agent that controls disease during pregnancy.",
"   </p>",
"   <p>",
"    The following studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review identified seven studies (including 659,675 patients) reporting pregnancy outcomes in women being treated with topic glucocorticoids for various conditions, but concluded that the quality of the evidence was insufficient to detect an association between this class of agents and congenital abnormalities, preterm birth, or stillbirth [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/60\">",
"       60",
"      </a>",
"      ]. However, there was a possible association between low birthweight and very potent topical glucocorticoids.",
"     </li>",
"     <li>",
"      In one case, severe symmetric intrauterine growth restriction was associated with the topical use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      , which at a strength of 0.1 percent, is classified as a moderate potency agent. In this report, the mother applied 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of triamcinolone cream topically from 12 to 29 weeks of gestation because of atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a topical corticosteroid is required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (0.5 to 2.5 percent) is a good initial choice, as it has a low potential for adrenal suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients should be counseled to use stronger agents sparingly, and only on those areas of the body that do not respond to weaker agents. There are no data upon which to recommend one particular medium potency topical corticosteroid over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients not responding to low or medium potency topical corticosteroids, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be preferable to the use of significant amounts of more potent topical preparations. If possible, oral glucocorticoids should be avoided during the first trimester. After that, prednisone is preferred over other oral agents. The safety of prednisone in pregnancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Topical tacrolimus and pimecrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of pregnancies in women taking oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for preservation of organ transplants have been generally reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?3/52/3914/abstract/42\">",
"     42",
"    </a>",
"    ], although data on these agents are limited. Until more information is available, we suggest avoiding tacrolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment of bacterial superinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious exacerbations of atopic dermatitis, generally secondary to S. aureus, should be treated with penicillinase-resistant synthetic penicillins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    in patients who are allergic to penicillin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Management of infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/21/18770?source=see_link\">",
"       \"Patient information: Asthma and pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=see_link\">",
"       \"Patient information: Taking over-the-counter medicines during pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"       \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"       \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=see_link\">",
"       \"Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with significant allergic disease should ideally be evaluated",
"      <strong>",
"       before",
"      </strong>",
"      they become pregnant, so that any skin testing, challenge procedures, or other exposures that might be necessary for definitive diagnosis can be safely performed, and a plan for management during pregnancy can be formulated. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic measures, such as nasal saline irrigation, can be helpful in all forms of rhinitis. (See",
"      <a class=\"local\" href=\"#H2251392\">",
"       'Non-drug therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy rhinitis refers to nasal congestion and discharge lasting six weeks or more during pregnancy, in the absence of other causes of rhinitis, with resolution within two weeks of delivery. In most women, pregnancy rhinitis can be managed with nonpharmacologic measures alone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy rhinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients requiring oral H1 antihistamines for treatment of allergic disease in pregnancy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      over other agents. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For the treatment of allergic rhinitis during pregnancy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest intranasal cromolyn (one spray per nostril up to six times per day) for patients with mild symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest glucocorticoid nasal sprays for patients with moderate to severe disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest AVOIDING oral decongestants in the first trimester of pregnancy and in any pregnant women with hypertension (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). After the first trimester, we counsel patients to limit their use of these to occasional relief of severe nasal congestion. Decongestant nasal sprays should only be used in a limited manner as well, since they may cause rebound congestion after a few days of use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of atopic dermatitis during pregnancy should emphasize avoidance of triggering factors, maximal use of emollients, and oral antihistamines as needed to control pruritus. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Atopic dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with symptoms despite the above measures, we suggest topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      , 0.5 to 2.5 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients should be counseled to use stronger topical corticosteroids sparingly, and only on those areas of the body that do not respond to weaker agents.",
"     </li>",
"     <li>",
"      During pregnancy, limited courses of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      may be preferable to the use of significant amounts of more potent topical corticosteroids. However, oral glucocorticoids should be avoided during the first trimester if possible.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Scialli A, Lone A. Pregnancy effects of specific medications used to treat asthma and immunological diseases. In: Asthma and immunological diseases in pregnancy and early infancy, Schatz M, Zeiger RS, Claman HN (Eds), Marcel Dekker, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/2\">",
"      Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 1978; 61:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/3\">",
"      Schatz M, Zeiger RS. Diagnosis and management of rhinitis during pregnancy. Allergy Proc 1988; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/4\">",
"      Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/5\">",
"      Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am Fam Physician 2009; 80:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/6\">",
"      Garavello W, Somigliana E, Acaia B, et al. Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study. Int Arch Allergy Immunol 2010; 151:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/7\">",
"      Eccles R. Nasal airflow in health and disease. Acta Otolaryngol 2000; 120:580.",
"     </a>",
"    </li>",
"    <li>",
"     Schatz M, Zeiger RS, Falkoff R, et al. Asthma and allergic diseases during pregnancy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, St. Louis 2009. p.1423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/9\">",
"      Turnbull GL, Rundell OH, Rayburn WF, et al. Managing pregnancy-related nocturnal nasal congestion. The external nasal dilator. J Reprod Med 1996; 41:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/10\">",
"      Stroud RH, Wright ST, Calhoun KH. Nocturnal nasal congestion and nasal resistance. Laryngoscope 1999; 109:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/11\">",
"      Gani F, Braida A, Lombardi C, et al. Rhinitis in pregnancy. Eur Ann Allergy Clin Immunol 2003; 35:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/12\">",
"      Elleg&aring;rd EK. The etiology and management of pregnancy rhinitis. Am J Respir Med 2003; 2:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/13\">",
"      Elleg&aring;rd E, Hellgren M, Tor&eacute;n K, Karlsson G. The incidence of pregnancy rhinitis. Gynecol Obstet Invest 2000; 49:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/14\">",
"      Elleg&aring;rd EK. Pregnancy rhinitis. Immunol Allergy Clin North Am 2006; 26:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/15\">",
"      Elleg&aring;rd EK. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin Rev Allergy Immunol 2004; 26:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/16\">",
"      Elleg&aring;rd EK, Karlsson NG, Elleg&aring;rd LH. Rhinitis in the menstrual cycle, pregnancy, and some endocrine disorders. Clin Allergy Immunol 2007; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/17\">",
"      Elleg&aring;rd E, Karlsson G. IgE-mediated reactions and hyperreactivity in pregnancy rhinitis. Arch Otolaryngol Head Neck Surg 1999; 125:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/18\">",
"      Elleg&aring;rd EK, Hellgren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol Allied Sci 2001; 26:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/19\">",
"      Kircher S, Schatz M, Long L. Variables affecting asthma course during pregnancy. Ann Allergy Asthma Immunol 2002; 89:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/20\">",
"      Somosk&ouml;vi A, B&aacute;rtfai Z, Tam&aacute;si L, et al. Population-based case-control study of allergic rhinitis during pregnancy for birth outcomes. Eur J Obstet Gynecol Reprod Biol 2007; 131:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/21\">",
"      Franklin KA, Holmgren PA, J&ouml;nsson F, et al. Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. Chest 2000; 117:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/22\">",
"      Ayrm A, Keskin EA, Ozol D, et al. Influence of self-reported snoring and witnessed sleep apnea on gestational hypertension and fetal outcome in pregnancy. Arch Gynecol Obstet 2011; 283:195.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/24\">",
"      Wilson J. Use of sodium cromoglycate during pregnancy. J Pharm Med 1982; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/25\">",
"      National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 2005; 115:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/26\">",
"      Shaikh WA. A retrospective study on the safety of immunotherapy in pregnancy. Clin Exp Allergy 1993; 23:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/27\">",
"      Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/28\">",
"      Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/29\">",
"      Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/30\">",
"      Gilbert C, Mazzotta P, Loebstein R, Koren G. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf 2005; 28:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/31\">",
"      K&auml;ll&eacute;n B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146.",
"     </a>",
"    </li>",
"    <li>",
"     Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy, PSG Publishing, Littleton, MA 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/33\">",
"      Rayburn WF, Anderson JC, Smith CV, et al. Uterine and fetal Doppler flow changes from a single dose of a long-acting intranasal decongestant. Obstet Gynecol 1990; 76:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/34\">",
"      Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992; 45:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/35\">",
"      Torfs CP, Katz EA, Bateson TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996; 54:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/36\">",
"      K&auml;ll&eacute;n BA, Olausson PO. Use of oral decongestants during pregnancy and delivery outcome. Am J Obstet Gynecol 2006; 194:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/37\">",
"      Smith CV, Rayburn WF, Anderson JC, et al. Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow. Obstet Gynecol 1990; 76:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/38\">",
"      Hatton RC, Winterstein AG, McKelvey RP, et al. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother 2007; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/39\">",
"      Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009; 102:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/40\">",
"      Smith NT, Corbascio AN. The use and misuse of pressor agents. Anesthesiology 1970; 33:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/41\">",
"      Cottle MK, Van Petten GR, van Muyden P. Effects of phenylephrine and sodium salicylate on maternal and fetal cardiovascular indices and blood oxygenation in sheep. Am J Obstet Gynecol 1982; 143:170.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.org (Accessed on August 31, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/43\">",
"      Dombrowski MP, Schatz M, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol 2008; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/44\">",
"      Sorri M, Hartikainen-Sorri AL, K&auml;rj&auml; J. Rhinitis during pregnancy. Rhinology 1980; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/45\">",
"      Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969; 81:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/46\">",
"      Palmer GW, Claman HN. Pregnancy and immunology: selected aspects. Ann Allergy Asthma Immunol 2002; 89:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/47\">",
"      Bierman SM. Autoimmune progesterone dermatitis of pregnancy. Arch Dermatol 1973; 107:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/48\">",
"      Farah FS, Shbaklu Z. Autoimmune progesterone urticaria. J Allergy Clin Immunol 1971; 48:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/49\">",
"      Boiko S, Zeiger R. Diagnosis and treatment of atopic dermatitis, urticaria, and angioedema during pregnancy. Immunol Allergy Clin North Am 2000; 20:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/50\">",
"      Snyder JL, Krishnaswamy G. Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: a case report and literature review. Ann Allergy Asthma Immunol 2003; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/51\">",
"      Oskay T, Kutluay L, Kaptanolu A, Karabacak O. Autoimmune progesterone dermatitis. Eur J Dermatol 2002; 12:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/52\">",
"      Cocuroccia B, Gisondi P, Gubinelli E, Girolomoni G. Autoimmune progesterone dermatitis. Gynecol Endocrinol 2006; 22:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/53\">",
"      Walling HW, Scupham RK. Autoimmune progesterone dermatitis. Case report with histologic overlap of erythema multiforme and urticaria. Int J Dermatol 2008; 47:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/54\">",
"      Meggs WJ, Pescovitz OH, Metcalfe D, et al. Progesterone sensitivity as a cause of recurrent anaphylaxis. N Engl J Med 1984; 311:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/55\">",
"      Bhatia PL, Singh MS, Jha BK. Laryngopathia gravidarum. Ear Nose Throat J 1981; 60:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/56\">",
"      ROTH HL, KIERLAND RR. THE NATURAL HISTORY OF ATOPIC DERMATITIS. A 20-YEAR FOLLOW-UP STUDY. Arch Dermatol 1964; 89:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/57\">",
"      Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol 1991; 125:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/58\">",
"      Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/59\">",
"      Weatherhead S, Robson SC, Reynolds NJ. Eczema in pregnancy. BMJ 2007; 335:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/60\">",
"      Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2009; :CD007346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/52/3914/abstract/61\">",
"      Katz VL, Thorp JM Jr, Bowes WA Jr. Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. Am J Obstet Gynecol 1990; 162:396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5552 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-C3EBFED581-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3914=[""].join("\n");
var outline_f3_52_3914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      General approach to treating allergy in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Medication use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FDA categories",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RHINITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2251392\">",
"      Non-drug therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy rhinitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effect of pregnancy on preexisting rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Allergic rhinitis/conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cromolyn sodium nasal spray",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Glucocorticoid nasal sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antihistamine nasal sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Decongestants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antihistamines and decongestants combined",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rhinitis medicamentosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute bacterial rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      URTICARIA AND ANGIOEDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Laryngopathia gravidarum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ATOPIC DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Emollients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Oral antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Topical tacrolimus and pimecrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment of bacterial superinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5552\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5552|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/49/22303\" title=\"picture 1A\">",
"      PUPPP hives and plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/40/5761\" title=\"picture 1B\">",
"      PUPPP striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/39/22132\" title=\"picture 2\">",
"      Prurigo of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5552|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43548\" title=\"table 2\">",
"      Nasal irrigation instruct",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=related_link\">",
"      Anaphylaxis in pregnant and breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=related_link\">",
"      Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=related_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=related_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/21/18770?source=related_link\">",
"      Patient information: Asthma and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=related_link\">",
"      Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/56/37762?source=related_link\">",
"      Patient information: Taking over-the-counter medicines during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/442?source=related_link\">",
"      Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=related_link\">",
"      Physiology and clinical course of asthma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35816?source=related_link\">",
"      The skin, hair, nails, and mucous membranes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36344?source=related_link\">",
"      Treatment of respiratory infections in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_52_3915="Probability abnormal test";
var content_f3_52_3915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of an abnormal screening test result",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Number of independent tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability of abnormal test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        19 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        26 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        64 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        92 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3915=[""].join("\n");
var outline_f3_52_3915=null;
var title_f3_52_3916="Conditions associated with ZES";
var content_f3_52_3916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features associated with peptic ulcer disease in patients with gastrinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal reflux disease, especially when severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Association with diarrhea, steatorrhea, or weight loss (due to the high rate of acid secretion and secondary disruption of digestion enzyme and absorptive function)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple ulcers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptic ulcers in H. pylori-negative, NSAID-negative subjects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcers beyond the duodenal bulb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased gastric folds on upper GI series or endoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Findings suggestive of&nbsp;multiple endocrine neoplasia type I (see Family history)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive family history of ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Family history or other findings suggestive of multiple endocrine neoplasia type I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypercalcemia or nephrolithiasis due to primary hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoglycemia due to insulinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Functioning or nonfunctioning pituitary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diarrhea due to VIPoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Natural history and response to treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcers resistant to medical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent recurrences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcer recurrences after surgical treatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H. pylori: Helicobacter pylori; NSAID: nonsteroidal antiinflammatory drug; GI: gastrointestinal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3916=[""].join("\n");
var outline_f3_52_3916=null;
var title_f3_52_3917="IVC-related infx defs";
var content_f3_52_3917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used clinical definitions of intravascular catheter-related infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Infection",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Catheter colonization",
"      </td>",
"      <td>",
"       Significant growth of &ge;1 microorganism in a quantitative or semiquantitative culture of the catheter tip, subcutaneous catheter segment, or catheter hub",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phlebitis",
"      </td>",
"      <td>",
"       Induration or erythema, warmth, and pain or tenderness along the tract of a catheterized or recently catheterized vein",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Exit site infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Microbiological",
"      </td>",
"      <td class=\"sublist_other\">",
"       Exudate at catheter exit site yields a microorganism with or without concomitant bloodstream infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Clinical",
"      </td>",
"      <td class=\"sublist_other\">",
"       Erythema, induration, and/or tenderness within 2 cm of the catheter exit site; may be associated with other signs and symptoms of infection, such as fever or purulent drainage emerging from the exit site, with or without concomitant bloodstream infection*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tunnel infection",
"      </td>",
"      <td>",
"       Tenderness, erythema, and/or induration &gt;2 cm from the catheter exit site, along the subcutaneous tract of a tunneled catheter (eg, Hickman or Broviac catheter), with or without concomitant bloodstream infection*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pocket infection",
"      </td>",
"      <td>",
"       Infected fluid in the subcutaneous pocket of a totally implanted intravascular device; often associated with tenderness, erythema, and/or induration over the pocket; spontaneous rupture and drainage, or necrosis of the overlying skin, with or without concomitant bloodstream infection*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\">",
"       Bloodstream infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Infusate related",
"      </td>",
"      <td class=\"sublist_other\">",
"       Concordant growth of a microorganism from infusate and cultures of percutaneously obtained blood cultures with no other identifiable source of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Catheter related",
"      </td>",
"      <td class=\"sublist_other\">",
"       Bacteremia or fungemia in a patient who has an intravascular device and &gt;1 positive blood culture result obtained from the peripheral vein, clinical manifestations of infection (eg, fever, chills, and/or hypotension), and no apparent source for bloodstream infection (with the exception of the catheter). One of the following should be present: a positive result of semiquantitative (&gt;15 cfu per catheter segment) or quantitative (&gt;10",
"       <sup>",
"        2",
"       </sup>",
"       cfu per catheter segment) catheter culture, whereby the same organism (species) is isolated from a catheter segment and a peripheral blood culture; simultaneous quantitative cultures of blood with a ratio of &gt;3:1 cfu/mL of blood (catheter vs. peripheral blood); differential time to positivity (growth in a culture of blood obtained through a catheter hub is detected by an automated blood culture system at least 2 h earlier than a culture of simultaneously drawn peripheral blood of equal volume). Note that this definition differs from the definition of central line-associated bloodstream infection used for infection-control surveillance activities.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Adapted in part from Pearson",
"    <sup>",
"     [1]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"     cfu: colony forming units.",
"     <br>",
"      * For surveillance purposes, patients with positive results of blood culture would be classified as having central line-associated bloodstream infection.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Pearson ML. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:438-73.",
"     <br>",
"      Reproduced with permission from: Mermel, LA, Allon, M, Bouza, E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3917=[""].join("\n");
var outline_f3_52_3917=null;
var title_f3_52_3918="Drug and toxin induced mental status changes";
var content_f3_52_3918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced mental status alterations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Central nervous system depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Belladonna alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Selective serotonin reuptake inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Monoamine oxidase inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Simple asphyxiants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbon dioxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inert gases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cellular asphyxiants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydrogen sulfide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methemoglobinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbamates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympatholytics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Benzodiazepines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Muscle relaxants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiepileptics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gamma-hydroxybutyrate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Volatile inhalants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohols",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Agitated delirium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amantadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenylpropanolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Atropine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Scopolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiparkinson agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antispasmodics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Muscle relaxants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Plants containing belladonna alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Central hallucinogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lysergic acid diethylamide (LSD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phencyclidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mescaline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psilocybin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ketamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Designer amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Synthetic cannabinoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug withdrawal states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metals",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3918=[""].join("\n");
var outline_f3_52_3918=null;
var title_f3_52_3919="Thyroid hormones in serum";
var content_f3_52_3919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transport and metabolism of thyroid hormones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 448px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forms of T4 (thyroxine) and T3 (triiodothyronine) in serum and pathways of T4 and T3 production and degradation.",
"    <div class=\"footnotes\">",
"     TBG: thyroxine-binding globulin; TTR: transthyretin.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Utiger RD. The Thyroid: Physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Endocrinology and Metabolism, 3rd ed, Felig, R, Baxter, JD, Frohman, LA (Eds), McGraw-Hill, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_52_3919=[""].join("\n");
var outline_f3_52_3919=null;
